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Complement is a key part of innate immunity and vital in the first line of defence 
against invading pathogens. The understanding of the role of complement in the host’s 
immune defence has undergone its first major change when it became clear that 
complement is also required for the optimal induction and function of adaptive 
immunity, particularly B cell activation and T cell effector responses. It is now also 
becoming increasingly clear that complement plays a key role in the contraction of T 
cell responses and thus, by definition, in immune homeostasis.   
The first part of this thesis focuses on such least understood role of complement. 
Firstly, evidence is reported for a novel mechanism by which the complement 
regulatory protein CD46 regulates the key T helper type 1 cytokine IFN-γ and the 
canonical immunosuppressive cytokine IL-10. The production of both IFN-γ and IL-10 
is shown to be temporally regulated by TCR and CD46 signals in CD4
+
 T cells in an 
IL-2-dependent fashion and is shown to be defective in rheumatoid arthritis patients. 
The molecular pathways linked to the CD46-induced switch of TH1 cells are largely 
undefined and were investigated. Gene array studies highlighted the asparagine 
endopeptidase (AEP) as a candidate molecule involved in the regulation of the switch 
of TH1 cells towards IL-10 production. The CD46-driven IFN- secretion, but not the 
intracellular expression, was found to be substantially reduced by AEP inhibition; IL-
10 production was consequently affected confirming the importance of IFN- 
signalling in the CD46-induced “switch” mechanism.  
The cytokines produced by T cells activated via CD46 may also be important in the 
crosstalk with surrounding tissues. Here the functional consequences of CD46 signals 
were further investigated in the context of intestinal epithelial cells to allow the 
discrimination of the effects of CD46 signals in the two different cells types. A novel 
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1.1 Interplay between innate and adaptive immunity – an overview  
The Nobel Prize in Physiology or Medicine 2011 was divided “with one half jointly to 
Bruce A. Beutler and Jules A. Hoffmann for their discoveries concerning the activation 
of innate immunity and the other half to Ralph M. Steinman for his discovery of the 
dendritic cell and its role in adaptive immunity” (Nobel Prize Press Release, 2011). 
Since the 20
th
 century the immune network has been academically and theoretically 
characterised as dichotomous with the two systems that define it, commonly identified 
as innate and adaptive immunity. The jointed Nobel Prize awarded in 2011 unifies this 
text-book definition of immunity highlighting how protection of the host can be fully 
achieved only as a result of the successful cooperation between innate and adaptive 
immune responses. 
Today we understand that the immune system is essential in order to maintain a 
healthy homeostatic physiological state. It is necessary in the protection against 
pathogens but also controls and removes danger associated to injured and transformed 
tissues and actively takes part to wound healing processes. 
The merits of Hoffmann and Beutler rely to the discovery of a key class of pattern 
recognition receptors (PRRs) involved in the innate immune responses which provide 
the first line of defence against microbes and modified cells (Lemaitre et al., 1996; 
Poltorak et al., 1998). They described the functional importance of Toll-like receptor 
(TLR) 4 in the response to the microbial product lipopolysaccharide (LPS). TLRs are a 
prime example of germline-encoded receptors able to recognise antigens without any 
previous exposure. Thanks to PRRs such as TLRs, nucleotide oligomerisation domain-
like receptors (NLRs) and lectin like receptors, the innate response is “fast tracking” 
although not highly specific to the antigen since it recognises highly conserved 
molecular patterns expressed by classes of microbes. Hence, innate immunity is able to 
recognise pathogen associated molecular patterns (PAMPs) and danger associated 
molecular patterns (DAMPs) and initiate mechanisms to prevent or eliminate infection 
and favour wound healing (Akira, 2000). To achieve these complex aims PRRs 
function in conjunction to cellular components (including granulocytes, mast cells, 
macrophages and NK cells) and soluble pattern recognition molecules (complement –
described in paragraph 1.3-, coagulation, pentraxins). 
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The evolutionary younger adaptive immune system is a more efficient network in 
terms of specificity. Furthermore, a key feature of the adaptive responses is 
immunological memory; subsequential exposure to the same antigen induces a quicker 
and stronger response (McFarland et al., 2000). The main players of adaptive 
immunity are represented by lymphocytes; a cell type able to clonally expand in order 
to generate a highly specific immune response. Lymphocytes are divided in B cells and 
T cells which have different functions. B cells (named after the Bursa of Fabricius – 
the organ from which they were discovered in birds) have been initially identified as 
adaptive cells key in producing pathogen specific antibodies able to recognise antigens 
in their native form and neutralise pathogens in extracellular compartments (Abbas et 
al., 2011). 
T lymphocytes are a class of immune cells which, unlike B cells, are only able to 
recognise protein antigens presented by specialised cells and in association with class I 
or II MHC molecules (Mazza and Malissen, 2007). In 1973 Steinmann was able to 
identify a novel cell type named dendritic cell (DCs), after the prolonged membrane 
projections that characterised their morphology (Steinman and Cohn, 1973), critical in 
eliciting T cell responses. DCs, and more generally antigen presenting cells, are 
sentinel cells well equipped with co-stimulatory molecules (e.g. namely CD80, CD86 
and Notch for DCs) important in T cell development; they express a wide array of 
PRRs (TLRs, Complement receptors, NLRs, Fc receptors) and have been shown to be 
key in immune responses since mutations affecting this cell type impairs adaptive 
immunity. Moreover, impairments influencing an effective trigger and/or development 
of an immune response can lead to chronic inflammatory- or auto-immune diseases 
which result from excessive inflammation and uncontrolled immune activation 
(Hambleton et al., 2011; Rouse and Sehrawat, 2010). The Noble Prize raised the 
importance of how innate signals (e.g. PRRs) are vital in delivering signals for the 
development of adaptive immunity.  
This requirement of a successful crosstalk between innate and adaptive immunity has 
been the focus of interest for decades of immunology related research and considerable 
progress has been made in understanding the underlying mechanisms of danger 
recognition and adaptive immune instruction. However, the recent notion supporting a 
role for innate immunity in the contraction of B and/or T cell responses is relatively 
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novel and not yet broadly accepted. The study developed in this thesis focused on this 
particular field of immunology and delineated the role of complement-derived innate 





1.1.1 T lymphocyte development  
 
The thymus represents the main site of maturation of committed lymphoid progenitors 
which arise in the bone marrow from haematopoietic stem cells (Zuniga-Pflucker, 
2004). The different stages of thymocytes development are identified by the expression 
of surface markers including CD4, CD8, CD25 and CD44 and by the rearrangement 
status of the T cell receptor (TCR) (Godfrey and Zlotnik, 1993). The first phase of 
intra-thymic development is known as the double negative (DN) stage 1. Thymocytes 








 and have no TCR expression 
(Godfrey and Zlotnik, 1993; Groettrup and von Boehmer, 1993). Thymocytes in DN1 
can differentiate into T, B, natural killer (NK) cells or dendritic cells (DCs) but not into 


















 in the DN3 stage; in this stage they become 
committed to the T cell lineage and are able to generate either αβ or γδ T cells (Capone 
et al., 1998). The loss of CD25 expression in DN4 identifies the pre-stage of double 
positive (DP) lymphocytes co-expressing CD4 and CD8 (Robey and Fowlkes, 1994). 
As cells maturate through DN2 and DN4, the rearrangement of TCR β, γ and δ chains 
is possible. In 90% of the cases, successful TCR rearrangements of the β chain leads to 
the differentiation of αβ T cells whilst in less than 10% of the cases successful 
rearrangement of TCR γ and δ anticipates the rearrangements of α and β and generates 
γδ T cells (Germain, 2002). In the transition between DN4 to double positive (DP) T 
cells, the αβ CD4+CD8+ cells undergo proliferation and subsequently interact with 
MHC class I and class II associated self-peptides presented by thymic epithelial cells 
(Rothenberg and Dionne, 2002). The nature of the MHC molecule (class I vs. class II) 
and the strength of the TCR signals will determine whether a DP cell will become 
single positive for CD4 or CD8; only intermediate levels of signalling will translate in 
the positive selection of T cells (Izon et al., 2001). A pivotal role in fate decision 
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during T cell development has been also described for the Notch pathway (Anderson et 
al., 2001). In fact, the interaction between Notch receptor-expressing thymocytes and 
Notch ligand-expressing thymic stromal cells, triggers key signals during the T-cell 
maturation process promoting the commitment towards the αβ T cell lineage inducing 
the generation of either CD4
+
 T cells or CD8
+ 
cytotoxic T cells (Robey et al., 1994). 
 
 
1.1.2 αβ T cells 
Mature T cells that leave the thymus may be already lineage committed as in the case 
of natural regulatory T cells or may still not be functionally differentiated (Maggi et 
al., 2005; Zuniga-Pflucker, 2004); in the latter case they are known as naïve T 
lymphocytes because although mature they have not encountered the antigen they are 
specific for. Once they leave the thymus naïve T cells re-circulate through the blood 
and lymph in a resting state. The activation process of T cells into an effector 
phenotype requires the input of several signals; signal 1 (T cell receptor engagement), 
signal 2 (costimulation) and signal 3 (cytokine receptor engagement). These three 
signals are delivered generally by activated antigen presenting cells (APCs) because 
they express peptide-loaded MHC (pMHC) class I and II molecules required for T cell 
receptor (TCR) engagement, ligands for T cell costimulation and T cell effector 
function-defining cytokines (Croft, 2003). The interaction between T cells and APC is 
anatomically confined to specialised lymphoid tissues known as secondary lymphoid 
organs (Bousso, 2008; Steinman and Cohn, 1973). These include the spleen and lymph 
nodes, and represent the tissues to which protein antigens are shuttled once they are 
captured by APCs at the level of skin, gut and lungs (Abbas et al., 2011). 
 
1.1.3 Mechanisms and induction of effector CD4+ T cells 
1.1.4 TCR signalling (Signal 1) 
The αβ TCR is a heterodimer composed of two transmembrane polypeptides known as 
α and β (Figure 1.1). Both α and β are composed of an amino-terminal variable region 
responsible for the recognition of the antigen peptide and a carboxi–terminal constant 
region non-covalently associated to signalling proteins known as the CD3 complex and 
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ζ (Figure 1.1) (Bentley et al., 1995; Fields et al., 1995; van der Merwe and Dushek, 
2011). The TCR interaction with the pMHC is the first step in triggering T cell 
activation (Signal 1). Key in the process of TCR-pMHC interaction is the role of co-
receptors CD4 and CD8 (Rudolph et al., 2006). The CD4 co-receptor interacts with 
non-polymorphic regions of the MHC class II molecule driving T cell immunity 
towards antigens captured from the extracellular space (i.e. parasites and extracellular 
bacteria) while MHC class I will present cytosolic antigens (i.e. from viruses or cancer 
cells) that specify for a CD8 T cell response (Abbas et al., 2011). Sufficient 
engagement of MHC-peptide/TCR complexes leads to the formation of the 
immunological synapse (IS) as a platform for subsequent signalling events required for 
T cell activation (Fooksman et al., 2010).  
 
Figure 1.1 Structure of the T cell receptor complex. 
The αβ TCR is a heterodimer which comprises two chains; α and β. The two chains are 
associated through a disulphide bridge ad stabilised by intra-disulphide bridges. The 
carboxy–terminal constant region is non-covalently associated to signalling proteins on 
the intracellular region known as the CD3 complex and ζ. The three different subunits 
of CD3 γ, δ and ε, form heterodimers and comprehend one immunereceptor tyrosine-
based activation motif (Nagasawa et al.) (Nagasawa et al.) each. The ζ signalling 
molecule forms homodimers that associate with the TCR and each ζ is characterised by 
the presence of three ITAMs (Abbas et al., 2011).  
 
 
At the level of the IS segregation of TCR, CD3, CD4 or CD8 and CD28 from CD45 
and other inhibitory molecules takes place and allows for T cell activation (Dustin and 
Depoil, 2011). Several signalling pathways activated by the TCR engagement are 
required for the initiation of cell cycle progression and the production of the key T cell 
growth factor IL-2; additional incoming signals from co-stimulators and cytokine 
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receptors will subsequently complement TCR signals and define the T cell effector 
functions.  
Antigen recognition and CD4/CD8 co-receptor engagement induce different T cell 
signalling pathways; the mostly studied are the mitogen activated protein (MAP) 
kinase pathway and the phospholipase C-γ1 (PLC-γ1) pathway.  
MAPK signalling is activated through the phosphorylation of CD3 and ζ by adaptor 
molecule LAT (Figure 1.2). LAT regulates the guanine nucleotide exchange factor son 
of sevenless (Sos) that activates Ras (a GTPase linked to lipids of the cell membrane) 
(Abraham and Weiss, 2004). Activated Ras triggers the extracellular signal regulated 
kinase (Wingender et al.) cascade by inducing phosphorylation of ERK1 and ERK2. 
This results in the activation of c-Fos, a transcriptional regulator of activator protein 1 
(AP1). AP1 is a transcription factor particularly important in the synthesis of IL-2 the 
key growth cytokine produced by T cells (Smith-Garvin et al., 2009).  
TCR induced activation of the adaptor molecule LAT (Figure 1.2) also promotes the 
recruitment of phospholipase C-γ1 (PLC-γ1). Activated PLC-γ1 hydrolyses 
phosphatidyl inositol-4,5 biphosphate (PIP2) into inositol trisphosphate (IP3) and 
diacylglycerol (Smith et al.). IP3 is a second messenger that induces increases in Ca
2+
 
intracellular levels. Calcium acts as a signalling molecule activating calmodulin, an 
important serine threonine phosphatase that activates transcription factors including the 
nuclear factor of activated T cell (NFAT). NFAT acts in conjunction with AP1 and is 
pivotal in the regulation of genes such as IL-4 and IL-2 hence in the regulation of TH1 
and TH2 responses (Hermann-Kleiter and Baier, 2010). DAG is able to activate protein 
kinase C-θ (PKCθ) and activate NF-kB, a crucial transcription factor for the 
production of  cytokines (e.g. IL-2, IFN-γ and IL-12) (Abraham and Weiss, 2004).  
 




Figure 1.2 TCR activation and signalling.  
TCR signalling is only initiated when the TCR stably interacts with the peptide 
associated to MHC molecules. Once the TCR has stably interacted with the pMHC, the 
tyrosines present in the ITAMs of CD3 and ζ are phosphorylated by Lck and Fyn 
kinases which are in an active state due to the removal of phosphogroups by the 
phosphatase CD45. The phosphorylation of ITAMs at the level of TCR ζ favours the 
interaction with a tyrosine kinase known as zeta associated protein 70 (ZAP70); the 
bound ZAP70 is phosphorylated by Lck. As a result ZAP70 initiates PLC-γ1 and MAP 
kinases pathways through adaptor molecules such as LAT and VAV which promote 
the production of second messengers including inositol 3,4,5-triphosphate (IP3) and 
diacylglycerol (Smith et al.). IP3 can induce an increase in Ca
2+
 concentration whilst 
DAG can in turn activate RAS guanyl nucleotide-releasing protein (RASGRP) 
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1.1.5 Co-stimulatory signals for CD4+ T cells (Signal 2) 
In order to achieve complete T cell activation, TCR triggered signals need to be 
complemented by signalling of co-stimulatory molecules. To date several positive co-
stimulators of T cell activation have been identified including CD2, CD28, CD30 
CD40L, inducible T cell co-stimulator (Hutloff et al., 1999) and OX40 (Croft, 2003). 
However, the best characterised co-stimulator is CD28.  CD28 is a homodimer with a 
single Ig extracellular domain (Kovacs et al., 2005). It is expressed on 90% of CD4
+
 
human T cells and its physiological activation is triggered by the APC expressed CD28 
ligands, CD80 (B7-1) and CD86 (B7-2) (Riley and June, 2005). PRRs (TLRs or NLRs 
or LLRs) engagement, complement opsonised antigens and cytokine signalling 
increase the expression of MHCII, CD80 and CD86 molecules favouring APCs 
maturation (Carroll, 2004). Lack of CD28 co-stimulation has been shown to impair T 
cells responses towards infecting pathogens highlighting the importance of positive 
costimulation in T cell activation and skewing (Jankovic et al., 2001; Shahinian et al., 
1993). In conjunction with TCR engagement, CD28 contributes to T cell activation 
through enhancement of tyrosine phosphorylation events (Michel et al., 2000). Upon 
CD28 engagement, the intracellular tail of CD28 associates with the PI3 kinase 
activating PLC-γ1, PKCθ and MAPK pathways (Ueda et al., 1995) inducing cellular 
proliferation and IFN-γ, IL-2 and TNF production (Thompson et al., 1989). As a result 
of these events CD28 positively regulates T cells proliferation, differentiation and 
cytokine secretion. CD28 is the canonical example of a positive T cell co-stimulatory 
molecule; however negative co-stimulatory molecules are necessary to assure the 
appropriate contraction of T effector responses. To date several negative co-stimulators 
of T cell proliferation/activation have been described including Cytotoxic T-
lymphocyte antigen 4 (CTLA4), T cell immunoglobulin mucin-(TIM)-3 and 
programmed cell death (Figure 1.3) (Acuto and Michel, 2003; Tivol et al., 1995; 
Waterhouse et al., 1995; Zakrzewski et al., 2006). T cell co-stimulatory molecules bare 
high potential for therapeutic applications. Noteworthy is the development of a 
CTLA4-Ig protein (Abatacept) which has been successfully used for the treatment of 
rheumatoid arthritis (Ruderman and Pope, 2005). 




Figure 1.3 TCR co-stimulatory molecules 
CD28 and CTLA4 are two examples of “second signal” co-stimulatory molecules with 
positive and negative properties respectively. CD40 ligand (CD40L) expression is 
induced during antigen recognition by T cells. The interaction with its receptor CD40 
expressed on the APC induces increased expression of B7 molecules CD80, CD86 and 
OX40 ligand (OX40L) favouring T cell activation. Expression of inducible co-
stimulatory molecule ligand (ICOSL) by activated APCs (including DCs and B cells) 
has been shown important in TH2 induced antibody production and in the development 









 Chapter 1 Introductions 
27 
 
1.1.6 Induction of effector functions via cytokines (Signal 3) 
The magnitude and specificity of signals 1 and 2 are pivotal in the initiation of T cell 
lineages decisions. However, T cell subset-instructing cytokines which trigger signal 3 
ultimately define the effector function of an activated T cell (Croft, 2003). T cells can 
differentiate in several subsets each specific for classes of pathogens and characterised 
by signature transcription factors and secreted cytokines. The publication on the 
Journal of Immunology in 1986 of Tim Mosmann and Bob Coffman (Mosmann et al., 
1986) was the first to identify two main mouse CD4
+
 T cell subsets known as Type 1 T 
helper cells (TH1),  characterised by IFN-γ production and Type 2 T helper cells (TH2), 
characterised by IL-4 production. In the 1990s, Susan Swain started pivotal 
experiments in the race to decipher T helper subsets. She showed that naïve T cells 
could only produce IL-4 in the presence of TCR stimulation and IL-4 receptor 
signalling (Swain et al., 1990). Murphy’s group in 1993 showed that it was possible to 
induce TH1 cells through macrophage derived IL-12 (Hsieh et al., 1993). In 1994 a 
“tolerant” T cell subtype was identified by Weiner. This cell subpopulation was called 
Th3 and was characterised by the production of immunosuppressive TGF-β (Ehret et 
al., 2001). In 2003 Rudensky and Sakaguchi’s groups revolutionised immunological 
research focused on tolerance through the identification of the key transcription factor 
of regulatory T cells; Foxp3. The in vivo relevance of these findings was further 
confirmed with the identification that the human immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome was associated with 
mutations in Foxp3 (Hori et al., 2003; Patel, 2001; Wildin et al., 2001). With the 
insight of these studies immunologists recognise now an increasing number of T cell 
subsets. The identification of novel T cell subsets and cytokines is an active field of 
research, and a novel concept of T cell plasticity by which specific T helper subsets 
can revert their phenotype has been proposed and proved (Murphy and Stockinger, 
2010). Recently T cells secreting abundant IL-9 (Dardalhon et al., 2008; Veldhoen et 
al., 2008) and IL-22 (Trifari et al., 2009; Veldhoen et al., 2008) have been identified 
and named TH9 and TH22 respectively. However, since no transcriptomic signature has 
been associated to such subsets, the following paragraphs will only focus on the main 
characteristics of TH1, TH2, and TH 17 effector cells. 
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1.1.7 T helper 1 lymphocytes - TH1  
TH1 cells provide the cell-mediated immune response against intracellular bacteria 
including listeria, salmonella and mycobacteria and to intracellular parasites such as 
leishmania (Hultgren et al., 2004; Ravindran et al., 2005; Sullivan et al., 2005; Szabo 
et al., 2000). They are also vital in the activation of cytotoxic CD8
+
 T cells fighting 
viral infections (Actor et al., 1994; Shirai et al., 1998). The direct infection of DCs 
and/or macrophages or the engagement of germ-line encoded PRR (i.e. TLRs or 
NLRs) with intracellular pathogen antigens, triggers the APCs to produce IL-12. The 
IL-12 receptor comprises the IL12Rβ1 chain (Figure 1.4) which is expressed on all 
naïve T cells and the IL-12Rβ2 chain which is induced by TCR activation and 
maintained by IL-12 (Afkarian et al., 2002; Moon et al., 1997). In conjunction with 
TCR and CD28, IL-12 signalling induces phosphorylation of the signal transducer and 
activator of transcription (STAT) 4 leading to the synthesis of IFN-γ, the key effector 
cytokine for TH1 lymphocytes (Kaplan et al., 1996b). IFN-γ production by TH1 is not 
only functionally important for macrophage activation and DCs maturation during 
pathogen clearance; it is also essential to enhance the positive feedback loop for TH1 
skewing, by inducing the STAT1 through the IFN-γ receptor (Afkarian et al., 2002). 
Furthermore, it promotes the inhibition of the TH2 and TH17 subsets. The main 
mechanism of such process is governed by T-bet, the key transcription factor 
associated to TH1 differentiation (Szabo et al., 2000). T-bet is a T-box transcription 
factor able to bind and promote transcription of the Ifng gene whilst inhibiting IL-4 
transcription (crucial in TH2 development) and preventing activation of the RORγt gene  
(essential for TH17 skewing) (Doffinger et al., 2002). The in vivo relevance of TH1 
cells is clear; mice with defects in TH1 induction (i.e. T-bet knockout mice) are unable 
to clear infection of intracellular pathogens including L. major, M. tuberculosis or S. 
typhimurium. Further such animals are susceptible to typical TH2 diseases such as 
asthma (Ravindran et al., 2005; Sullivan et al., 2005; Szabo et al., 2000). In a similar 
way, mutations in the IL-12 or IFN-γ-induced T-bet pathway lead to TH1 exaggerated 
induction and have been associated to autoimmune disorders such as type 1 diabetes 
(Hultgren et al., 2004; Manoury-Schwartz et al., 1997; Sasaki et al., 2004). 
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1.1.8 T helper 2 cells - TH2 
TH2 lymphocytes are essential in fighting infections against helminths and in 
developing a response to allergens. TH2 cells are defined by the expression of the key 
transcription factor GATA-3 (Figure 1.4) and by the signature cytokines IL-4, IL-5 and 
IL-13 (Glimcher and Murphy, 2000). The main effector functions of TH2 cells include 
induction of IgE production in B cells (Kopf et al., 1993; Ueda et al., 1990), alternative 
macrophage activation through IL-4/13 production and recruitment of eosinophils 
through IL-5 secretion (Coffman and Carty, 1986; Gordon, 2003). The initial source of 
the TH2 driving IL-4 has been enigmatic for a long time as APCs do not produce this 
cytokine. Initially it was suggested that the basal IL-4 production induced in the 
presence of a TH promoting environment and the IL-4 positive feedback loop could be 
sufficient in enhancing and directing TH2 skewing (Kaplan et al., 1996a; Swain et al., 
1990; Zheng and Flavell, 1997). However, to date other sources of IL-4 have been 
identified including mast cells and basophils, which could be supporting in vivo TH2 
induction (Paul, 2010). An important role for TH2 unwanted induction against 
innocuous antigens in asthma has been demonstrated and a correlation of disease 
severity with frequencies of TH2 cells and cytokines highlights the importance of such 
subset in human disease (Robinson et al., 1992).  
  
1.1.9 T helper 17 cells - TH17 
TH17 cells are defined by the production of IL-17a and were described in 2005 for the 
first time (Bendelac et al., 1997). TH17 cells are important in mediating immunity 
towards extracellular bacteria including gram-positive (e.g. Propionibacterium acnes) 
and gram-negative species (e.g. Citrobacter rodentium, Klebsiella pneumonia) and 
towards fungi (Conti et al., 2009; Itoh et al., 1991; Miossec et al., 2009). The 
differentiation of TH17 was initially described as dependent on IL-6 and TGF-β; these 
cytokines induced the transcription factor RORγt (Figure 1.4) which has since then 
been defined as the master regulator of TH17 cells (Ivanov et al., 2006; Mangan et al., 
2006; Veldhoen et al., 2006). TH17 cells have been shown to be able to secrete an array 
of cytokines with contrasting functions including: IL-17a, IL-17f, IL-21, and IL-22. 
IL-17a and IL-17f are genetically linked and often co-synthesized. They both bind to 
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the IL17 receptor A (IL-17RA) although IL-17a has higher affinity. IL-17a and IL-17f 
can activate neutrophils inducing active responses towards fungi and extracellular 
bacteria (Ferretti et al., 2003). IL-17a can induce the production of the pro-
inflammatory cytokine IL-6 and the chemotactic interleukin IL-8. IL-21 produced by 
TH17 cells is a stimulatory factor for TH17 differentiation and serves as the positive 
feedback amplifier (Korn et al., 2007). Importantly, mutations in the signal transducer 
STAT3 which is important in TH17 differentiation are associated with recurrent fungal 
and bacterial infections further attesting to the importance of this subset of TH cells in 
vivo (Milner et al., 2008).  
A prominent role for TH17 in autoimmune disease has also been proven. Initial 
observations showed that IL-17a deficiency was protective in a model of experimental 
autoimmune encephalomyelitis (Andreae et al.), which resembles human multiple 
sclerosis (Komiyama et al., 2006). A subsequent study by Murphy’s group clarified 
that the pathogenic effect in EAE was caused by the cytokine IL-23 (Cua et al., 2003). 
Further, the effect was not mediated by TH17-derived IL-22 since IL-22 knockout mice 
are not protected from EAE (Kreymborg et al., 2007). A role for TH17 cells has been 








Figure 1.4 T helper cell subsets.  
The differentiation of CD4
+
 T cells into a specific lineage initiates upon cognate 
interaction between Naïve CD4
+
 TH cells (Thp) and APCs which provides Signal 1 
(TCR) and Signal 2 (CD28/ICOS). The cytokine milieu determines the lineage 
commitment and effector function of TH cells (Signal 3). IL-12 induces the activation 
of STAT4 signalling promoting production of IFN-γ. Signalling via the IFN-γ receptor 
induces STAT1 and transcription factor T-bet. As a result the expression of IL-12Rβ2 
and IFN-γ are increased and promote TH1 skewing. IL-4 induces STAT6 activation 
and consequently the expression of the transcription factor GATA-3 which directs TH2 
cell lineage differentiation and suppresses TH1 skewing. TH17 differentiation can be 
induced by different cytokines; IL-6 and TGF-β1 as well as IL-21 and IL-23 receptor 
engagement are pivotal in promoting the expression of the lineage transcription factor 
RORγt. High environmental IL-2 is a requirement for the induction of STAT5 
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1.1.10 CD8+ T cells 
CD8
+
 T cells recognise peptide antigens presented in association with MHC class I 
molecules (Russell and Ley, 2002). CD28 costimulation, through APCs expressing 
CD80 and CD86, and signalling of inflammatory cytokines, mainly through IL-12 and 
type I interferons, promote naïve CD8
+
 T cells proliferation and differentiation into 
cytotoxic T lymphocytes (CTLs) (Cui et al., 2009; Curtsinger et al., 2005). CTLs 
recognise and kill infected cells that express the MHC class I associated antigen, which 
triggers the differentiation of the naïve CD8
+
 T cells. Two main mechanisms of target 
cell killing by CD8
+
 T cells have been described. The granule-dependent mechanism 
relies on the targeted delivery of CTLs granules containing perforin and granzymes to 
the point of contact with the target cell (Catalfamo and Henkart, 2003). Perforin, a 
homologue of complement component C9, forms pores in the target membrane and 
facilitates the release of granzymes in the cytosol of the target cell allowing the 
initiation of apoptosis (Persechini et al., 1992). A second mechanism of CTLs target 
killing is granule-independent and relies on the binding of Fas (CD95), expressed on 
the target cell, by the Fas ligand which also results in the activation of caspase 
enzymes and ultimately apoptosis of the target cells (Delves and Roitt, 2000; Itoh et 
al., 1991; Yonehara et al., 1989). CTLs have the capacity to secrete  cytokines 
including IFN-γ and TNF-α which promote phagocytic activity of macrophages and 
increase the expression of MHC class I on virus-infected cells for enhanced 





 T cell-mediated responses have highlighted the ability of CD4
+
 T cells to 
provide help for CD8
+
 activation directly via the secretion of cytokines or indirectly by 
potentiating APCs function (e.g. through the CD40/CD40L axis) (Schoenberger et al., 
1998). Although this mechanism seemed to be specific according to the infecting 
pathogen latest findings support the theory that CD4
+
 T cells provide help for most 
CTL responses and that they are key in providing signals for effective secondary 
response and differentiation into memory CD8
+
 T cells (Janssen et al., 2003; von 
Herrath et al., 1996).  
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1.1.11 γδ T cells 
γδ T cells represent a subset of “non-conventional” T cells which, unlike αβ T cells, do 
not recognize MHC associated peptide antigens. Similarly to the αβ TCR, the γδ TCR 
is associated to CD3 and ζ proteins and its engagement induces the signalling events 
described above (paragraph 1.1.4). γδ T cells are mainly distributed in epithelial 
surfaces and in the mucosa of the respiratory, digestive and reproductive systems 
(Hahn et al., 2004; Inagaki-Ohara et al., 2005; Lewis et al., 2006).  Extensive studies 
on the antigens recognised by γδ T cells have shown that this particular subset of T 
cells responds to a variety of stress induced molecules, DAMPs and PAMPs. Ligands 
for the γδ TCR comprise MHC related molecules (e.g. CD1c molecules) and MHC 
class I unrelated molecules such as viral glycoproteins, lipids and phospho-antigens 
(Hayday, 2009). However, a key feature of γδ T cells is the recognition of antigens 
through non-clonal receptors but rather through natural killer receptors (NKR) and 
TLRs. The natural killer group 2, member D (NKG2D) receptor has been highly 
investigated (Groh et al., 1998). NKG2D, which is broadly expressed by γδ T cells, is a 
lectin-like receptor which recognises MHC class I related ligands usually up-regulated 
on transformed or virally infected cells (Eagle and Trowsdale, 2007). NKG2D-
mediated signals have been shown to trigger the cytotoxic activity of γδ T cells and to 
function in conjunction with γδ TCR activation through the retinoic acid early 
transcript 1 (RAE1) and the MHC class polypeptide-related sequence A (MICA) (Groh 
et al., 1999). 
The effector mechanisms of γδ T cells include the killing of infected or transformed 
cells via the engagement of FAS or TNF-related apoptosis-inducing ligand receptors 
(Dalton et al., 2004). The cytotoxic activity of γδ T cells may be also mediated by the 
secretion of perforins and granzymes (e.g. granzyme B) which are up-regulated upon 
activation of γδ T cells (Fahrer et al., 2001; Vermijlen et al., 2007). Furthermore, γδ T 
cells have been shown to secrete a wide array of cytokines including TNF, IFN-γ, IL-4, 
IL-5, IL-13 and IL-17 promoting T helper responses in the host defence against 
intracellular and extracellular pathogens (Hahn et al., 2004; Roark et al., 2007; Tagawa 
et al., 2004). Importantly, although γδ T cells have strong inflammatory and cytotoxic 
properties, it has been shown that they also express epithelial growth factors, which 
promote processes of wound-healing (Jameson and Havran, 2007; Toulon et al., 2009). 
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1.1.12 NKT cells 
NKT cells represent a population of αβ T cells with limited diversity within the α chain 
of the αβ TCR (Borg et al., 2007). They express typical NK markers such as CD56 and 
are particularly abundant in the liver and bone marrow where they represent between 
30-50% and 20-30% of mature mouse T cells respectively (Bendelac et al., 1997). 
NKT cells are specific for glycolipid antigens presented by MHC class I-like 
molecules such as CD1d (Benlagha et al., 2000). NKT cells can produce cytokines 
with distinct downstream effects reflecting the existence of different NKT subtypes. 
CD4
+
 NKT cells have been shown to produce TH1 and TH2 cytokines while CD4
-
 NKT 
cells mainly produce TH1 cytokines (Doherty et al., 1999). Several studies have shown 
that NKT cells are able to secrete cytokines rapidly and it has been suggested that they 
have a role in promoting marginal zone B cells to produce antibodies against lipid 
antigens (e.g. mycobacterial antigens) (Chang et al., 2011). Environmental cytokines 
can influence responses of NKT cells; for instance IL-12 has been show to promote 
IFN-γ production (Leite-De-Moraes et al., 1998). The effector functions of NKT cells 
include cytolytic activity via the Fas ligand, which is constitutively expressed on NKT 
cells and can target Fas expressing targets, or via perforin-dependent mechanisms 
(Arase et al., 1994; Smyth et al., 2000). The role of NKT cells in human disease 
remains a matter of investigation. Thus far, roles for NKT cells in infection, mainly 
mycobacteria, and cancer rejection have been shown (Grant et al., 1999; Nakagawa et 
al., 1998). Further elucidation of the mechanisms involved will shed light on the in 
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1.2 Immunological Tolerance 
The ability of the immune system to clear infecting pathogens and then initiate the 
required tissue repair at the site of infection is dependent on a fine balance between 
effector and regulatory mechanisms. Central in maintaining the functionality of the 
immune system is its ability to induce tolerance towards self or innocuous antigens 
(e.g. commensals) (Sakaguchi et al., 2008). The concept of immunological tolerance 
refers to the ability of the immune system to remain unresponsive to the presence of 
innocuous antigens; this is critically important at host-environmental interfaces (i.e. 
gut, skin and lungs) where there is continuous exposure to danger (invading 
pathogens) and non-danger (commensals, food) signals. Impairment to maintain 
tolerance towards non-dangerous (self) antigens translates into pathological conditions 
including hypersensitivity diseases, IBD, asthma, allergy and autoimmune diseases 
including rheumatoid arthritis, multiple sclerosis (Astier et al., 2006; Coombes et al., 
2005; Hawrylowicz and O'Garra, 2005; Kearley et al., 2005). Central tolerance refers 
to the mechanisms that allow for the discrimination and removal of high and low 
avidity self-reactive lymphocytes in the generative lymphoid tissues (e.g. thymus and 
bone marrow)(Hogquist et al., 2005). Peripheral tolerance refers to the immunological 
mechanisms that are in place to control self-reactive T cells, which have escaped 
central tolerance and have migrated into peripheral tissues (Vignali et al., 2008). Auto-
reactive T cells in the periphery may be suppressed in three main ways including, 
anergy (functional unresponsiveness), activation induced cell death and suppression 
via regulatory T cells or tolerogenic DCs (Mazzucchelli et al., 1996). 
The following paragraphs will focus on the mechanisms of immunological tolerance 
mediated by CD4
+
 regulatory T cells, since these are most pertinent to the studies 
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1.2.1 Natural T-regulatory cells in peripheral tolerance 
T regulatory lymphocytes (T-regs) are pivotal in order to maintain immune 
homeostasis at the host/environment interface and limit immunopathologies during 
inflammatory reactions (Sakaguchi et al., 2008). Currently, two major T-reg 
populations are recognised. The first group, natural T-regs are thymus-derived and 
pivotal in suppressing self-reactive effector T cells. They are characterized by high 
CD25 expression, the requirement of high environmental IL-2 for their expansion 
(Sakaguchi et al., 1995) and the expression of the forkhead transcription factor Foxp3 
(Hori et al., 2003). Mutations in the Foxp3 gene are associated with the immune 
dysregulation, poliendocrinopathy, entheropathy (IPEX) syndrome (Bennett et al., 
2001). Children affected by IPEX develop diabetes mellitus, enteropathy, eczema and 
severe allergies as a consequence of an altered function of natural T-regs stressing their 
in vivo importance in immune regulation (Caudy et al., 2007; van der Vliet and 
Nieuwenhuis, 2007). Several mechanisms have been proposed for the suppression of 
effector T cells by natural T-regs. Cell contact-independent mechanisms of suppression 
(Figure 1.5) include secretion of immunosuppressive cytokines such as TGF-β, IL-10 
and IL-35 and IL-2 (Vignali et al., 2008). Cell/cell contact-dependent mechanisms of 
suppression include perforin- or granzyme-secretion and delivery of negative signals in 
the responder cell such as cAMP (Sakaguchi et al., 2008). Natural T-regs may also 
suppress T cell responses by preventing dendritic cell (DC) maturation and function 
via down regulation of CD80, CD86 and MHCII expression.  
 
1.2.2 Adaptive T regulatory cells in peripheral tolerance 
The second group of T-regs is known as adaptive T-regs and they are thought to 
mediate tolerance towards non-self antigens specifically at the host/environment 
boarders such as the gut, skin and lung (Roncarolo et al., 2001; Rubtsov et al., 2008). 
Diverse subsets of adaptive T-regs have been described including type 1 regulatory T 
cells (Tr1) which are IL-10 producing (Groux et al., 1997) and Th3 cells (TGF-β 
producing) (Carrier et al., 2007; Ehret et al., 2001). However, specific conditions are 
required to obtain each subset of adaptive T-regs in vitro and unlike the natural T-regs 
there is no unique marker to enable their identification ex-vivo (Roncarolo et al., 2006). 
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Although the in vivo functionality has not been ascertained, it is well established that 
the main common feature of adaptive T-regs is their ability to suppress T effector cells 
through the secretion of the canonical immunosuppressive cytokine IL-10 (Battaglia et 
al., 2006b; Roncarolo et al., 2006). In line with this is the fact that IL-10-deficient mice 
or humans with mutations in the IL-10 receptor suffer from colitis (Kuhn et al., 1993; 
Ziegler-Heitbrock et al., 2003). Although the induction/expansion of IL-10-secreting 
adaptive regulatory T cells has been proven using biological molecules including 
retinoic acid (Mucida et al., 2009), vitamin D3 (Xystrakis et al., 2006) and chemical 
compounds such as rapamycin (Battaglia et al., 2006a; Battaglia et al., 2006c) there is 
still a massive lack in the understanding of their induction and regulation pathways. 
This is clearly a void that needs to be filled as these cells may bear high potential to be 
used/targeted therapeutically in the settings of transplantation or autoimmunity. A 
current question relevant to the field is whether IL-10-producing T-regs constitute a 
separate lineage or whether they are rather a specific ‘phase’ during the life cycle of an 
effector T cell response (Cope et al., 2011).The latter notion is lately gaining weight 
among scientists, particularly because it has been observed that the main effector T cell 
subpopulations (TH1, TH2 and TH17) can secrete IL-10 when activated under 
appropriate conditions (McGeachy et al., 2007). The work in this thesis further 
contributes to this understanding and demonstrates that such particular signals (here 















Figure 1.5 Mechanisms of suppression of natural T-regs.  
Suppression of T effector cells by natural T-regs includes cell contact-independent 
mechanisms such as secretion of IL-10, TGF-β and IL-35 (a), granzyme A or B 
secretion (b) and increase of intracellular levels of cAMP (c). Cell contact-dependent 
mechanisms include inhibition of DC maturation and function through the down 
regulation of CD80, CD86 via CTLA4 function and MHC II molecules (adapted from 
Vignali et al. 2008). 
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1.3 IFN-γ and IL-10 in the immune system 
1.3.1 IFN-γ; signalling pathways and functions 
The study published by Wheelock in Science in 1965 reported that the exposure of 
human leukocytes to the mitogen phytohemagglutinin was able to induce the 
production of an interferon-like molecule with antiviral activity (Wheelock, 1965). The 
molecule Wheelock identified is today known as IFN-γ or type II interferon. The term 
“interferon” indicates the ability of this class of molecules to “interfere” with viral 
replications. Although this was the characteristic that allowed the identification of 
IFN-γ, it is now known that the structure and the receptors of IFN-γ share limited 
homology with the one of type I interferons (i.e. IFN-α and IFN-β) and its signalling 
on effector cells of the immune system, rather than its anti-viral function, mediates its 
predominant role (Pestka et al., 2004). The IFN-γ gene is located on the human 
chromosome 12 and encodes for a non-covalent homodimer (Zimonjic et al., 1995). 
Several transcriptional factors bind to the IFN-γ promoter positively regulating gene 
transcription suggesting that the activation of this gene is multifactorial and requires 
several steps. The promoter of IFN-γ contains binding sites for the transcription factors 
ying yang 1, nuclear factor of activated T cells (NFAT), activated protein 1, nuclear 
factor kB and the master regulator of TH1 differentiation, T-bet (Kiani et al., 2001; 
Sica et al., 1997; Sweetser et al., 1998; Szabo et al., 2000). Hence, the activation of 
IFN-γ is dependent on and can be initiated by different stimuli. The receptor for IFN-γ 
belongs to the type II cytokine receptor class and comprises of two subunits known as 
IFNGR1 and IFNGR2, which upon interaction with IFN-γ oligomerize and form a 
heterodimer (Ahmed and Johnson, 2006). The IFN-γ receptor signalling chains have 
binding motifs for the Janus tyrosine kinase (Jak)1, Jak2 and STAT1 which are 
recruited during signal transduction and mediate the intracellular pathways of IFN-γ 
signalling (Katsoulidis et al., 2005). Upon the interaction between IFN-γ and its 
receptor, Jak2 auto-phosphorylates and consequently induces Jak1 phosphorylation. In 
turn, Jak1 phosphorylates target tyrosines on the IFN-γ receptor allowing the docking 
and formation of STAT1 dimers (Leonard, 2001). Activated STAT1 dimers dissociate 
from the receptor intracellular chains and translocate to the nucleus where they 
promote or inhibit transcription of target genes (Ehret et al., 2001; Nguyen et al., 
2000). IFN-γ is a major effector cytokine of TH1 cells as it promotes the development 
of TH1 responses (see paragraph 1.1.7) both on a transcriptional level (e.g. positive 
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regulation of T-bet and inhibition of GATA-3) and on a cellular level (e.g. induction of 
TH1 skewing cytokines by APCs). Several studies have shown that IFN-γ is not only 
the main TH1 cytokine but that it is also produced by other immune cells including 
CTLs, NK cells, NKT cells, monocyte/macrophage and DCs (Mosmann et al., 1997; 
Leite-De-Moranes et al., 1998; Wherry et al., 1991). Whilst innate production of IFN-γ 
is thought to be associated with promotion of inflammation during the early phases of 
an immune response towards a pathogen, the production of IFN-γ by T cells is known 
to be important in orchestrating adaptive immune responses (Schoenborn and Wilson, 
2007). The production of IFN-γ is mainly induced in response to IL-12 or IL-18 
cytokines, which can induce an increase of IFN-γ production by macrophages, NK 
cells and T cells (Akira, 2000; Munder et al., 1998; Schindler et al., 2001). Other 
activating signals can induce IFN-γ production independently of cytokine signalling; 
for example NK cells, via the engagement of TLRs and NKG2D, can secrete IFN-γ 
(Girart et al., 2007). Macrophage infection or activation up-regulates the production of 
IL-12 and chemokines such as macrophage inflammatory proteins (MIPs). Such 
chemokines are pivotal in promoting migration of innate cells, such as NK cells, to the 
site of infection inducing the concomitant production of IL-12, which in turn promotes 
the synthesis and secretion of further IFN-γ (Salazar-Mather et al., 2000). Numerous 
IFN-γ regulated proteins involved in the migration of immune cells to the site of 
inflammation have been described. IFN-γ has been shown to up-regulate the 
expression of chemokines such as chemokine (C-C motif) ligand 5, MIP-1α and IFN-
inducible protein 10; these factors promote leukocyte diapedesis and the induction of 
adhesion molecules expression such as intercellular adhesion molecule 1 (ICAM) and 
vascular cell adhesion molecule-1 (VCAM-1) (Gil et al., 2001; Jesse et al., 1998; Taub 
et al., 1993a; Taub et al., 1993b). 
In addition to regulating cell trafficking and cytokine production, IFN-γ impacts 
several other pathways of cell mediated immunity. These include: MHC class I and 
class II antigen presentation pathways, macrophage activation, B cell isotype switching 
and T helper differentiation (Schoenborn and Wilson, 2007). IFN-γ stimulation 
induces the up-regulation of both the class I MHC heavy chain and the β2-
microglobulin which interacts with the class I MHC heavy chain for the formation of 
the MHC I. This associates with foreign antigens favouring presentation to CTLs in 
order to promote cytotoxic activity mainly against viral antigens (Decker et al., 2002; 
Johnson and Pober, 1990; Wallach et al., 1982). IFN-γ also impacts on the 
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composition of the proteasome subunits favouring the formation of the immunosome; 
this is achieved by up-regulating the expression of MHC encoded subunits (i.e. Low 
Molecular Mass Polypeptide 2 and 7) which can replace the β1 , β2 and β5 subunits of 
the proteasome increasing the quantity and efficiency of MHC I peptide generation and 
loading (Belich et al., 1994). IFN-γ has also a key role in the up-regulation of MHC II 
molecules mainly in APCs including B cells, DCs, monocytes and macrophages 
(Cresswell, 1994). IFN-γ up-regulates MHC II expression by increasing the expression 
of the invariant chain (Ii), and of cathepsins B, H and L, which are cysteine proteases 
implicated in the processing of antigens and in the maturation of MHC II molecules at 
the level of lysosomes (Lafuse et al., 1995; Lah et al., 1995). The key mediator 
regulating the expression of such genes is the class II transactivator (CIITA), an IFN-γ 
induced protein which acts as the limiting component in a multimeric complex 
involved in the transcriptional regulation of MHC II associated genes (Chang and 
Flavell, 1995). 
One of the most important functions of IFN-γ is the activation of macrophages 
characterised by enhanced phagocytic and microbicidal functions in the contest of 
intracellular microbes infections. Macrophages stimulated by IFN-γ in conjunction 
with other activating signals, such as TLRs engagement by microbial antigens or 
CD40 signalling, up-regulate the expression phagolysosomal enzymes (Ahmed and 
Johnson, 2006). A pivotal enzyme in the activation of macrophages is the inducible 
nitric oxide synthetase (iNOS) (Ma et al., 2003). iNOS catalyses redox reactions 
producing nitric oxide a key mediator of microbe killing by macrophages (Shiloh et 
al., 1999). The microbicidal activity of macrophages is also enhanced by the IFN-γ 





). The NADPH oxidase generates reactive oxygen species such as 
superoxide O
2-
 (Cassatella et al., 1990). The importance of the NADPH oxidase 
activity is highlighted by human genetic deficiencies which cause chronic 
granulomatous diseases with recurrent and fatal infections (Song et al., 2011). IFN-γ 
has been also implicated in the regulation of B cell isotype switching. Different 
cytokines are involved in such process with IL-4 playing a preponderant role (Pene et 
al., 1988). However, it has been reported that IFN-γ stimulates B cell isotype switching 
favouring the subclasses IgG2a and IgG2c which are also involved in classical 
complement activation (Bossie and Vitetta, 1991; Finkelman et al., 1988; Yoshida et 
al., 1994). Similarly to the opposing effects of IFN-γ to IL-4 on T helper skewing (i.e. 
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favouring of TH1 rather than TH2 differentiation) IFN-γ has been found to have an 
antagonistic effect to the IL-4 mediated isotype switching by inhibiting isotypes such 
as IgE and IgG1 (Coffman and Carty, 1986). 
 
1.3.2 IL-10; signalling pathways and functions 
The immunosuppressive properties of IL-10 were clear since its discovery as it was 
initially identified as a cytokine synthesis inhibitory factor of TH1 induced cytokines 
such as IFN-γ, TNF and IL-2 (Fiorentino et al., 1989). IL-10 is now widely recognised 
as the canonical immunosuppressive cytokine and numerous studies have shed light on 
its structure and signalling pathways highlighting its therapeutic potential in 
inflammatory, infectious and autoimmune pathologies (Moore et al., 2001). The IL-10 
gene is located on human chromosome 1 and encodes for a heterodimer of 36 kDa. 
The two subunits of IL-10 consist of six amphipathic helices and are stabilized by 
intra-molecular disulphide bridges (Zdanov et al., 1995). The regulation of the IL-10 
gene is complex and several transcription factors have been described. STAT3, the 
transcription factor specific protein 1 (SP1) and the IFN-regulatory factor 1 (IRF1) are 
among the main trans-activators of the IL-10 promoter described for human and mouse 
macrophages and T cells (Asadullah et al., 2003; Staples et al., 2007; Ziegler-
Heitbrock et al., 2003). The IL-10 promoter comprises also binding sites for GATA3, 
which was shown to be a key transcription factor for IL-10 in TH2 cells, and c-Maf, 
which enhances IL-10 expression in LPS stimulated macrophages and has been 
associated to IL-10 production in different T helper subsets (Cao et al., 2005; 
Shoemaker et al., 2006). The receptor for IL-10 belongs to the type II cytokine 
receptor family and is composed of two chains, known as IL-10R1 and IL-10R2 
characterised by extracellular, transmembrane and intracellular domains (Liu et al., 
1994). Jak1 and the Tyrosine Kinase-2 (Tyk2) constitutively interact with the IL-10R1 
and IL-10R2 respectively, mediating the first signalling events upon IL-10/IL-10R 
interaction (Finbloom and Winestock, 1995). Upon activation Jak1 and Tyk2 
phosphorylate tyrosine residues of the IL-10R1 intracellular chain promoting the 
association of STAT3 to the IL-10R1 (Donnelly et al., 1999). Phosphorylation of 
STAT3, STAT1 and STAT5 proteins allows the generation of homo- or hetero-dimers 
which translocate into the nucleus where they bind to STAT-binding elements and 
regulate the transcription of several genes (Schaefer et al., 2009; Tsuji-Takayama et 
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al., 2008). STAT3 has been implicated in the regulation of the transcription of anti-
apoptotic and cell-cycle progression genes such as BCLXL, cyclins and c-Myc (Otero 
et al., 2006; Pandey et al., 2009). Important mediators of IL-10 signalling are the 
suppressors of cytokine synthesis (SOCS)-1 and SOCS-3 which have been shown to be 
induced by IL-10 signalling via a Jak-STAT dependent pathway (Yoshimura et al., 
2007). In particular, SOCS-1 inhibits IFN-γ and IL-4 signal transduction by binding to 
Jak kinases and interfering with their enzymatic activity (Alexander et al., 1999). 
SOCS3 has been shown to inhibit the expression of TNF and IL-1 in monocytes 
(Meisel et al., 1996). Importantly IL-10 has also been shown to negatively regulate the 
p38/MAPK activation pathway consequently inhibiting TNF translation by interfering 
with the LPS-induced polysome coupling of TNF-mRNA in macrophages 
(Kontoyiannis et al., 2001).  
IL-10 can be produced by many cell types of the innate and adaptive immune system; 
in the latter IL-10 production is not only associated to T cells with regulatory activity 
(paragraph 1.2); T helper cells subsets and CD8
+
 T cells are able to produce IL-10 
(Moore et al., 2001). Furthermore, IL-10 production by innate cells of the immune 
system has been reported. In fact, macrophages, DCs and neutrophils can express IL-
10 in response to appropriate stimuli. IL-10 production by macrophages and myeloid 
DCs can be stimulated upon the engagement of TLR2, TLR4 and TLR9 (Boonstra, A. 
et al., 2007; Siewe et al., 2006). TLR-independent production of IL-10 has been 
demonstrated as in the case of dectin 1 (a C-type lectin) stimulation of DCs (Rogers, et 
al., 2005). Immunosuppressive agents (e.g. Vitamin D3) and IL-10 itself have been 
shown to induce the differentiation of a specific subset of DCs known as tolerogenic 
DCs due to their ability to induce T cells with regulatory activity in vitro and in vivo 
(Adorini et al., 2004; Wakkach et al., 2003; Chu et al., 2012). Importantly other innate 
immune cells associated mainly with pro-inflammatory functions have been shown to 
produce IL-10 upon TLR and/or C-type lectin receptors engagement. Neutrophils 
(Zang et al., 2009) and mast cells (Grimbaldeston et al., 2007) can in fact be sources of 
IL-10 upon such stimuli. Moreover, in the adaptive immune system T cells do not 
represent the only source of IL-10. B cells with IL-10-mediated regulatory activity 
have been identified in mouse and human systems and their impaired function has been 
described in settings of chronic inflammation and autoimmunity (Blair et al., 2010; 
Burdin et al., 1997). The functions exerted by IL-10 are numerous and go beyond the 
initially identified suppression of IFN-γ, IL-2 and TNF. Acting on T helper subsets IL-
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10 negatively affects proliferation and the activities of several cytokines including IL-2 
and IL-4 consequently inhibiting T cell differentiation and function (Petska et al., 
2004). IL-10 inhibits the expression of MHC class II and costimulatory molecules such 
as CD80 and CD86 on monocytes, macrophages and DCs and also inhibits IL-12 
production (Aste-Amezagaet al., 1998; Ding et al., 1993). IL-10 has also been shown 
to negatively affect chemokine production in DCs, interfering and blocking their 
migration to lymph nodes (Demangel et al., 2002). In particular, IL-10 seems to down-
regulate the expression of CCR7 and up-regulate the expression of CCR5 impacting on 
DCs chemotaxis in vitro and impairing the in vivo homing of DCs to secondary lymph 
nodes (Takayam et al., 2001). Adhesion molecules are also negatively regulated in 
human monocytes by IL-10; in these cells IL-10 has been shown to down-regulate the 
expression of intercellular adhesion molecule 1 (ICAM-1) and of B7 molecules 
(Willems et al., 1994). Moreover, IL-10 promotes the development of B1 cells (Ishida 
et al., 1992) and in combination with IL-18, favours the cytotoxic activity NK cells 
(Cai et al., 1999). The importance of IL-10 in the maintenance of immune homeostasis 
has been reported in vivo by human mutations of the IL-10 receptor chains which are 
associated to colitis and by murine models of IL-10 deficiency characterised by fatal 
immunopathology in several infection models including Toxoplasma gondii, malaria, 
and Trypanosoma cruzi (Franke et al., 2008; Taub et al., 1993a) Gazzinelli et al., 1996; 
Hunteret al., 1997; Li et al., 1999). 
 
1.4 The complement system – an outline  
The canonical view of complement places this enzymatic cascade as an effector 
mechanism of the mammalian innate immune system. Since its discovery the main 
effector functions of the complement system have been related to bacterial lysis, 
opsonisation and phagocytosis of invading microbes. However, the understanding of 
complement as a sole innate effector system able to rapidly react to pathogen 
associated molecular patterns (PAMPs) has been challenged in the past decades. New 
roles have emerged for complement in tissue homeostasis and adaptive immunity and 
multiple efforts from the scientific community have shown how complement guides 
multiple other processes that include: initiation of local inflammation, clearance of 
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immune complexes, processing of apoptotic and necrotic cells, shaping and regulation 
of the humoral and cell-mediated adaptive immune responses (Ricklin et al., 2010).  
The link between complement and adaptive immunity has been evident since the 
discovery of the complement activity against bacteria by Jules Bordet in 1901. In fact, 
the term complement was used by Bordet to explain how a heat sensible fraction 
present in immunized serum was essential to integrate (i.e. complement) the activity of 
antibodies for the lysis of cholera vibrios (Bordet et al., 1901). This was the first 
observation indicating not only an important effector function of the complement 
system but also suggesting a modality of humoral immunity regulation by complement 
components. Several mechanisms of adaptive immune responses regulated by 
complement have been highlighted and are described in the following paragraphs.  
 
1.4.1 Complement activation and key effector functions 
To date the components of the complement system account for more than 30 players 
including proteases, anaphylatoxins, receptors and regulators (Carroll, 2008). Three 
different activation pathways of the complement system are widely accepted and 
converge into a key process; the cleavage of the third component of the cascade C3 
into C3a and C3b (Figure 1.6). The antibody dependent pathway of complement 
activation inferred by Bordet is known as classical pathway (CP) (Lafuse et al., 1995). 
The activation of the complement cascade in the CP pathway requires the binding of 
complement component C1 to the Fc region of IgG clusters or IgM antibodies that 
have recognised antigen (Figure 1.6). Thanks to the C1-associated proteases C4 is 
cleaved into C4a and C4b. C4b binds C2 which is also cleaved into C2a and C2b to 
generate the CP C3 convertase C4b2b (a change in the nomenclature identifies C2b as 
the protease fragment rather than the small non proteolytic fragment)(Ricklin et al., 
2010). 
The alternative pathway (AP) refers to the constant hydrolytic ‘tick over’ of C3, a 
process that is innocuous to the host (Lafuse et al., 1995). The hydrolysis of C3 
generates the C3(H2O) accessible to the binding of factor B which in turn is cleaved by 
factor D generating a soluble C3 convertase, C3(H2O)Bb which can cleave further C3; 
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the generated C3b can then bind on target surfaces covalently via an activated thioester 
and initiate the generation, in the presence of factor B and factor D, of the AP C3bBb 
convertases. Properdin is also able to induce the alternative pathway activation; 
properdin is a PRR able to recognise foreign cells and to bind fluid phase C3b in order 
to generate the C3bBbproperdin convertase (Spitzer et al., 2007). 
The lectin pathway is initiated by the recognition of carbohydrates structures expressed 
on pathogens by different lectins including the mannan binding lectin (Hambleton et 
al.) and the ficolins (Carroll, 2004; Gros et al., 2008). The details of each activation 
pathway can be found in Figure 1.6. Briefly, MBL interacts with an MBL associated 
serine protease (MASP) which cleaves C4 and/or C2 to generate the C3 convertase 
C4b2b. The lectin pathway is likely to be the oldest in terms of evolution since 
prochordates (Le Friec and Kemper, 2009) present MBL like proteins. The presence of 
complement components in different evolutionary phyla is a reflection of the efficacy 
and the importance of such system as a defence mechanism. The activation of the 
complement pathway on a target cell induces generation of further C3b deposition and 
opsonisation or bind to C3 convertases generating the C5 convertases (AP, C3bBb3b 
or LP and CP, C4b2b3b) (Ricklin et al., 2010). The C5 convertases cleave C5 in C5a 
and C5b. In the terminal pathway of the complement activation C5b interacts with C6 
and C7 and once it is inserted in the membrane it interacts with C8. Only when C9 is 
bound complement membrane attack complex (MAC) activity is maximal and lytic 
pores can be formed to promote lysis of pathogens such as gram negative bacteria and 
parasites (Bhakdi and Tranum-Jensen, 1988).
The three complement activation pathways generate C3 and C5 fragments of circa 9 
kDa known as anaphylatoxins C3a and C5a (Carroll, 2004). These are potent signal 
triggers for the G protein-coupled receptors; C3aR and C5aR. Such receptors are 
expressed on mast cells, eosinophils, basophils, neutrophils and lymphocytes; they 
participate to inflammatory processes by inducing the recruitment and activation of the 
above mentioned cell types and by promoting macrophage phagocytosis (Gerard and 
Gerard, 1991; Itoh et al., 1991). Parallel to the effect of the anaphylatoxins is the 
activity of opsonins among which C3b, C4b and downstream product C3d are key in 
inducing phagocytic activity in neutrophils and macrophages via the binding of the 
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respective complement receptors (i.e. CR1 and CR2) (Dempsey et al., 1996; Law et al., 
1980; Ricklin et al., 2010). 
 
Figure 1.6 Complement cascade. 
The activation of the complement cascade via the classical pathway requires the 
binding of complement multimeric complex of C1 to the Fc region of IgG clusters or 
IgM antibodies that have recognised antigen. C1 is composed of C1q –the molecule 
recognising the Fc region-, C1r2 and C1s2, two serine proteases. By binding two Fc 
regions of immunoglobulins C1q allows for the associated protease C1r to cleave and 
activate C1s. As a consequence of C1s activation, C4 is cleaved and C4b binds C2 
which is then cleaved into C2a and C2b. This generates the C3 convertase C4b2b. The 
lectin pathway is initiated by mannose-binding lectins (Hambleton et al.) or ficolins 
recognised sugars. MBL associated serine proteases (MASPs) cleave C4 and/or C2 and 
generate the C3 convertase C4b2b. The AP is initiated by the spontaneous hydrolysis 
of C3 to C3(H2O) which can bind factor B (fB). Bound fB can be cleaved by factor D 
allowing the generation of the AP C3 convertase C3bBb. Amplification of the 
complement cascade by C3 convertases favours binding of C3b to either CP, AP or 
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lectin pathway C3 convertases generating C5 convertases which cleave C5 into C5a 
and C5b. The association of the following fragments of the complement cascade (i.e. 
C6-9) to C5b determines the formation of the membrane attack complex and 
promoting cellular lysis (Lafuse et al., 1995). 
 
1.4.2 Complement regulation 
The autocatalytic nature of the complement amplification and the indiscriminate 
diffusion of complement effector molecules to surrounding surfaces require a rapid and 
tight control of the cascade’s activation to prevent unwanted deposition on self (Kohl, 
2006). This need is reflected in the fact that the number of complement regulators and 
inhibitors is actually higher than the core zymogens identified in the complement 
system (C1 to C9) (Table 1.1). Complement regulators/inhibitors are divided in fluid 
phase or membrane bound; they are essential in allowing the enzymatic cascade to 
neatly differentiate between the host and non-self surfaces or self-modified cells 
(Carroll, 2004). This allows avoiding acute and/or chronic activation that would 
otherwise produce excessive damage among the tissues surrounding the site of 
infection (Zipfel and Skerka, 2009). Fluid phase complement regulators are present in 
the blood, lymph, synovial and vitreous fluids. They include alternative pathway 
inhibitors such as Factor H, FHL1 and properdin and classical and lectin pathway 
inhibitors such as C1 inhibitor and C4 binding protein (C4BP) (Table 1.1). Membrane 
bound regulators include CD35 (CR1), CD46, CD55 (DAF), CD59 and CRIg 
(complement receptor of the immunoglobulin family) and are more generally directed 
towards C3 and C4 inhibition rather than being specific for a particular pathway as the 
fluid phase inhibitors. 
Complement inhibitors can: 1. Bind directly to their target (C1 inhibitor) and inhibit its 
function, 2. Act as cofactors for the factor I-mediated cleavage of C3b and C4b 
(cofactor activity; factor H, C4BP, CD46 –i.e. membrane cofactor protein, MCP- and 
CD35 –i.e. complement receptor 1, CR1-) 3. Accelerate the decay of convertases 
(CD35 and CD55 –decay accelerating factor, DAF-) or 4. Prevent the formation of the 
MAC and the terminal pathway formation (CD59, clusterin and vitronectin). Further 
additional proteases such as carboxypeptidase N can degrade the anaphylatoxins C3a 
and C5a respectively into C3a desArg and C5a desArg which have less potent pro-
inflammatory properties. 
 













Soluble regulators and effectors 
Factor H None AP C3b and C3d Acquired to 
surface 
Cofactor of Factor I and 
acceleration of AP C3 
convertase decay 
FHL1 None AP C3b Acquired to 
surface 
Cofactor of Factor I and 
acceleration of AP C3 
convertase decay 
Properdin None AP C3 Binds to 
apoptotic 
surfaces 





CP and LP C3a, C4a and 
C5a 
NA Inactivation of anaphylatoxins 
C3a and C5a 
C4BP None CP and LP C4 Acquired to 
surface 
Cofactor for factor I and 
acceleration of CP C3 
convertase decay 





Activation of CP 
C1INH None CP and LP C1r, C1s and 
MASP2 
NA Blocks serine protease, suicide 
substrate for C1r, C1s, MASP2, 
coagulation factors and C3b 




Inhibition of C5  convertase and 
TCC assembly 
Clusterin SP-40, 40 and  
apolipoprotein j 
TP C7, 8B, C9 
and TCC 
NA Transport of cholesterol, HDL, 
APOA1 and lipids 
Vibronectin S-protein TP C5b-7 and 
TCC 
NA Adhesion protein, fibronectin-
mediated cell attachment and 
Arg-Gly-Asp site coagulation I 
immune defence against 
Streptococcus spp. 
 
Surface bound regulators and effectors 
CR1 CD35, Immune 
adherence receptor 
C3 C3b, iC3b, C4b 
and C1q 
Nucleated cells, 
erythrocytes, B cells,  
leukocytes, monocytes 
and FDCs 
Clearance of IC 
CR2 CD21 and Epstein-
Barr virus receptor 
C3 C3dg, C3d and 
iC3b 
B cells, T cells and 
FDCs 
Regulation of B cell 
function, B cell co-
receptor and receptor of 
C3d tagged ICs 
CR3  MAC1,CD11b-CD18 
and αMβ2 integrin 











 T cells 
iC3b enhances the 
contact of opsonized 
targets, resulting in 
phagocytosis and 
adhesion by CR3 
CR4 CD11c-CD18 and 
αXβ2 integrin 




CRIg VSIG4 C3 C3b, iC3b and 
C3c 
Macrophages iC3b-mediated 















Ligand Cell surface binding 
or expression 
Function 
Surface bound regulators and effectors 
CD46 MCP C3 C3b and C4b All cells except 
erythrocytes 
C3 degradation, cofactor 
for factor I and factor H, 
and effector for T cell 
maturation 
CD55 DAF C3 C4b2b ad 
C3bBb 
GPI anchor expression 
by most cell types 
including erythrocytes, 
epithelial and endothelial 
cells 
Inhibition of TCC 
assembly 
CD59 Protectin TCC C8 and TCC GPI anchor expression 
by most cell types and 
most nucleated cells 
Inhibition of TCC 
C3aR None C3 C3a Neutrophils, monocytes, 
eosinophils, APCs, T 
cells, astrocytes, 
neurons and glial cells 
Immune cell recruitment 
and inflammation 
C5aR CD88 C5 C5a Myeloid cells, 
neutrophils, monocytes, 
eosinophils, APCs, T 
cells endothelial cells 
and renal tubular cells 
Immune cell recruitment 
and inflammation 
C5L2 None C5 C5a Macrophages and 
neutrophils 
Immune cell recruitment 
and inflammation and 
possibly acts as a decoy 
receptor 
C1qR CD93 CP C1q Monocytes and B cells Phagocytosis and cell 
adhesion 
SIGNR1 CD209 CP C1q DCs and microglial cells Signalling and 
phagocytosis 
 
Table 1.1 Description of complement regulatory and complement receptor 
proteins substrates and functions. Complement regulators can be divided in fluid 
phase and membrane bound. Fluid phase regulators include; Factor H, FHL1, 
properdin (AP inhibitors), C1 inhibitor, C4 binding protein (C4BP), CFHR1 and 
carboxypeptidase N (CP and lectin pathways inhibitors). Membrane bound regulators 
include CD35 (CR1), CD46, CD55 (DAF), CD59 and CRIg (complement receptor of 
the immunoglobulin family). Complement receptors (CR) CR1, CR2, CR3 and CR4 
are expressed on different subsets of immune cells and are involved in multiples 
cellular processes (Zipfel and Skerka, 2009). APOA1, apolipoprotein A; C, 
complement component; C1INH, C1 inhibitor; C52L C5a receptor-like 2; CFHR1, 
complement Factor H related protein 1; DAF, decay-accelerating factor; DCs, 
dendritic cells; FDCs, follicular dendritic cells; FHL1, Factor H-like protein 1; GPI, 
glycosylphosphatidylinositl; HDL, high-density lipoprotein; ICs, immune complexes 
MASP2, mannan-binding lectin serine protease 2; MCP, membrane cofactor protein; 
NA, not applicable; SIGNR1, mouse homologue of DC-SIGN, SIGN-related 1; TCC, 
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1.4.3 Complement and adaptive immunity - B cells 
Experimental evidence linking the complement system to humoral immunity has only 
become available several decades after the discovery of complement by Bordet in 
1901. In the 1970s, following the identification of receptors for C3 on B cells 
(Nussenzweig, 1971), Pepys demonstrated that transiently depleting serum of C3 
through cobra venom factor (which leads to consumption of circulating C3) impairs 
the humoral response towards T cell dependent antigens (Pepys, 1972). Moreover, 
mice deficient for complement fragments C1q, C3 and C4 (Cutler et al., 1998; Moon et 
al., 1997) and complement receptors CR1 (CD35) and CR2 (CD21) (Ahearn et al., 
1996; Karp et al., 1996; Ochsenbein et al., 1999) do not develop a normal humoral 
response and are characterised by impaired antibody class isotype switching and a 
reduced size and number of germinal centres. Complement fragments also influence B 
cell activation and differentiation. The co-ligation of the BCR with the co-receptor 
CD21/19/81 through C3d coated antigens, lowers the threshold of B cell activation up 
to 10.000 fold (Dempsey et al., 1996). Further, survival signals mediated by the 
CD19/21/81 and the BCR have been shown to be vital for B cells in germinal centres. 
In fact, CR2
-/- 
B cells are outgrown by WT CR2 B cells in an active humoral response; 
hence CR2 signals are fundamental in lowering BCR reactivity which allows for B cell 
maturation (Barrington et al., 2005). Although most of the in vivo evidence described 
so far comes from mouse models, also human genetic deficiencies stress the 
importance of complement in B cell responses. C3 and C4 deficiencies are associated 
to impaired antibody responses towards T cell dependent and independent antigens 
(Carroll, 2008). In particular, Drouet’s group recently showed that a C3-deficient 
paediatric patient was unable to generate B cell memory; in fact attempt of vaccination 
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1.4.4 Complement and adaptive immunity - T cells 
Given the strong links between complement and the activation/maturation of B cells, a 
role for the complement system in the shaping of T cell responses has been easily 
envisaged. Most of the information available to date on the complement/T cell axis has 
been generated using small animal models (Botto et al., 2009; Zhou, 2012). The most 
studied complement molecules impacting on T cell immunity are the anaphylatoxins 
receptors and complement regulators (e.g. CD46, CD55 and CD59) (Kemper et al., 
2007). Because CD46 is only expressed widely in humans but not on rodent somatic 
cells (Riley-Vargas et al., 2004), a clear separation between data generated using 
mouse models and human cell lines/primary cells is necessary. Thus, whilst the 
following background information is in large part derived from mouse models, human 
related studies will be highlighted to clarify what is known in the two systems. Given 
that the focus of the study in this thesis has been on T cells, the following paragraphs 
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1.4.5 Complement - indirect effects on the shaping of T cell responses 
The influence of complement on T cell biology was initially identified to be mainly via 
the modulation of the function of APCs. As described above (see paragraph 1.3), target 







 or factor D
-/-
 mice have defective antigen uptake/processing and 
lead to weaker allospecific T cell reactivity (Heeger et al., 2005; Kerekes et al., 2001; 
Lalli et al., 2007; Lalli et al., 2009; Peng et al., 2008; Peng et al., 2006; Schoenberger 
et al., 1998; van Montfoort et al., 2007). Several studies have highlighted how local 
synthesis of complement components upon cognate interactions between APC and T 
cells is a key process in T cell immunity (Heeger et al., 2005; Lalli et al., 2007; Peng et 
al., 2008; Strainic et al., 2008). Heeger’s study (2005) initially identified the 
importance of local complement production in mouse APCs. In this study, absence of 
DAF (CD55) on APCs induced a stronger T cell proliferation and cytokine production 
in comparison to WT APCs due to the increased production of local complement 
components. Further studies by Peng et al., (2006), Strainic et al., (2008) and Pavlov et 
al., (2008) supported the importance of immune cell-derived complement describing 
the impact of local synthesis of alternative pathway complement components such as 
C3, Factor B, Factor D and C5 on the way APCs shape T cell responses in vitro and in 
in vivo models of transplantation and infection. Several studies demonstrated that 
engagement of C3aR and C5aR G-protein-coupled receptors on human monocytes-
derived DCs and on mouse DCs induce a down-regulation of cAMP levels and 
promotes activation of PI3k/AKT, ERK and NF-kB pathways (Peng et al., 2009; 
Schoenberger et al., 1998; Strainic et al., 2008). Importantly these signalling events 
promote the up-regulation of key APC co-stimulatory molecules including MHC II, 
CD80, CD86 and CD40L and the production of TH1 and TH17 skewing cytokines, 
mainly IL-12 and IL-23 in both human and mouse systems (Hawlisch et al., 2004; 
Schoenberger et al., 1998; Strainic et al., 2008). Interfering with either APC-T cell 
interaction at the level of B7-1/CD28 recognition or with C3aR and C5aR signalling, 
translates into lower expression of co-stimulatory molecules (namely MHC II, CD80, 
CD86), lower production of IL-12 and as a consequence weaker stimulation of TH1 
cells in comparison to WT APCs (Peng et al. 2006; Lalli et al., 2007; Strainic et al., 
2008). Importantly anaphylatoxin signalling seems to be involved in TH2 biology; in 
fact in a mouse model of asthma C3aR deficiency was found to be associated with 
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decreased IL-4 production and TH2 responses  with consequent protection against 
airway hyperreactivity (Drouin et al., 2002). Further examples of how complement can 
influence T cell function via DCs are given by CD46. Engagement of CD46 on human 
DCs promotes IL-23 production which induces higher secretion of IL-17 by CD4
+
 T 
cells (Vaknin-Dembinsky et al., 2008). Pathogens binding to CD46 have also been 
shown to affect T cell responses. Neisseria species, human herpes virus 6 and measles 
virus bind to CD46 reducing the expression of IL-12 in APCs thus inhibiting TH1 
responses and favouring infection through cellular immune suppression (Karp and 
Wills-Karp, 2001). Interesting insights have risen regarding the network of TLR and 
complement signalling in APCs. Hawlisch et al., (2005) reported of the negative 
regulation of C5a on TLR4 and CD40 signalling in IFN-γ primed macrophages which 
consequently decreased cytokine production (IL-12, IL-23 and IL-27) and limited TH1 
development (Hawlisch et al., 2005). A more recent study from Kohel’s group 
determined the importance of the C5aR expressed on splenic DCs regarding its 
influence in the differentiation of T-reg cells and TH17. In the absence of C5a 
signalling on TLR2 stimulated splenic DCs there was a down modulation of TH1 
skewing cytokines and an increase in the production of TH17 and T-reg skewing 
cytokines including TGF-β, IL-23 and IL-6 (Sweetser et al., 1998).  
1.4.6 Complement; direct effects on the shaping of T cell responses 
Pivotal complement mediated signals on T cells can also be directly delivered by the 
anaphylatoxins C3a and C5a (Zhou et al., 2011). The expression of the C3aR and 
C5aR has been documented in both mouse and human T cells. Whilst human C3aR is 
only expressed upon T cell activation (Werfel et al., 2000), the C5aR is constitutively 
expressed at low levels and upregulated following T cell activation (Nataf et al., 1999). 
Mouse T cells have been shown to upregulate the expression of C3aR and C5aR upon 
activation and to induce signalling through the PI3k and Akt pathways.  Such signals 
transmit anti-apoptotic signals (through the up-regulation of B-cell lymphoma 2) and 
promote proliferation (Lalli et al., 2008; Strainic et al., 2008). 
Several complement receptors and regulators can function as co-stimulators of T cell 
activation and influence T cell immunity (Kemper et al., 2007; Zhou, 2011). The 
expression of CR1 been shown to be present in only 15% of circulating human T cells, 
thus its general role in T cell regulation is unclear. However, functional studies with 
monoclonal antibodies towards CR1 have shown that engagement of this receptor 
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translates in an inhibition of T cell proliferation and of IL-2 and IFN-γ synthesis 
(Mazzucchelli et al., 1996). 
T cell immunity has been shown to be also directly regulated by DAF (CD55) in a 
study by Liu et al. (2005). The authors demonstrated that in the absence of DAF, 
experienced T cells become “hyper-responsive” upon antigen exposure increasing 
IFN-γ and IL-2 production (whilst decreasing IL-10) in comparison to WT T cells 
(Cao et al., 2005). To attest for the importance of these findings in a pathological 
setting the authors investigated the effect of DAF deficiency on the animal model of 
multiple sclerosis known as EAE and showed that DAF deficiency correlated with the 
highest disease score. The hyper-reactivity of DAF-deficient T cells was due to the 
increased availability of complement fragments (i.e. C3a and C5a) due to a decrease in 
complement inhibition in DAF deficient cells. However, as described under 1.3.5 later 
studies showed that local complement fragments are essential in regulating both APCs 
and T cells functions, further extending the initial findings by Liu’s. The role of DAF 
has also been investigated in the human immune system. The co-engagement of CD3 
and DAF (CD55) on CD4
+
 T cells in the presence of IL-2 is able to induce lymphocyte 
proliferation and up-regulation of the activation markers CD25 and CD69. T cells 
activated through CD3 and DAF, via monoclonal antibodies or natural ligands (i.e. 
CD97) also showed a significant increase in the secretion of IL-10 and GM-CSF. 
Importantly the authors showed that the effects mediated by CD3 and DAF were not 
due to the decreased complement inhibition but rather to DAF signalling (Capasso et 
al., 2006). Similarly, Korty et al., (1991) showed that the engagement of the MAC 
inhibitor CD59, in the presence of phorbol myristate acetate (PMA) and ionomicin and 
of anti-Ig antibodies, was also able to induce signalling events in human resting T 
cells. The authors described an increase of intra-cytoplasmic Ca
2+
 and IP3 and a 
concurrent increase in IL-2 production and T cells proliferation (Korty et al., 1991). 
Further studies on CD59 on human CD4
+
 T cells have shown that CD59 expression is 
increased in the memory subset of T cells. Blocking CD59 on T cells stimulated 
through CD3 in the presence of APCs translated in a dose dependent increase of T cell 
proliferation and IFN-γ production in comparison to CD3 only stimulated T cells 
(Sivasankar et al., 2009). A role of complement regulator CD46 in T cell regulation 
has also been described (Kemper et al., 2003.). Given the central role of CD46-
mediated signalling events on human T cells in this thesis, the role of CD46 will be 
discussed in a separate paragraph (see paragraph 1.4). 




1.5.1 CD46; structure and signaling 
CD46 is a type I transmembrane glycoprotein firstly identified as a complement 
inhibitor but involved in many biological processes including pathogen infection 
(Gaggar et al., 2003), fertilization (Riley et al., 2002) and T cell regulation (Shalapour 
et al.). In humans, the gene encoding CD46 is located on chromosome 1q32 within the 
regulators of complement activation gene cluster (Lublin et al., 1988). CD46 
comprises four short consensus repeats (SCRs), an alternatively spliced region (B 
and/or C regions), highly glycosylated and rich in the aminoacids serine, threonine and 
proline (STP) followed by 12 amino acids and a transmembrane region (Figure 1.7). 
Due to alternative splicing, CD46 can be expressed with two distinct cytoplasmic tails: 
CYT-1 (16 amino acids) or CYT-2 (23 amino acids), both containing signaling motifs 
and putative nuclear localization sequences. The co-expression of the two isoforms on 
all human nucleated cells leaves their specific functions difficult to analyze. An 
important limitation in the analysis of CD46 signaling is the lack of a small animal 
model. Indeed, rodents only express CD46 on the spermatozoal acrosome membrane, 
and CRRY, the closest functional homologue of CD46, only shares the complement 
inhibitor features but not the T cell modulatory or pathogen-binding functions 








 Chapter 1 Introductions 
57 
 
1.5.2 CD46 functions 
1.5.2.1 Complement regulation 
The complement regulatory function of CD46 was the first to be described (Lublin et 
al., 1988). CD46 acts as a cofactor for the factor-I mediated cleavage of C3b and C4b 
deposited on host tissue, and therefore plays a key role in the inhibition of unwanted 
complement activation on self-tissue (Kemper et al., 2005). This complement 
regulatory function has been attributed to SCRs 2-4 through which CD46 binds C3b or 
C4b (Persson et al., 2010). Mutations that occur in the CD46 gene have been shown to 
predispose to the complement mediated disease (Richards et al., 2003), atypical 
Hemolytic Uremic Syndrome. HUS is characterized by microangiopathic haemolytic 
anaemia, thrombocytopenia and acute renal failure that occur as a consequence of 
microthrombi in the glomeruli (Maga et al., 2011). Different mutations of the CD46 
gene can affect either the availability of CD46 to bind C3b or the expression levels of 
CD46 on the endothelium. As a consequence the impaired ability to inhibit C3b 
deposition on host cells determines an increased activity of complement activation on 
the host through alternative pathway activation and increased deposition of C3b and 
thus damage of the endothelium (Goodship et al., 2004). 




Figure 1.7 CD46 Structure. 
The extracellular portion of CD46 comprises four short consensus repeats (SCR1 to 4) 
which are exploited by pathogens as docking sites for cellular infection. SCR1 is 
responsible for the sperm-egg interaction whilst SCR2 to 4 are involved in the 
complement regulatory function of CD46. Recent insights on the structure of the 
extracellular portion of CD46 by Personn et al., (2010) suggest a “bend” between 
SCR3 and SCR4 schematically represented in the figure. The highly glycosylated and 
serine, threonine and proline (STP)-rich regions B and/or C are generated by 
alternative splicing and are followed by a 12 amino acids peptide linked to the 
transmembrane region. Each of the two distinct cytoplasmic tails, CYT-1(16 amino 
acids) or CYT-2 (23 amino acids), contains phosphorylation sites (e.g. for protein 
kinase C in CYT1 and for Src in CYT2) and mediates intracellular signaling (Cardone 
et al., 2011). 
 
1.5.2.2 Pathogen receptor 
CD46 is also an entry receptor for several pathogens. Both measles virus (MV) and 
adenoviruses bind the extracellular domains SCR1 and 2 of CD46, via the viral 
proteins hemaglutinin and fiber knob, respectively (Gaggar et al., 2003; Naniche et al., 
1993). The interaction of human herpesvirus-6 (HHV-6) and CD46 requires SCR2 and 
SCR3 (Santoro et al., 1999). Engagement of CD46 by pathogens has a direct impact on 
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the innate response by modulating cytokine secretion of innate immune cells and 
attests to its ability to transmit intracellular signals. For instance, MV and HHV-6 
inhibit respectively primary monocytes and macrophages production of IL-12, a key 
cytokine involved in the TH1 differentiation and activation of both NK and T cells 
(Smith et al., 2003). Moreover, recombinant adenovirus 35 is able to inhibit DCs 
maturation and naïve CD4
+
 T cell proliferation and IL-2 production (Adams et al., 
2011). Streptococcus pyogenes interacts with SCR3 and SCR4 of CD46 through the 
bacterial M protein and is able to induce IL-10 production in activated CD4
+
 T cells 
(Giannakis et al., 2002; Okada et al., 1995; Sweetser et al., 1998). Further, the type V 
pili of Neisseria gonorrhoeae and Neisseria meningitidis recognize an epitope on 
SCR3 and the region STP of CD46 (Kallstrom et al., 2001). A role for CD46 in the 
infection of urinal tract by uropathogenic Escherichia coli (E. coli) has also been 
suggested. C3b opsonised uropathogenic E. coli can exploit the binding of C3b to 
CD46 and infect human kidney tubular epithelial cells (Otero et al., 2006). The 
highlighted studies underline CD46’s role as a pathogen receptor and show that its 
engagement induces intracellular signals upon engagement. Particularly the 
observation that CD46 activation strongly modulates cytokine production by 
macrophages (Karp et al., 1996) paved the way for the notion that pathogen’s may 
bind to CD46 because of its immunomodulatory function. The seminal discovery by 
Astier in 2000 that CD46 functions as a co-stimulatory molecule during human CD4
+
 
T cell activation (described in 1.4.2.3) then further increased the interest in the 
signalling capabilities of CD46 on immune competent cells (Astier et al., 2000). 
 
1.5.2.3 CD46: a T cell co-stimulatory molecule 
The most comprehensive data on CD46 signaling pathways have been described in T 
cells. Following CD46 crosslinking with antibodies on Jurkat cells, CD46-CYT-2 
undergoes tyrosine phosphorylation by the Src kinase Lck (Taub et al., 1993b). In 
primary T CD4
+
 cells, engagement of CD46 alone induces activation of the adaptor 
proteins p120CBL and LAT (Astier et al., 2000). Additionally, concurrent activation 
of TCR and CD46 leads to tyrosine phosphorylation of the guanine-nucleotide-
exchange factor Vav, the GTPase Rac and the extracellular signal-regulated kinases 
ERK1/ERK2, important regulators of the MAPK pathway (Zaffran et al., 2001). The 
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functional consequences of the described signaling events are an increased 
proliferation of T cells (Astier et al., 2000) and a strong regulation of cytokine 
production (Kemper et al., 2003). High IL-10 secretion is indeed a feature of CD4
+
 T-





 (Kemper et al., 2003) and γδ T-cells (Truscott et al., 2010) highlights an 
important link between complement and adaptive immunity. Further studies have 
shown how TCR/CD46 engagement on T cell modulates the function of other immune 
cells including DCs and B cells. CD46-activated T cells secrete soluble CD40 ligand 
and granulocyte–macrophage colony-stimulating factor (GM-CSF) supporting DCs 
maturation (Barchet et al., 2006). Further, co-culturing B cells with CD46-induced T 
cells favors B cell production of immunoglobulins (Ig) IgM and IgG1 (Fuchs et al., 
2009). The mechanisms underlying such boost in antibody production is not 
understood but it requires cell-cell contact and secretion of IL-10. Attesting for the 
importance of this mechanism are the findings that T cells from a CD46-deficient 
patient are impaired in promoting Ig production (Fuchs et al., 2009) and that circa 30% 
of CD46 deficient patients develop Common Variable Immunodeficiency (CVID), a 
syndrome characterized by hypo-gammaglobulinemia (Fremeaux-Bacchi et al., 2006). 
Recent data on the effects of CD46 activated T cells on antigen specific T cells 
revealed a mechanism of contact-independent suppression towards mycobacterial 
specific effector T cells. Interestingly the main soluble factor responsible for down 




 and γδT cells was not IL-10 (Truscott et al., 2010). 
This study was the first to prove that supernatants from CD46 activated T cells do not 
have adverse effects on antigen-specific DCs confirming the previous finding of a 
positive influence of CD46 on DC maturation and antigen presentation (Barchet et al., 
2006).  
 
1.5.3 CD46 in Multiple Sclerosis  
Multiple sclerosis (MS) is a neurological disease of that affects the central nervous 
system (CNS). The aetiology of MS is unknown but is thought to result from genetic 
and environmental risk factors (Ramagopalan et al., 2010). Damage to the CNS is 
mediated by auto-reactive T cells and this research area has been highly investigated. 
T-reg cells have been found to be impaired in MS patients, suggesting that T effectors 
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cells would be able to drive an uncontrolled immune response towards CNS derived 
auto-antigens (Haas et al., 2005). In line with these findings is the work by Astier et 
al., (2006) on CD46-induced T cells (Astier et al., 2006): these studies showed that 
CD46 mediated Tr-1 cells induced from lymphocytes of MS patients have a defect in 
the production of IL-10 when compared with healthy donors. Further analyses on the 
function of CD46 in MS patients showed how CD4
+
 T cells are not able to suppress 
bystander effector T cells (Martinez-Forero et al., 2008). Confirming the previous 
studies are in vivo data obtained using a Cynomolgus monkey model of MS. T cells 
proliferation and IL-10 secretion, but not IFN-γ, were impaired upon CD46 activation 
of T cells derived from animals with Experimental Autoimmune Encephalomyelitis 
(Itoh et al., 1991). Patients with MS have been also investigated for DC function upon 
CD46 engagement (Vaknin-Dembinsky et al., 2008). IL-23 increased expression by 
myeloid DCs activated through CD46 was shown to be able to induce IL-17 secretion 
by T cells. IL-17 has been recently identified as a component responsible for the 
damage to CNS and TH17 cells seem to have a pivotal role in driving MS. A recent 
study describing higher IL-17 production in MS derived T cells upon TCR and CD46 
engagement (Yao et al., 2010) further suggests that CD46 signaling may be involved 
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1.6 Hypothesis and aims of the thesis 
The description of the signaling pathways triggered by the engagement of CD46 on 
CD4
+
 T cells (Astier et al., 2000; Zaffran et al., 2001) shed light on the costimulatory 
properties of CD46 and uncovered an existing link between complement and T cell 
biology. The functional significance of CD46 signals in CD4
+
 T cells was shown to be 
of an immunoregulatory nature with important links to human pathology (Astier et al., 
2006; Kemper et al., 2001). In fact, high IL-10 secretion is indeed a feature of CD4
+
 T-
cells stimulated through TCR, CD46 and the IL-2 receptor and impairments in CD46-
induced IL-10 production have been described in multiple sclerosis. Although the 
nature of CD46-activated T cells was found to be mainly immunosuppressive 
(Shalapour et al., ; Truscott et al., 2010) an important additional feature of these cells is 
the secretion of IFN-γ. The biological significance of this observation is not clear. In 
addition, from a translational perspective, the secretion of IFN-γ poses a main barrier 
for the potential usage of CD46-induced IL-10 secreting cells as a therapeutic tool to 
ameliorate graft rejection or autoimmunity and needs to be addressed. 
Given the importance of both the specificity and the strength of signaling in the 
induction of T cell activation and cytokine secretion it was hypothesized that: 
- CD46-induced pro-inflammatory (IFN-γ) and anti-inflammatory (IL-10) 
cytokines are differentially modulated by the strength of the inducing signals 
TCR, CD46, and IL-2 receptor.  
Hence, the main objectives of this study were to: investigate the influence of the 
strength of activating signals on the secretion of IFN-γ and IL-10, understand whether 
specific signals could preferentially skew T cells towards IFN-γ or IL-10 production 
and identify pathways involved in such modulation.  
The identification of a cellular switch mechanism between IFN-γ and IL-10 secreting 
cells, triggered by CD46 and IL-2 signals, prompted further analyses of the different 
cytokine secreting populations in CD46-induced T cells as it was postulated that 
crucial intermediaries in the regulation of such switch mechanism were likely to exist. 
The transcriptional signature of CD46-induced IFN-γ secreting cells was compared 
with the one of IL-10 secreting cells identifying a transcriptional profile consistently 
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observed across biological replicates. The asparagine endopeptidase (AEP) which was 
one of the most differentially expressed genes between IFN-γ and IL-10 producing 
cells, was investigated in order to gather whether this enzyme is a key mediator in the 
switch induced by CD46 or whether it impacts on the production/secretion of IFN-γ 
and IL-10. 
The pathways triggered in CD46-induced IFN-γ and IL-10 producing cells are likely to 
impact in vivo not only bystander immune cells but also the surrounding tissues. In 
addition to the transcriptional signature of CD46-induced IFN-γ and IL-10 producing 
cells, which showed an up-regulation of inflammatory and tissue repair genes 
respectively, previous data generated from the laboratory of Dr. Kemper identified 
molecules involved in epithelial barrier integrity. The CD46 binding kinase, 
Ste20/SPS1-related serine/threonine kinase (SPAK), is important in T cell signalling. 
SPAK has also important functions in epithelial cells and plays key a role in epithelial 
cell barrier integrity (Yan, et al., 2007). Hence, it was postulated that CD46 signals 
may impact intestinal epithelium indirectly via T cell cytokines and growth factors and 
directly via CD46 signalling. In this study the consequences of CD46 activation on 
epithelial cells were assessed with the aim of describing the main consequences of 
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2.1 Cell sources 
2.1.1 Blood and synovial fluid samples 
T cells were obtained from blood samples of healthy volunteers under the approval of 
the South London Research Ethics Committee; reference number 09/H0804/72. Blood 
or synovial fluid from patients with rheumatoid arthritis was collected and processed 
with the approval of the Bromley Research Ethics Committee; reference number 
06/Q0705/20. Healthy donors or patients with inflammatory arthritis (including 
rheumatoid arthritis and juvenile idiopathic arthritis) were recruited and informed 
consent was obtained from all subjects included in the study. Patients with rheumatoid 
arthritis were all female and of the age of 62 (RA patient 1), 39 (RA patient 2) and 54 
(RA patient 3). The juvenile arthritis patient was female and 20 years old (Figure 
3.14). All patients had a disease activity score for 28 joints of over 5.1, representing 
moderately severe activity, despite therapy with a combination of the disease-
modifying anti-rheumatic drugs methotrexate, hydroxychloroquine and sulfasalazine. 
Synovial fluid was obtained during therapeutic arthrocentesis of knee joints performed 
by the leading clinician and collaborator, Professor Andrew Cope (KCL). Healthy 
donors (HD) were all female and of the age of 31 (HD1), 37 (HD2) and 33 (HD3) 
(Figure 3.14). 
2.1.2 Caco-2 cell line  
The Caco-2 (HTB-37) cell line, derived from human colorectal adenocarcinoma was 
obtained from the American Tissue Culture Collection (ATCC) and cultured as per 
manufacturer’s protocol.   
 
2.1.3 Bacteria 
The uropathogenic E.coli strain J96 is a serum-resistant, hemolysin-secreting strain 
that expresses type 1 and P fimbriae and was obtained from ATCC (clone 700336). 
J96 bacteria were grown in Luria-Bertani broth (Sigma Aldrich, Saint Louis, USA) and 
bacteria numbers assessed by photospectometry at 600 nm.  
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2.2 Tissue culture media 
2.2.1 T cell medium 
CD4
+
 T cells and Jurkat T cells were maintained in RPMI 1640 medium (HyClone, 
Thermoscientific, Massachusetts, US) with 10% foetal calf serum (HyClone, 
Thermoscientific, Massachusetts, US), 100U/ml penicillin, 100 mg/ml streptomycin 
and 2 mM GlutaMAX (all from GIBCO, US). Serum was heat inactivated at 56°C for 
30 min, aliquoted and stored at -40°C. Before use all components of tissue culture 
media were filter sterilised and stored at 4°C. 
 
2.2.2 Caco-2 cell medium 
Caco-2 cells were cultured in Eagle's Minimum Essential Medium with 20% FCS, 
100U/ml penicillin, 100 mg/ml streptomycin and 2mM GlutaMAX. Serum was heat 
inactivated at 56°C for 30 min and stored at -40°C. Before use all the components of 
tissue culture media were filter sterilised and stored at 4°C. 
 
2.3 Antibodies  
2.3.1 Activating and neutralizing antibodies  
Cell-stimulating antibodies were purified from a specific hybridoma line (anti-CD3; 
OKT-3) or purchased from BD Biosciences (anti-CD28; CD28.2). The monoclonal 
antibody to CD46, TRA-2-10, recognizes an epitope in the first repeat of the 
complement control protein repeats (Liszewski et al., 2000) and was generated in 
house (Wang et al., 2000). The monoclonal antibody to human CD46, GB24 binds to 
complement control protein repeats 3 and 4 (Liszewski et al., 2000), was generated in 
house and kindly provided by John Atkinson. The function-neutralizing monoclonal 
antibodies to human IL-2 (MQ1-17H12), IL-4 (8D4-8), IL-10 (JES3-9D7), IL-12 
(C8.6) and IFN-γ (4S.B3) were purchased from BD Pharmingen.  
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2.3.2 Antibodies used for flow cytometry staining, confocal microscopy and 
Western blot 
Surface, intracellular staining and Western blot analyses for specific marker/protein 
expression were performed using the antibodies in Table 2.1. Antibodies that required 
fluorochrome labelling were directly conjugated using the Zenon Mouse R-
phycoerythrin Mouse IgG1 Labeling kit (Invitrogen, Paisley, U.K.). The monoclonal 
antibody to human ICER/CREM was labelled with phycoerythrin using the Zenon 
labeling kit. According to the protocol, 1 μg of antibody was incubated with 5 μl of the 
Zenon mouse IgG labelling reagent for 5 min. Following the incubation time, 5 μl of 
the Zenon blocking reagent were added and the mixture was incubated for 5 min. The 
complex was used for cell staining within 30 min of labelling. 
Table 2.1 Antibodies used for flow cytometry staining, confocal microscopy and 
immunoblotting 
Target Isotype Clone Fluorophore Supplier 
AEP Rabbit polyclonal 
IgG 
ab47146 Unconjugated Abcam 
β-actin Mouse IgG1 mAbcam8226 Unconjugated Abcam 
CD3 Mouse IgG1 HIT3a PE BD 
CD4 Mouse IgG1 RPA-T4 PE BD 
CD4 Mouse IgG2a RPA-T4 APC BD 
CD4 Mouse IgG1 RPA-T4 Pacific Blue BD 
CD25 Mouse IgG1 M-A251 FITC BD 
CD25 Mouse IgG1 M-A251 APC BD  
CD45RA Mouse IgG2b HI100 FITC BD 
CD45RA Mouse IgG2b HI100 PE BD 
CD45RO Mouse IgG2a UCHL1 FITC BD 
CD45RO Mouse IgG2a UCHL1 APC BD 
CD46 Mouse IgG2k E4.3 FITC BD 
CD69 Mouse IgG1 FN50 APC BD 
CD197 (CCR7) Mouse IgG2a 150503 Cy7 BD 
Foxp3 Mouse IgG1 236A/E7 PE BD 
Granzyme B Mouse IgG1 GB11 FITC BD 
ICER/CREM Mouse IgG1 ab54625 Unconjugated Abcam 
IFN-γ Mouse IgG1 4S.B3 FITC BD 
IL-10 Rat IgG2a JES3-19F1 APC BD 
LAMP1 Mouse IgG1 ab25630 Unconjugated Abcam 
SPAK Rabbit polyclonal #2281 Unconjugated Cell Sign. Tec.* 
Stat4 (pY693) Mouse IgG1 38/p-Stat4 PE BD 
Stat5 (pY694) Mouse IgG1 47 PE BD 
Stat6 (pY641) Mouse IgG2a 18/P-Stat6 PE BD 
* Cell Signaling Technology 
 




Table 2.2 Secondary Antibodies  
 
Target Isotype  Dilution Format Supplier 
IgG Rabbit 
polyclonal 








   1:200 Alexafluor 488 conjugated Invitorgen 
IgG Rabbit 
polyclonal 
   1:200 TRITC conjugated Southern 
Biotech 
 
2.4 Recombinant proteins 
2.4.1 Recombinant cytokines 
Recombinant human IL-4, IL-10, IL-12 and IFN-γ (for in vitro TH1 or TH2 skewing) 
were from BD Biosciences. Recombinant human IL-2 was kindly provided by Dr. 
Christine Pham (Washington University, Saint Louis, USA). 
 
2.4.2 Soluble CD46 
Soluble CD46 was generated by cloning of cDNA encoding short consensus repeats 1–
4 of human CD46 into the pET15-b vector (Merck, Nottingham) by Dr. Teresa 
Melchionna and Dr. Richard Smith (King’s College London). BL21 DE3 bacteria 
(Merck) were transfected with the construct and recombinant soluble CD46 was then 
purified from the inclusion bodies and refolded according to a published method 
(White et al., 2004). 
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2.5 Purification of CD4+ T cells and CD4+ T cell subpopulations 
2.5.1 Purification of PBMCs from whole blood  
PBMCs were isolated from buffy coats, leukocyte cones or blood samples from 
healthy volunteers by using gradient centrifugation with Ficoll Histoplaque (GE 
Healthcare; Waukesha, Wisconsin). Blood was diluted 1:1 with PBS 1X (HyClone, 
Thermoscientific, Massachusetts, US) and layered on 15 mL of Ficoll. The preparation 
was then centrifuged at 1600 RPM for 30 min without brakes. Following the 
centrifugation step the leukocyte layer was harvested by aspiration, washed 3X in PBS, 
then subjected to cell isolation using magnetic cell sorting. 
 




 T lymphocytes were isolated from PBMCs or synovial fluid with CD4 
MicroBeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the 
manufacturer’s protocol. In brief, PBMCs were washed in PBS and centrifuged for 10 
min at 1400 RPM counted and resuspended in 80 µl of bead buffer per 10
7
 cells. CD4 
microbeads were added using 20 µl per 10
7
 cells and the mixture was incubated at 4°C 
for 15 min. Cells were then washed using 25 ml of bead buffer, filtered through a 
70μM cell strainer (BD, Bedford, USA) and applied onto an LS column (Miltenyi 
Biotec) attached to a magnet. T cells retained in the column were washed 3 times with 
3 ml of bead buffer and subsequently eluted by removing the LS column from the 
magnet and applying 3 ml of bead buffer to the column. The purity of isolated CD4
+
 T 
cells was routinely evaluated by FACS analysis as approximately 99% using the gating 
strategy shown in Figure 2.1. Total CD4
+
 cells were then counted and activated 
accordingly. 
 





















































Figure 2.1 Gating strategy and staining controls of purified CD4
+
 T cells. 
Following magnetic sorting via positive selection, T cells were gated according to the 
FSC and SSC profile. Purity of CD4
+ 
T cells was verified by surface staining with an 
anti-CD4 antibody. Representative gating strategy with unstained T cells and isotype 
control antibody staining. Values shown represent the percentage of positive cells 
within the relevant FSC/SSC gate or FL-1 vs FL-2 quadrant. 
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2.5.3 Isolation of naïve CD4+ T cells (CD45RA+/CD45RO-) via magnetic 
labelling (negative selection) 
Isolation of naïve T cells via negative selection from PBMCs was carried out 
following the Miltenyi Biotec instructions. PBMCs were washed in PBS and 
centrifuged for 10 min at 1800 RPM counted and resuspended in 40 µl of bead buffer 
per 10
7
 cells. The naïve CD4
+
 T Cell Biotin-Antibody cocktail II was added (10 µl per 
10
7
 cells). Cells were mixed and incubated for 15 min at 4°C. Cells were then washed 
using 1 ml of bead buffer per 10
7 
cells. Cells were centrifuged and then resuspended in 
80 µl of bead buffer per 10
7
 cells. Anti-Biotin microbeads were added (20 µl per 10
7
 
cells) and cells were incubated for 15 min at 4°C in the dark. Following incubation, 
cells were resuspended in 500 µl of buffer per 10
7
 cells and filtered through a 70 μM 
cell strainer (BD, Bedford, USA). Cells were then applied onto an LS column 
(Miltenyi Biotec) and the flow-through containing the naïve subset of CD4
+
 T cells 
was collected. The purity of isolated naïve T cells was routinely assessed by FACS 
analysis as approximately 98%. FACS analysis was performed using the antibodies 

























































































Figure 2.2 Gating strategy and staining controls of purified naïve 
(CD45RA+/CD45RO-) lymphocytes. Following magnetic sorting via negative 
selection, the purity of naïve T cells was assessed by surface staining with antibodies 
to CD45RA (FITC) and CD45RO (APC) and matched isotype control antibodies. T 
cells were gated according to the FSC and SSC profile. Values shown represent the 
percentage of positive cells within the relevant FSC/SSC gate or staining quadrant. 




2.5.4 Isolation of naïve CD4+ T cells (CD45RA+/CD45RO-) via cell sorting 
To purify naïve lymphocytes through FACS sorting whole CD4
+
 T cells were initially 
sorted from peripheral blood via magnetic cell sorting with CD4 Miltenyi beads 
(positive selection). Subsequently, CD4
+
 lymphocytes were resuspended in FACS 
buffer at a concentration of 30 x 10
6
 cells per 500μl and surface stained with antibodies 
to CD4, CD45RA, CD45RO, CD25 and CCR7 (Figure 2.3). Staining was carried out 
at 4°C for 30 min in the dark. Lymphocytes were then washed twice in FACS buffer, 
resuspended in media at a concentration of 30 x 10
6
 cells per ml. Sorting was 
performed on a BD FACSAria™ II Cell Sorter using the gating strategy in figure 2.3. 
The purity of isolated T cells was verified post-sort and was approximately 97% for 
CD45RA
+ 
























naïve T cells. Following a CD4 positive selection of T cells with Miltenyi microbeads 
from peripheral blood mononuclear cells, T cells were surface stained for sorting using 
CD4, CD45RA, CD45RO, CD25
 
and CCR7 antibodies. a) Pre-sort gating strategy of 
CD4
+
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upper central dot plot), CD4+ cells (P3, upper right dot plot), CD45RA+/CD45RO- 
cells (P4, lower left dot plot), CD25- and CCR7+ cells gates (P5, lower right dot plot). 
b) Post-sort purity was verified by analysing 10.000 events. Values shown refer to the 
percentage of positive cells within the relevant gate. 
 
2.6 T cell activation and gating strategy 
Purified CD4
+
 T cells were activated in 96 or 48-well culture plates (Iwaki, Japan). 
Wells were coated overnight at 4°C with mAbs to CD3, CD28 and/or CD46 at a 
concentration of 2.0μg per ml of PBS. Each well was coated with 75 µl in the case of 
96-well plates and 125 µl in the case of 48-well plates. Post purification T cells were 
resuspended in media, containing recombinant human IL-2 (rhIL-2), with 
concentrations varying between 1 and 100 Units/ml, according to the experiment. Cells 
were then seeded at a concentration of 1.5 × 10
5
 (96-well plates) to 3.5 × 10
5
 (48-well 
plates) cells per well. Following activation cells were stained according to the 
experiment requirements. Non-activated or activated CD4
+
 T cells were gated 
according to the FSC and SSC profile in order to include blasting cells and exclude 
dead cells from the analysis. Propidium iodide staining was used to assess cell viability 
within the FSC and SSC gate (Figure 2.4). The percentage of non-viable cells within 
































 T cells were plated in a 48 well plate coated with activating 
antibodies to CD3, CD28 or CD46 at a concentration of 2 μg/ml. Cells were activated 
for 36 hours in the presence of 50 U/ml of rhIL-2. Following activation CD4
+
 T cells 
were harvested, washed twice with FACS buffer and stained with propridium iodide 
(PI) to discriminate non-viable cells within the FSC/SSC gate. b) Anti-CD3/CD28 
activated T cells were activated as in (a) and treated with 100μM of Staurosporin. 
Viability was assessed in non-gated (left dot plots) and gated (right dot plots) cells 






















Anti-CD3/CD28 + Staurosporine b 
a 
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through PI staining. Values are indicative of the percentage of positive cells within the 
relevant gate. 
 
2.7 TH1 and TH2 skewing of naïve CD4
+
 T cells 
TH1 and TH2 cells were generated from sorted naïve CD4
+
 T cells as follows: naïve T 
cells were activated through plate-bound mAb to CD3 and mAb to CD28 (2 μg/ml 
each) at a concentration of 0.5-1x10
6
 cells per well in 48-well plates. TH1 skewing 
media included function-neutralizing mAb to IL-4 (10 μg/ml) and recombinant human 
IL-12 (10 ng/ml). TH2 skewing media contained anti-IFN-γ (10 μg/ml) and 
recombinant human IL-4 (20 ng/ml). Following 48-72 hours of activation cells were 
expanded by transfer in 24 well plates coated with mAb to CD3 and mAb to CD28 (2 
μg/ml each). Skewing media was added according to TH1 and TH2 induction in 
addition to rhIL-2 (5 U/ml). Expansion was carried out for a maximal period of 13 
days before cytokine staining and marker analysis of successful TH1 (IFN-γ and T-bet 
positive) and TH2 (IL-4 and GATA3 positive) generation. 
 
2.8 Caco-2 culture and activation 
Cells were cultured in 48-well plates (3 x 10
4
 cells/well) (Iwaki, Asahi Glass Co., 
LTD., Japan), 24 trans-well systems (polycarbonate membrane, pore size 0.4 μm, 
membrane insert Ø 12 mm; Corning, USA) or in wells provided by the CytoSelect
TM
 
24-Well Wound Healing Assay (Cell Biolabs Inc., USA) for 6-7 days minimum to a 
fully confluent monolayer. Cells were initially seeded at a concentration of 3 × 10
4
 
(48-well plates) or 5 × 10
4
 (24-well plates) cells per well.  Epithelial cell layer integrity 
(i.e. formation of functional tight and adherens junctions) was monitored by trans 
epithelial resistance measurement using the epithelial voltohmmeter EVOM2 (World 
Precision Instruments Inc.,Sarasota, FL, USA). When TER values reached a minimum 
of 1000 Ω/cm2, mAbs to CD46, an isotype control mAb (10 μg/ml), or EtOH (final 
concentration of 15%) was added and TER measured at different time points post 
activation. 
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2.9 Assays measuring T cell viability and proliferation 
2.9.1 Viability assay  
CD4
+
 T cell viability was tested using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Promega), a colourimetric method for determining the number of 
viable cells in proliferation. The conversion of MTS into soluble formazan is 
accomplished by viable cells and is measured by the absorbance at 490 nm. CD4
+
 T 





96 Aqueous One Solution Reagent was added using 20 μl per well and cells were 
incubated between 1 and 4 hours at 37°C (5% CO2). The absorbance was then 
measured at λ=490nm on a SPECTRA max plus reader (Molecular Devices, Berkshire, 
UK).  
 
2.9.2 Suppression assay 
The suppressive abilities of supernatants collected from activated T cells were 
evaluated using the viability assay (paragraph 2.9.1). CD4
+
 T cells were plated in 96- 
well plates at a concentration of 1.0 x 10
5 
per well. Cells were activated through plate-
bound mAb to CD3 and mAb to CD28 (2 μg/ml). Supernatants were added using a 
volume of 100 µl per well and cellular proliferation was tested at day 6 through the 
viability assay. 
 
2.9.3 Proliferation assay  
Cellular proliferation of T cells activated in the presence of carrier solution or AEP 
inhibitor was assessed by identifying cellular division cycles through 5-(and 6) 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) staining. Purified CD4
+
 T 
cells were pelleted at 1400 RPM for 10 min and washed twice in PBS. The CFSE 
solution was prepared by diluting CFSE (Molecular probes, Invitrogen) in PBS to a 
final concentration of 2.5 µmol/L. Lymphocytes were resuspended in CFSE solution at 
a concentration of 10
7
 cells per ml of CFSE solution and incubated in the dark at room 
temperature for 3 min. Lymphocytes were then washed in complete medium, 
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centrifuged at 1400 RPM for 10 min and resuspended in the appropriate medium 
before experimental activation. 
 
2.10 Methods for protein expression, quantification and interaction 
2.10.1 T cell staining and flow cytometry 
Surface and intracellular staining of activated or non-activated T cells was performed 
in order to analyse the expression and/or phosphorylation status of proteins of interest 
on the cell surface or within the cytoplasm. Surface staining was either carried out 
alone or in conjunction with intracellular staining. The BD Cytofix/Cytoperm 
Fixation/Permeabilization Kit (BD Biosciences, San Diego, USA) was used for surface 
and intracellular staining accordingly; purified CD4
+
 T cells were washed twice in 
PBS and resuspended in staining buffer (PBS, 1% FCS) at a concentration of 10
6
 per 
50 µl of staining buffer. Surface staining was carried out at 4°C for 30 min. Cells were 
then washed twice with staining buffer and fixed by resuspending them into the 1X BD 
Perm/Wash buffer solution for 20 min at 4°C. Cells were then washed twice in 1X BD 
Perm/Wash buffer and resuspended in 50 µl of BD Perm/Wash buffer containing an 
optimal concentration of antibodies for staining. Staining was carried out at 4°C for 30 
min in the dark. Cells were then washed with 1X BD Perm/Wash buffer and 
resuspended in staining buffer for flow cytometry analysis. Flow cytometry was 
carried out on a BD FACSCalibur™ (BD Biosciences, San Jose, USA) and data was 
analysed using the Venturione software (Sheffield, UK). 
 
2.10.2 Measurement of Foxp3 expression 
The Foxp3 staining was carried out using the FOXP3 Fix/Perm Buffer Set from 





cells, 1 ml of the BioLegend FOXP3 Fix/Perm solution was 
added. Samples were mixed and incubated in the dark for 20 min at room temperature. 
Cells were then washed once in PBS and subsequently in the 1X BioLegend's FOXP3 
Perm buffer. Samples were then incubated at room temperature in the dark for 15 
minutes and spun down. The pellets were resuspended in 100 μl of 1X BioLegend's 
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FOXP3 Perm buffer. Anti-human Foxp3 (table 2.1) was added, using 3  μl per sample 
and cells were incubated for 1 hour in the dark. After washing the samples twice in 
PBS staining was analysed on the FACScalibur (BD Biosciences). 
 
2.10.3 Assessment of the phosphorylation status of signal transducers and 
activators of transcription (STAT) proteins  
Staining for phospho-STAT4, phospho-STAT5 and phospho-STAT6 was carried out 
using BD anti-pSTAT4, anti-pSTAT5 and anti-pSTAT6 (Table 2.1). The intracellular 
phospho-staining was performed using BD Phosflow Perm Buffer III and diluted 
Permfix Phosflow buffer. The phospho-staining was performed according to the 
manufacturers’ protocol (Alternative protocol 2; BD); following surface staining, cells 
were fixed by adding 10 volumes of pre-warmed Lyse/Fix Buffer to the samples and 
incubated at 37°C for 10 min. Cells were then centrifuged at 1800 RPM for 6 min. 
Supernatants were removed, cells were resuspended and washed in PBS with an 
equivalent volume to the one of the Lyse/Fix Buffer. The pellet was washed as 
described above and cells were permeabilized by incubation on ice for 30 min in Perm 
Buffer III. Cells were then washed twice in Staining Buffer and resuspended in 250 μl 
for FACS analysis. 
 
2.10.4 Confocal microscopy for asparagine endopeptidase (AEP) expression and 
localization 
Intracellular staining of T cells was performed in order to analyse the expression and 
localization of the AEP protein through confocal microscopy. CD4
+
 T were fixed and 
permeabilized with the BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD 
Biosciences, San Diego, USA) as in 2.10.1. Following permeabilization primary 
antibodies were added for 1 hour at room temperature at a dilution of 1:100. Cells were 
then washed twice and resuspended in Perm 1X solution. Secondary antibodies were 
added at a dilution of 1:200 and samples were incubated for 1 hour. Cells were then 
washed twice in 1X BD Perm/Wash and centrifuged on slides using a cytocentrifuge. 
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The nuclear die, Dapi-Fluoromount-G (SouthernBiotech, USA) was added before 
samples were analysed on the A1R Si Confocal microscope (Nikon, Japan).  
 
2.10.5 Measurement of protein expression by Western blot 
2.10.5.1 Purification of proteins from sub-cellular compartments 
Protein extraction from isolated nuclei and cytosolic fractions of either unstimulated or 
activated T cells was carried out using the ProteoJET Cytoplasmic and Nuclear Protein 
Extraction Kit (Fermentas, Thermoscientific, Massachusetts, USA). Activated CD4
+
 T 
cells were harvested and washed with PBS twice. The cell pellet was then lysed by 
adding Cell lysis buffer to pelleted cells (e.g. 100 μl of CER I for 10 μl cell pelleted 
volume). Cells were then vortexed for 10 sec, set on ice for 10 min and vortexed again. 
The cytoplasmic fraction was separated from nuclei by centrifuging at 3500 RPM for 7 
min at 4°C. The supernatant containing the cytosolic protein extract was then 
transferred to a new tube and cleared by centrifuging at 16,000 RPM for 15 min at 
4°C. The supernatant was transferred in a new labelled tube and stored at -80°C. The 
nuclei pellet was washed once using 500 μl of Nuclei Washing buffer, vortexed and set 
on ice for 2 min. Nuclei were then centrifuged for 7 min at 3500 RPM at 4°C. The 
supernatant was removed and 100-150 μl of the Nuclei storage buffer was used to 
resuspend the pellet containing the nuclei protein extract which was stored at -80°C. 
Given that the ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit was 
discontinued in June 2011, protein extraction was then carried out using the NE-PER 
kit (Thermo scientific, Massachusetts, USA). Harvested cells were washed twice in 
PBS and 1-10x 10
6
 cells were then transferred in a 1.5 ml tube and pelleted at 3500 
RPM for 3 min. Ice-cold CER I buffer was added to the cell pellet (e.g. 100 μl of CER 
I for 10 μl cell pelleted volume) vortexed for 15 sec and incubated on ice for 10 min. 
Ice-cold CER II buffer was added (5.5 μl of CER II for a starting pellet of 10 μl of 
volume) and cells were vortexed for 5 sec, then centrifuged for 5 min at 16.000 RPM. 
The supernatant was transferred to a chilled tube and stored at -80°C.  The pellet was 
resuspended on ice-cold NER buffer and vortexed for 15 sec every 10 min for 5 times 
and then centrifuged at 16.000 RPM for 10 min. The supernatant was then transferred 
to a pre-chilled tube and stored at -80°C. 
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2.10.5.2 Protein quantification 
Protein quantification was performed using the Bradford assay reagent (Sigma Aldrich, 
USA) and reporting the absorbance values of unknown samples to a standard curve 
generated with bovine albumin serum (BSA) (Sigma Aldrich, St. Louis, USA). The 
assay was performed in 96-well plates using 5 μl of a 0.1–1.4 mg/ml protein sample. 
Protein standards were prepared in buffer (PBS or ddH2O) ranging from 0.1–1.4 
mg/ml using a BSA standard. Protein standards and samples were added in triplicate to 
separate wells using 5 μl of material per well. To the blank wells, 5 μl of buffer was 
added. To each well being used, 250 μl of the Bradford reagent were added and mixed 
on a shaker for 30 sec. Samples were then incubated 5 to 45 min and the absorbance at 
(λ= 595 nm) was recorded. 
 
2.10.5.3 Western blot methodology 
Protein samples were denatured by heating samples at 95°C for 5 min. Lane reducing 
or non-reducing marker (ThermoScientific, Rockford, USA) was added to samples at a 
dilution of 1:5. Samples were separated using precast polyacrylamide NuPAGE Bis-
Tris Gels gels 4-12% (Life technologies, New York, USA) with TBE 1X buffer (see 
Buffers) at 150 Volts using a Bio-Rad basic PowerPac (Bio-Rad, California, USA) and 
transferred to the nitrocellulose membrane. The iBlot system (Invitrogen) was used for 
the transfer of proteins onto a nitrocellulose membrane which was then incubated in 
blocking buffer (5% milk in TBS-Tween) for 1 hour at 4°C under agitation. After 
blocking, the membrane was rinsed twice for 10 seconds in TBS-T (see Buffers). After 
the second wash the membrane was incubated with the primary antibody (dilution 
range 1:3.000 to 1:5000) in blocking buffer overnight. The membrane was then 
washed and the horseradish peroxidase (HRP)-conjugated secondary antibodies were 
added for 12 hours (Biosciences, NJ, USA). Detection was performed using the West 
Pico Luminol Enahncer Kit (ThermoScientific, Rockford, USA) and the exposure of 
the membrane to radio film with its subsequent development in a CompactX2 
(Xograph Healthcare Ltd, Xograph House, Gloucester, UK).  




Caco-2 cells were cultured for 7 days in 24-well plates.  A mAb to CD46 (TRA-2-10) 
or an isotype control mAb was added at 10 μg/ml for 3 hours. Cells were then lysed in 
lysis buffer (1% v/v maltoside, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM 
EDTA, 1.5 mM MgCl2, 10% glycerol), and protease and phosphatase inhibitors 
(Sigma Aldrich). Lysates were incubated with a mAb GB-24 (anti-CD46) or an 
isotype-matched control mAb covalently coupled to Sepharose (Amersham) overnight 
at 4 °C. After washing, bound proteins were eluted, quantitated and analyzed by 
Western blotting under reducing conditions. 
 
2.11 Cytokine measurement assays 
2.11.1 Intracellular FACS staining 
Intracellular protein expression was assessed by FACS staining either alone or in 
combination to surface staining according to the protocol in paragraph 2.11.1. 
 
2.11.2 Secretion assay 
Active single cell cytokine secretion was analysed using the Miltenyi Biotec Secretion 
Assay Kits according to the manufacturer’s protocol (Miltenyi Biotec, Bergisch-
Gladbach, Germany). Briefly for 10
6 
cells, 1 mL of cold buffer was used for washing 
and centrifuging cells at 1600 RPM for 10 min at 4°C. The cell pellet was resuspend in 
90 µl of cold medium and 10 µl of catch reagent per 10
6 
cells (e.g. IFN-γ catch 
reagent) were added. Samples were kept 5 min on ice. For two colour cytokine 
analysis 20 µl of pre mixed catch reagent (e.g. IFN-γ and IL-10) per 106 cells were 
added to each sample and incubated on ice for 5 min. Warm media was then added I 
order to have 10
6
 cells per mL of media and samples were incubated at 37°C for 45 
min under slow continuous rotation. Subsequently cells were washed in cold buffer, 
resuspended in 90 µl of buffer per 10
6
 cells and labelled by adding 10 µl per sample of 
the FITC, PE or APC conjugated detection antibody. Cells were incubated on ice for 
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10 min, washed by adding 2 ml of cold buffer and resuspended in 250 µl of cold buffer 
for flow cytometry analysis. 
 
2.11.3 Cytokine Bead Array (CBA) assay 
To quantify the amounts of IL-2, IL-4, IL-5, IL-10, TNF and IFN-γ secreted by 
activated T cells, the BD CBA Human Th1/Th2 Cytokine kit from Becton Dickinson 
was used according to the manufacturer’s suggestions. Each capture bead was 
resuspended and a 10 μl aliquot per sample was added to the master mix. After 
vortexing, 50 μl of the master mix were added to 50 μl of each standard dilution and 
unknown samples. Further 50 μl of the human Th1/Th2 PE detection reagent was then 
added to the tubes and incubated for 3 hours. Standard dilutions and unknown samples 
were then washed with 1 ml of wash buffer and centrifuged at 1400 RPM for 5 min. 
Beads were then resuspended in 300 μl of washing buffer and acquired through FACS 
(Figure 2.5 and 2.6). Subsequently, standard curves were generated for analysis using 
BD Fcap array software or the BD Excel analysis software (Figure 2.6b and 
Appendix).  
 
        
90%
   
 
Figure 2.5 FSC/SSC gating strategy for the identification of the BD CBA beads. 
For each standard or unknown sample 1800 events were acquired within the FSC/SSC 
gate. Value is indicative of the percentage of beads within the gate. b) Diagram 
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Figure 2.6 Standard curve generation for cytometric bead array analysis. a) 
Standard curves were obtained by serial 1:2 dilutions starting from the CBA top 
standard (5000pg/ml) in order to obtain the following concentrations: 2500 pg/ml, 
1250 pg/ml, 625 pg/ml, 312 pg/ml, 156 pg/ml, 80 pg/ml, 40 pg/ml and 20 pg/ml. The 0 
pg/ml standard was obtained by mixing 50 μl of the BD assay diluent with 50 μl of the 
master mix and 50 μl of the Th1/Th2 PE detection reagent. a) Dot plots relative to the 
fluorescent intensities for each standard bead. b) Standard curves generated for each 
bead through Fcap array software. Each standard curve had an R square value of fitting 
accuracy > than 99.86% (Appendix). IFNG= IFN-γ, TNF= Tumor necrosis factor. 
 
 
2.12 Deoxyribonucleic acid (DNA) and Riboxynucleic acid (RNA) methodologies 
2.12.1 RNA extraction from cells 
RNA extraction for gene expression quantification was carried out using the RNeasy 




 T cells were harvested 
and washed twice in PBS. Cell pellet was disrupted by adding 350 μl of buffer RLT. 
The lysate was then pipetted into a QIAshredder spin column plated in a 2 ml 
collection tube and centrifuged 2 min at full speed. An equal volume of 70% Ethanol 
was then added to the lysate and mixed. The lysate solution of 700 μl was then 
transferred into and RNeasy spin column placed in a 2 ml collection tube and 
centrifuged for 15 sec at 12.000 RPM. The flow-through was discarded and 700 μl of 
Cytokine (pg/ml) Cytokine (pg/ml) 
Cytokine (pg/ml) Cytokine (pg/ml) 
Cytokine (pg/ml) Cytokine (pg/ml) 
b 
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buffer RW1 were added to the RNeasy spin column and centrifuged for 15 sec at 
10.000 g. After discarding the flow through, 500 μl of buffer RPE were added to each 
spin column which was then centrifuged for 2 min at 12.000 RPM to wash the spin 
column. The RNAeasy spin column was then placed in a new 1.5 ml collection tube 
and 30-50 μl of RNase free water were added to the spin column which was then 
centrifuged for 1 min at 12.000 RPM. 
 
2.12.2 RNA quantification 
Quality screen and quantification of RNA was performed using a Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific, Wilmington, USA). RNA purity and 
integrity was screened by analysing the ratio of absorbance A260/280 with a value 
equal or great than 2 indicating high purity of RNA. RNA was stored at -40°C. 
 
2.12.3 Chromatin-immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) is a technique used to assess the association of 
proteins of interest with specific regions of the genome. Cells are fixed via 
formaldehyde treatment and the chromatin is sheared and immunoprecipitated via a 
highly specific antibody to sequence-specific DNA-binding proteins. To evaluate the 
binding of ICER/CREM to the IL-2 promoter the MAGnify Chromatin 
Immunoprecipitation system was used (Invitrogen, Paisley, U.K.). In the first step of 
the kit Dynabeads were coupled with the antibody of interest. After adding 100 μl of 
dilution buffer to 10 μl of Dynabeads Protein A/G, the 0.2 ml PCR tubes were placed 
in the DynaMAg-PCR magnet for 1 min; with the tubes in the magnet the liquid was 
then discarded without disturbing the bead pellet. After adding 100 μl of the dilution 
buffer, the antibody of interest (1 μg/sample) and the negative control antibody 
(provided) were added to the different samples and incubated for 1 hour at 4°C. In 
order to cross-link DNA and proteins with formaldehyde to preserve the chromatin 
structure, sorted CD4
+
 T cells were washed with 10 ml of room temperature PBS. 
Cells (10
5
 per each population analysed) were then resuspended in 500 μl of PBS and 
13.5 μl of 37% formaldehyde were added to achieve a final concentration of 1%. 
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Tubes were mixed by inverting, and incubated for 10 minutes at room temperature. In 
order to stop the reaction, 57 μl of room-temperature 1.25 M glycine were added to 
each sample. Samples were mixed by inverting, and incubated for 5 min at room 
temperature. Cross-linked cells were spun in a cold centrifuge (4°C) at 1200 RPM for 
10 min. All tubes were kept on ice from this point. The supernatant was aspirated 
without disturbing the pellet and cells were gently resuspended in 500 μl of cold PBS. 
Cells were then centrifuged at 1200RPM for 10 min at 4°C to obtain a pellet which 
was then wash once more in 500 μl cold PBS.  
The chromatin was sheared into 200–500-bp fragments for analysis by quantitative 
real-time PCR (qPCR) by sonication. Cells were sonicated with 3 cycles of 20 sec. 
Once the antibody of interest and the negative control antibody have been linked to the 
Dynabeads, the tubes were spun and placed in the DynaMag PCR Magnet. After 
discarding the supernatant, the tubes were removed from the magnet and 100 μl of 
diluted chromatin extract was added to each tube containing the appropriate Antibody-
Dynabeads complex. The tubes were rotated end-over-end at 4°C for overnight. The 
chromatin was then washed using buffer 1 and buffer 2 according to the 
manufacturer’s protocol. The crosslinking was the reversed by placing the tubes 
washed with IP buffer 2 in the DynaMag-PCR magnet and by adding 54 μl of Reverse 
Crosslinking Buffer prepared with Proteinase K to each tube. The immune-precipitated 
(IP) samples were placed at 55°C for 15 min in a thermal cycler. IP sample tubes were 
placed in the DynaMag™-PCR Magnet and the liquid (containing the sample) was 
transferred to new labelled 0.2 ml PCR tubes which were then incubated at 65°C for 15 
min. The DNA was purified by adding 70 μl of DNA Purification Magnetic Beads 
prepared with DNA Purification Buffer to each tube. The samples were then incubated 
at room temperature for 5 min and placed in the magnet in order to remove and discard 
the liquid. The tubes were removed from the magnet and 150 μL of DNA Wash Buffer 
were added to each tube. Samples were gently mixed 5 times and the DNA was then 
eluted by removal of the washed tubes from the magnet and by addition of 150 μL of 
DNA Elution Buffer to each tube. Samples were incubated at 55°C for 20 min in a 
thermal cycler, and placed in the magnet for a pellet to form. The liquid which contains 
the purified samples were then transferred to new tubes and the purified DNA was 
stored at –20°C. 
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2.12.4 Polymerase Chain Reaction (PCR) 
The DNA immune-precipitated in the Chip study was amplified in a PCR reaction in 
order to evaluate ICER/CREM binding to IL-2 promoter sequences. The IL2 
promoter–specific primer pair 5′-TTACAAGAATCCCAAACT-3′ (forward) and 5′-
TAGAGGCTTCATTATCAAA-3′ (reverse), between positions +301 and +510 
relative to the promoter site, was used for PCR amplification following the thermo 
cycles set in the table below. 
 
Table 2.3 PCR reaction cycles 
 
PCR reaction t T 
Initial PCR activation step 15 min 95°C 
3 step cycle    
Denaturation 1 min 94°C 
Annealing 1 min 56-64°C 
Extension 1 min 72°C 
Number of cycles 25-30 - 
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2.12.5 Quantitative real-time (qPCR) 
For the quantification of GATA-3 and AEP expression, mRNA was isolated from T 
cells as described above and equal amounts (250 ng) were reverse-transcribed using 
the iScript kit (Bio-Rad, Hemel Hempstead, U.K.), generating a master mix for the 
reactions as in table 2.4. The reverse transcription reaction was carried out by 
incubating the samples at 25°C for 5 min, followed by a step of 30 min at 42°C and a 
final incubation of 5 min at 85°C. The cDNA was used in Quantitative real-time PCR 
reactions containing TaqMan Universal PCR Master Mix (Applied Biosystems, 
Warrington, U.K) (Table 2.5) and a GATA-3-specific primer pair: 5′ 
CTCATTAAGCCCAAGCGA-3′ (forward) and 5′-TCTGACAGTTCGCACAGGAC-
3′ (reverse) used in conjunction with the Universal Probe (UPL) number 8. The primer 
pair for AEP, 5′ GAACACCAATGATCTGGAGGA-3′ (forward) and 5′-
GGAGACGATCTTACGCACTGA-3′ (reverse) was used in conjunction with the UPL 
probe number 27. The UPL probes are labelled with a fluorescent reporter dye (i.e. 
FAM or VIC) covalently bound to its 5’-end and a dark quencher dye at the 3’-end. 
During the PCR reaction, the polymerase cleaves the reporter dye from the probe, 
releasing it from its quencher and allowing it to fluoresce. The specific hybridization 
of the target sequence with the specific set of primers and the UPL probe allows the 
discrimination of the gene of interest. Since UPL probes do not bind double stranded 
DNA (including primer dimers), the fluorescent dye release corresponds to 
amplification of the specific target sequence. The probe for the endogenous control 
18S has a VIC reporter dye while the GATA-3 and AEP probes have a FAM reporter 
dye. Probes were used in separate reactions and for each set of primers a water control 
was performed to control for contamination. The reaction was performed in an ABI 
Prism 7700 Sequence Detection System with cycles described in table 2.6.  Results of 
individual samples were normalized to that of human 18S rRNA (housekeeping gene; 
hs9999990_s1, Applied Biosystems). The data obtained from real-time PCR reactions 
is expressed as arbitrary fold change units and calculated through the Delta-Delta Ct 
method by normalising the data through subtraction of the Ct value of the endogenous 
control from the target gene Ct (ΔCt). The ΔCt of the reference or control sample was 
next subtracted from the ΔCt of the other samples to give the ΔΔCt. Subsequently, the 
relative quantity of target genes mRNA expression was calculated using the equation: 
2^-(ΔΔCt). The ΔΔCt method assumes that standard and target genes have similar 
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amplification efficiencies. Hence, the validity of the approach should have been 
confirmed by performing serial dilutions of cDNA template with 18S or target 
primers/probes to calculate the linear regression slope of the dilution series. This 
would have allowed to demonstrate that amplification efficiencies of both 18S and 
target primers/probes were similar (i.e. having slopes with values ranging between -
3.60 to -3.10 and an R
2
 value of or greater than 0.98). 
 
Table 2.4 Reverse transcription reaction mix 
 
Component Volume per sample 
5x iScript Reaction Mix 4 μl 
iScript Reverse Transcriptase 1 μl 
Nuclease-free water Variable 
RNA template Variable 
Total Volume 20 μl 
 





Component Volume per sample Final concentration 
TaqMan Universal PCR 
Master Mix (2X) 
10 1X 
Forward primer (20X) 1 μl 1X 
Reverse primer (20X) 1 μl 1X 
TaqMan probe (2.5 μM)  10 μl 250 nM 
DNA sample  Variable 10 to 100 ng 
Water  Variable - 
 Total  20 μl - 
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Table 2.6 Thermal cycling conditions 
 
Step Hold Cycle (n=35-40)  
  Deanaturing cycle Annealing/Extension cycle 
Temperature 95 95 60 
Time 10 min 15sec 1 min 
 
2.13 Wound healing assay 
Caco-2 cells were cultured in 24 wells provided by the CytoSelect
TM
 24-Well Wound 
Healing Assay Kit. At day 7 of culture, the linear spacer inserted in the well was 
removed, which created a regular and defined ‘wound’ within the cell monolayer. 
Wells were either left untreated or treated with 10 g/ml mAb to CD46 or an isotype 
control mAb (conditions were performed in triplicate) and further cultured. Closure of 
wound areas was monitored by time-laps microscopy (Canon EOS 50D) (Canon UK 
Ltd., Surrey) and digital pictures were analyzed using MetaMorph software (Molecular 
Devices, Downingtown, PA).  
 
2.14 Gene array generation 
For the methodology of generation of the gene arrays refer to Chapter 4, paragraph 4.3. 
 
2.15 Statistical analysis 
Data were expressed as mean ± standard deviation (SD) as indicated in legends. Data 
were assessed for normal distribution using the D'Agostino-Pearson and the 
Kolmogorov-Smirnov tests. Statistical analyses were performed using the paired 
Student’s t test (Excel software; Microsoft) when comparing 2 means of normally 
distributed data. For more than 2 conditions the one way ANOVA was used (GraphPad 
Prism 4). The Wilcoxon test (2 conditions) or the Friedman test (>2 conditions) were 
used for non-normally distributed data (GraphPad Prism 4). Unpaired data were tested 
using unpaired t test for normally distributed data or the Mann-Whitney U test for non-
normally distributed data. p values < 0.05 were considered statistically significant.  
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2.16 Buffers and reagents 
All PCR related materials and reagents were purchased from Qiagen, or otherwise 
specified. 
 
Phosphate buffered saline (PBS): PBS 1X with 0.0067M PO4 and without Calcium, 
Magnesium or Phenol Red was purchased from Hyclone, Thermo Scientific 
(SH30256.021).   
 
Bead buffer and secretion assay buffer: Bovine serum albumin (BSA; Sigma, St. 
Louis, Missouri) was dissolved in phosphate buffered saline pH 7.2 (PBS) at a final 
concentration of 0.5% (e.g. 2.5g in 500 ml of PBS). EDTA (EDTA solution pH 8.0 
0.5M; Fisher scientific, Loughborough, UK) was added to obtain a 2mM final 
concentration (e.g. 1.5 ml of 0.5 mM stock in 500ml of PBS). The buffer was stored at 
4°C. 
 
Tris-Borate-EDTA: TBE was used for agarose gel electrophoresis and was prepared 
by adding 108g Tris base, 55g Boric acid and 9.3g EDTA to 1 L of distilled H2O. 
 
Agarose: Agarose was purchased from Sigma-Aldrich and added to TBE 1X to 
generate gels for DNA electrophoresis. 
 
Lysis buffer: 1% v/v maltoside, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM 
EDTA, 1.5 mM MgCl2, 10% glycerol. 
 
10X Tris saline buffer-HCl (TBS/Tris-HCl): TBS/Tris-HCl was prepared by 
dissolving 86.7 g, of sodium chloride (NaCl) and 12.1 g of Tris powder in 900 mL of 
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dH2O. The pH was adjusted to 7.4-7.5 using HCl and brought to a volume of 1 L with 
H2O. The buffer was stored at room temperature. 
 
TBS TWEEN (TBST): TBS 10X was diluted 10 times in dH2O and 0.05% of Tween 
20X (Calbiochem, Nottingham, UK) were added per litre of solution. The buffer was 
stored room temperature. 
 
Blocking buffer: Powder milk was added to TBST 1X to a final concentration of 5% 
(e.g 2.5 gr of powder milk in 50 ml of TBST 1X). 
 
PCR Buffer: 10X concentrated buffer contains Tris·Cl, KCl, (NH4)2SO4, 15 mM 
MgCl2; pH 8.7 (20°C). 
 
CoralLoad PCR Buffer: 10x concentrated buffer contains Tris·Cl, KCl, (NH4)2SO4, 
15 mM MgCl2, gel loading reagent, orange dye, red dye; pH 8.7 (20°C). 
 
MgCl2 solution: 25 mM of MgCl2. 
 
HotStarTaq Plus Master Mix: 2x concentrated master mix contains HotStarTaq Plus 
DNA Polymerase, PCR Buffer (with 3 mM MgCl2), and 400 μM each dNTP. 
 
DNA size marker: FastRule Low Range DNA Ladder (Fermentas). 
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Storage and Loading Buffer: 10 mM Tris-HCl (pH 7.6), 10 mM EDTA, 0.005% 
bromophenol blue, 10% glycerol (Fermentas). 
 
6X MassRuler™ DNA Loading Dye: 10 mM Tris-HCl (pH 7.6), 0.03% bromophenol 
blue, 60% glycerol and 60 mM EDTA (Fermentas). 
 
Tris-Base-EDTA 10X; TBE containing Tris base (890mM), boric acid (890mM) and 
EDTA (2mM) was purchased from Invitrogen, stored at room temperature and diluted 
1:10 before use. 
 
NuPage 2-(N-morpholino) ethane sulfonic acid 20X: NuPage MES was purchased 
from Invitrogen; 20X buffer contains 50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 
mM EDTA, pH 7.3. 
 
Protein size marker: SeeBlue Plus2 (Invitrogen) was run on 4–12% Bis-Tris Gel with 
MES SDS buffer. 
 
Protease inhibitors: Halt Protease inhibitor 100X (Thermoscientific) contained: 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (1mM), Aprotinin 800nM, 
Bestatin 50μM, (1S,2S)-2-(((S)-1-((4-guanidinobutyl)amino)-4-methyl-1-oxopentan-
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The contraction of T cell responses triggered by an infectious pathogen is critical for 
protection against immunopathologies that arise from exuberant inflammation. 
Similarly, the prevention of an immune response against self-antigen is vital in the 
prevention of autoimmunity. The anti-inflammatory cytokine IL-10 plays a key role in 
limiting immune responses (Fahrer et al., 2001) by inhibiting the production of TNF 
and IL-12 in macrophages and DCs (Fahrer et al., 2001; Meisel et al., 1996), and by 
suppressing IL-2 and IFN-γ production by effector T cells (Hahn et al., 2004). The 
importance of IL-10 for immune homeostasis in vivo is highlighted by the fact that IL-
10
-/-
 mice succumb to colitis because of their inability to regulate the unwanted 
immune response against the gut flora (Taub et al., 1993a). Likewise, susceptibility to 
colitis was recently reported for human families carrying mutations in genes encoding 
IL-10 receptor chains (Franke et al., 2008). Moreover, while murine IL-10 deficiency 
accelerates the clearance of infections by Toxoplasma gondii or Trypanosoma cruzi, 
the mice rapidly succumb to tissue damage caused by over-production of pro-
inflammatory cytokines (Bendelac et al., 1997; Meisel et al., 1996). IL-10 can be 
produced by many cell types including T and B lymphocytes, DCs, and macrophages 
(Fahrer et al., 2001). Among T lymphocytes, TH2 cells and adaptive T-regs have been 
recognized as prime sources of IL-10 (Benlagha et al., 2000; Fahrer et al., 2001; 
Meisel et al., 1996). However, it has become increasingly clear that under certain 
conditions, high amounts of IL-10 may be secreted by some natural T-regs (Inagaki-
Ohara et al., 2005), TH17 cells (Eagle and Trowsdale, 2007), and TH1 cells (Arase et 
al., 1994; Meisel et al., 1996; Taub et al., 1993a). This has emphasized the uncertainty 
regarding the origins of IL-10-producing cells in vivo, particularly in humans. IL10-
producing TH1 cells have sparked much interest because they appear key to regulating 
the immune response to certain infections (Eagle and Trowsdale, 2007; Jankovic et al., 
2007; Russell and Ley, 2002), and because their induction may be a mechanism by 
which tolerance is induced in the presence of persistent (self)-antigen (Hayday, 2009). 
Thus, there is particular interest in understanding the factors that might regulate IL-10 
production by TH1 cells. In mice, the co-engagement of TCR and CD28 in the 
presence of high amounts of IL-12 seems to induce strong IL-10 production in TH1 
cells (Saraiva et al., 2009); a similar combination of ‘switch receptors’ has not been 
identified yet for human TH1 cells.  However, almost a decade ago the complement 
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regulatory protein CD46 was identified as one of the strongest inducers of IL-10 in 
human T cells in in vitro cultures: co-engagement of the TCR and the complement 
regulator CD46 (by antibodies) on human CD4
+
 T cells, was found to induce a T cell 
response characterized by high IL-10 secretion, moderate IFN-γ production, granzyme 
B and perforin expression (Catalfamo and Henkart, 2003; Eagle and Trowsdale, 2007; 
Inagaki-Ohara et al., 2005). At minimum, CD3/CD46-activated T cells closely 
resemble Tr1 cells because they produce a similar cytokine pattern (IL-10+, IFN-γ+, 
IL-4-) and suppress the activation of bystander effector T cells through the 
immunosuppressive action of IL-10 and independently of Foxp3 (Eagle and 
Trowsdale, 2007). In addition, both CD46-dependent activation of IL-10 production 
and Tr1 generation are highly dependent on the presence of exogenous IL-2 
(Catalfamo and Henkart, 2003; Caudy et al., 2007; Meisel et al., 1996). Further work 
showed that also cross-linking of CD46 by its physiological ligands C3b and C4b 
during TCR activation induces Tr1-like suppressor cells (Shalapour et al.). Likewise, 
the presence of Streptococcus pyogenes (a CD46-binding pathogen) during TCR 
activation in vitro promotes IL-10-secreting Tr1-like cells (Inagaki-Ohara et al., 2005). 
This suggested that CD46 might be a key factor in IL-10 induction in human CD4
+
 T 
cells and that CD46-mediated signals can be induced via its physiological ligands. 
However, counter-intuitively, although the cell supernatants from TCR/CD46/IL-2 
activated T cells were suppressive, they also contained relatively high amounts of the 
pro-inflammatory cytokine IFN-. This was in line with a later study suggesting that 
CD46 is a strong inducer of a TH1 phenotype rather than Tr1 cells (Hahn et al., 2004). 
The key question of my thesis centred on understanding CD46 mediated signals during 
human CD4
+
 T cell activation and to assess if and how CD46 regulates possibly both, 
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3.2 Hypothesis and Aims 
Given the central role of CD46 in the induction of pro-inflammatory (i.e. IFN-γ) and 
anti-inflammatory (i.e. IL-10) cytokines by human CD4
+
 lymphocytes it was 
hypothesised that in human CD4
+
 T cells the nature of the secreted cytokine (e.g. pro-
inflammatory vs. anti-inflammatory) was dependent on or could be modulated by the 
strength of either TCR, CD46 or IL-2 signalling. Hence, the aims of this initial part of 
the thesis were to identify the significance of IFN-γ production and the characteristics 
of IL-10 induction by CD46 in human CD4
+
 T cells. In particular, a mechanism of 
TH1-Tr1 “switching” triggered by CD46 was investigated to potentially explain the 
simultaneous presence of IFN-γ and IL-10 in CD46-activated cultures. Lastly, to 
further infer the importance of CD46-mediated cytokine production, T cells from 
patients with T cell-mediated inflammatory disease were analysed ex vivo. 
 
3.3 CD46 and IL2 modulate IL-10 secretion of T cells  
Activation of purified human CD4
+
 T cells with stimulating mAbs to CD3 and CD46 
in the presence of IL-2 has been shown to induce high IL-10 secretion which mediates 
a suppressive phenotype, and induce high amounts of IFN-γ typical of TH1 responses 
(Sanchez et al., 2004; Shalapour et al.). To replicate these findings human CD4
+
 T 
cells were stimulated in vitro with plate-bound anti-CD3, anti-CD3 plus anti-CD28 or 
anti-CD3 plus anti-CD46 antibodies in the presence of recombinant human IL-2 (rhIL-
2) for 72 hours. Secreted IFN-γ and IL-10 were then quantified by cytometric bead 
array (CBA) (Figure 3.1). It was demonstrated that upon engagement of CD3 and 
CD46, greater amounts of IFN-γ and IL-10 were produced in comparison to CD3 or 
CD3/28 stimulations. To better understand these seemingly paradoxical effects of 
CD46 on the induction of pro- and anti-inflammatory cytokines, the role of the 
activating signals was investigated. In particular the CD3, CD46 and IL-2 signals were 
titrated in order to understand whether the secretion of IFN-γ and IL-10 could be 
regulated differently and if a particular combination of signals could induce 
preferential secretion of IL-10 given the previously described regulatory phenotype of 
CD46-induced CD4
+
 T cells. Firstly human CD4
+
 T cells purified from peripheral 
blood were activated in the presence of a titration of anti-CD3 and anti-CD46 
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activating antibodies with constant amounts of IL-2 (50 U/ml) (Figure 3.2). It was 
shown that the levels of secreted IFN-γ were up-regulated in the presence of 
intermediate (i.e. 1 μg/ml) and high (10 μg/ml) concentrations of either anti-CD3 or 
anti-CD46 activating antibodies when compared to low strength signalling (i.e. 0.1 
μg/ml) except in the case of donor 2 where anti-CD3 and anti-CD46 at 0.1 μg/ml 
showed high IFN-γ and IL-10 secretion; this finding was not replicated in the other 2 
donors (Figure 3.2). Further, IL-10 secretion was found to follow a similar pattern to 
IFN-γ. However, except from the low strength signal activation in donor 2, none of the 
activation conditions was able to induce equal amounts of IFN-γ and IL-10 or greater 
amounts of IL-10 than IFN-γ. Hence, although showing a modulation of cytokine 
secretion, with a tendency of highest secretion in response to the strongest strength 
signal, the titration of CD3 and CD46 signals did not induce a 1:1 ration between IFN-
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 T cells activated via CD3 and CD46 secrete IFN-γ and IL-10. 
Purified human CD4
+
 T cells were activated in a 96 well plate and seeded at a 
concentration of 1.5 x 10
5
 per well. Each activation was performed in triplicate with 
the indicated stimulating antibodies in the presence of 50 U/ml rhIL-2. At day 3 post 
activation supernatants were harvested and IFN-γ and IL-10 amounts were measured in 
the cell supernatants through CBA. a) CBA standard curves for IFN-γ and IL-10 
quantification expressed in picograms (pg) per ml. b) IFN-γ and IL-10 amounts in 
supernatants of non-activated (NA), anti-CD3 (CD3), anti-CD3 plus anti-CD28 
(CD3/CD28) or anti-CD3 plus anti-CD46 (CD3/CD46) activated samples.  Data 
represent means  SD of 8 separate experiments. p-values derive from one-way 
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Figure 3.2 CD3 and CD46 signal strength titration in the modulation of cytokine 
secretion. CD4
+
 T cells were purified via magnetic cell sorting (positive selection) 
from the peripheral blood of 3 healthy donors. Purified CD4
+
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seeded in a 96 well plate and activated with plate-bound mAbs in the presence of 50 
U/ml of rhIL-2. CD4
+
 T cells were activated with anti-CD3 mAbs at a concentration of 
0.1, 1 or 10 μg/ml and in combination with anti-CD46 mAbs at a concentration of 0.1, 
1 or 10 μg/ml as indicated. At day 3 post activation supernatants were harvested and 
the amounts of IFN-γ and IL-10 were measured for each activation condition through 
CBA. a) Standard curves for IFN-γ and IL-10 quantification. b) IFN-γ and IL-10 
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Next the IL-2 signals were investigated in order to understand whether added 
exogenous IL-2 could impact on IFN-γ and IL-10 secretion and favour IL-10 secretion 
in specific activating conditions. When human CD4
+
 T cells were activated in the 
presence of increasing concentrations of IL-2, but with constant anti-CD3 and anti-
CD46 strength signal (2 μg/ml), cytokine production of both IFN-γ and IL-10 was also 
found to be regulated (Figure 3.3). Specifically, in very low (<0.5 U/ml) IL-2 
concentration, CD3/CD46 activation induced high IFN-γ secretion, compared to T 
cells activated with anti-CD3 or anti-CD3 plus anti-CD28. Increasing IL-2 beyond 5 
U/ml did not further increase IFN-γ production, but in IL-2 concentrations of 5-10 
U/ml, CD3/CD46-activated T cells from different donors all displayed strong IL-10 
secretion in addition to IFN-γ, with the level of IL-10 produced increasing with the 
amount of IL-2. Hence, high IL-2 in combination with anti-CD3 and anti-CD46 
activating signals was found to be a condition able to induce high IL-10 secretion and 
that could favour IL-10 induction more than IFN-γ. The analysis of the kinetic of 
cytokine secretion showed that CD46-induced IFN-γ peaked 24 hours post activation 
and then steadily declined, whereas IL-10 was barely detectable before 24 hours and 
peaked at 72 hours (Figure 3.4). Thus, CD46-mediated IFN-γ production preceded IL-
10 secretion even in high IL-2 cultures that are most conducive to IL-10 production. 
The addition of a neutralizing mAb to IL-2 during CD3/CD46 activation abrogated cell 
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Figure 3.3 CD46 and IL-2 regulate IFN-γ and IL-10 secretion by TCR-activated 
CD4
+
 T cells. Purified human CD4
+
 T cells were purified from 3 healthy donors via 
magnetic cell sorting (positive selection). T cells were either left non-activated (-) or 
activated with anti-CD3 (CD3), anti-CD3 plus anti-CD28 (CD3CD28) in the presence 
of 20 U/ml of rhIL-2 or with anti-CD3 plus anti-CD46 (CD3CD46) mAbs with 
increasing amounts of rhIL-2. The concentrations of rhIL-2 ranged between 0 and 100 
U/ml. At day 3 post activation, IFN-γ and IL-10 amounts were measured in the cell 
supernatants through CBA. a) CBA standard curves for IFN-γ and IL-10. b) IFN-γ and 
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Figure 3.4 Kinetics of IL-2, IL-10 and IFN-γ secretion in CD3/CD46 activated T 
cells. Purified CD4
+
 T cells were left non-activated (white shapes) or activated (black 
shapes) with mAbs to CD3 and CD46 for up to 5 days. At each of the indicated time 
points supernatants were harvested to determine IFN-γ, IL-2 and IL-10 amounts by 
CBA. IFN-γ and IL-10 secretion was assessed in cultures containing 50 U/ml rhIL-2, 
while the experiments measuring IL-2 secretion were performed without the addition 
of exogenous rhIL-2. a) CBA standard curves for IL-2, IFN-γ and IL-10. b) Cytokine 
contents of indicated supernatants. Data represent means  SD of 3 separate 
experiments. 
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3.4 Successive induction of IFN- γ (TH1) and IL-10 (Tr1) cells upon CD46 
signals 
The single cell dynamics of IFN-γ and IL-10 secretion mediated by the engagement of 
the TCR and CD46 were next investigated. Purified CD4
+
 T cells were activated with 
mAbs to CD3 alone or in combinations with mAbs to CD28 and CD46 in the presence 
of a neutralizing mAb to IL-2, or either low (5 U/ml) or high (50 U/ml) doses of IL-2. 
Active cytokine secretion was measured 36 hours post activation (Figure 3.5). As 
stated above, blockage of IL-2 inhibited cytokine production under any conditions 
analysed. However, in the presence of IL-2, anti-CD3/CD46 activation and anti-
CD3/CD28/CD46 activation each induced three discrete T cell populations with 
distinct secretion profiles: IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells 
(Figure 3.5). Cultures containing 5 U/ml IL-2 had higher frequencies of IFN-γ 
secreting cells (17.5% ± 5.2%, IFN-γ+/IL-10(-) and IFN-γ+/IL-10+) compared to IL-
10-producing T cells (12.1% ± 1.8%, IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+), whereas 
50 U/ml IL-2 induced a significant increase in the double positive IFN-γ+/IL-10+ 
(26.3% ± 5.8% IL-10+) and single positive IFN-γ(-)/IL-10+ cells (12.2% ± 3.5% IL-
10+). By contrast, although CD3/CD28-stimulated cultures also contained all three 
IFN-γ/IL-10-secreting T cell populations, there was no IL-2-dependent change in the 
ratio of IFN-γ producing vs. IL-10-positive T cells, and the total number of IL-10-
producing cells remained low even in high IL-2 (Figure 3.5). The ability of the 
different cell populations induced by anti-CD3/CD46 to regulate T cell activation was 
then assessed. CD4
+
 T cells were activated through CD3/CD46 ligation and 
subsequently sorted into IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cell 
subsets, which were then cultured for 18 hours in 1 U/ml IL-2. The supernatants of the 
three cell types continued to contain high IFN-γ, approximately equal amounts of IFN-
γ and IL-10; and high amounts of IL-10, respectively (Figure 3.6). When freshly 
purified CD4
+
 T cells were cultured in the presence of these supernatants together with 
cross-linking antibodies to CD3 and CD28, their proliferation, measured at day 6, was 
substantially inhibited by the supernatants of the CD3/CD46-induced IFN-γ+/IL-10+ 
cells, and of the IFN-γ(-)/IL-10+ T cells (Figure 3.6). The inhibition was not evoked 
by supernatants from IFN-γ+/IL-10(-) T cells, nor by supernatants from T cells 
activated for 72 hours via CD3 and CD28. It was, however, almost completely blocked 
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by a neutralizing mAb to IL-10, demonstrating that the IL-10 secreted in response to 
CD3/CD46 activation is the primary soluble mediator of regulation from these cells. 


















Figure 3.5 CD46 and IL-2 induce three distinct populations of  IFN-γ+/IL-10(-), 
IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells. a) Purified T cells were either left non-
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(CD3/CD28), CD3 plus CD46 (CD3/CD46) or CD3 plus CD28 plus CD46 
(CD3/28/46) at a concentration of 2 ug/ml for each of the mAbs. Stimulations were 
carried out in the presence of a function-neutralizing mAb to IL-2 or with the addition 
of 5 or 50 U/ml rhIL-2. Following 36 hours of activation cells were harvested and 
active IFN-γ and IL-10 secretion was assessed using a combined cytokine secretion 
assay specific for IFN-γ and IL-10. a) FSC/SSC gating strategy for the blasting 
activated T cells. b) Percentages of IFN-γ and IL-10 secreting T cells in the indicated 
activating conditions. Values represent the percentage of positive cells in the relevant 
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Figure 3.6 Suppressive abilities of the three distinct populations of IFN-γ+IL-10(-
), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells induced by CD46 and IL-2. a)  Purified 
CD4
+
 T cells were activated with mAbs to CD3 and CD46 (2 μg/ml) in the presence of 
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populations were FACS-sorted according to the cytokine secretion profiles and rested 
for 18 hours. a) Supernatants from IFN-γ+/IL-10(-), IFN-γ+/IL-10+, IFN-γ(-)/IL-10+ 
cultures at 18 hours were harvested and quantified for secreted IFN-γ and IL-10 by 
CBA. Top panels represent the CBA standard curves for IFN-γ and IL-10. b) Purified 
CD4
+
 T cells were activated with mAbs to CD3 and CD28 and cultured in the presence 
of media only (white bar), with the supernatant derived from anti-CD3 plus anti-CD28 
(αCD3+αCD28) activated T cells or with supernatants from the sorted IFN-γ+/IL-10+, 
IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations in the presence of an isotype (IgG1, 
10 μg/ml) control antibody (grey bars). Black bars indicate the addition of a blocking 
antibody to IL-10 (10 μg/ml) to the indicated supernatants. Proliferation was measured 
at day 6. Data are representative of three experiments. *p < 0.05 derived from 
Friedman’s test with Dunn’s multiple comparisons. #p < 0.05 derived from Wilcoxon 
test. 
 
The described experiments were performed with purified CD4
+
 T cell populations that 
at minimum include naïve and memory CD4
+
 T cells, and natural T-regs. To exclude 
the possibility that the observed CD46-elicited populations reflect selective 
reactivation and/or expansion of one or more of these lineages, the anti-CD3/CD46 
activation protocols were applied to naïve T cells. In order to obtain highly purified 
naïve T cells, CD4
+
 T cells were purified from peripheral blood and subsequently 











 lymphocytes as shown in 
Figure 2.3. Post sort naïve T cells were activated with plate-bound antibodies to CD3 
and CD46 for 36 hours in the presence of 50 U/ml IL-2 (Figure 3.7). Subsequently, Dr 
Kemper and Dr Le Frïec analysed the secretion profiles for IFN-γ and IL-10 upon 3 
successive rounds of stimulation with either CD3 mAbs or CD3 and CD46 mAbs. The 
data generated showed that IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells 
were induced in low frequencies during the 1
st
 round of stimulation (Figure 3.7). The 
use of anti-CD3/CD46 to re-stimulate naïve cells previously activated and expanded 
with mAbs to CD3 and CD46 substantially increased the proportion of both IFN-
γ+/IL-10+ and IFN-γ(-)/IL-10+ T cells (Figure 3.7). Moreover, each additional 
CD3/CD46 re-stimulation evidently increased the frequencies of IFN-γ+/IL-10+ and 
IFN-γ(-)/IL-10+ cells compared to the previous activation cycle.  
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1st Stimulation 2nd Stimulation 3rd Stimulation
 
Figure 3.7 Naïve CD4
+
 T cell cultures gradually acquire the ‘phenotype’ of 
CD3/CD46-activated T cells cultures. Naïve human CD4
+











) were isolated through FACS-sorting as 
described in figure 2.3 and activated with mAbs to CD3 and CD46 in the presence of 
50 U/ml rhIL-2 for 36 hours (1
st
 stimulation). Cells were expanded 5 days in the 
presence of 5 U/ml rhIL-2 and then restimulated (2
nd
 stimulation) with mAbs to either 





stimulation) as shown in the presence of 50 U/ml rhIL-2. After each round of 
activation IFN-γ and IL-10 secretion was measured by cytokine secretion assay. Data 
shown are representative of two similarly performed experiments. ^Data provided by 
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3.5 CD46-induced IL10 production originates in a TH1 subset  
In accordance with the last data sets, several publications suggested that the major 
source of IL-10 in vivo may be TH1 cells that begun co-producing this cytokine in 
addition to IFN-γ (Meiler et al., 2008) rather than a designated lineage such as Tr1 
cells. Thus, in the next set of experiments, the origin of CD46-induced IFN-γ+/IL-10+ 
and IFN-γ(-)/IL-10+ T cells was investigated. As diagrammed in Figure 3.8 two 
hypotheses were viable: 1) IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ T cells could generate 
from the IFN-γ+/IL-10(-) TH1 cells or 2) Each cell population could arise from 
separate cell populations. Two sets of experiments were performed. First, purified 
CD4
+
 T cells were activated via CD3 and CD46 in high IL-2 in the presence of 
neutralizing mAbs to IFN-γ, a condition known to inhibit TH1 development (Murphy et 
al., 2000). Subsequently Dr Kemper performed secretion assays in order to identify 
IFN-γ and IL-10 secreting T cells in the different conditions. A significant decrease in 
the number of IFN-γ+/IL-10(-) cells was observed after 48 hours (from 14% ± 4% to 
4% ±2.5%, Figure 3.8). However, this treatment also substantially reduced the 
percentages of CD46-induced IFN-γ+/IL-10+ cells from 16% ± 2% to 2.5% ± 1.5%, 
and of the IFN-γ(-)/IL-10+ cells from 18% ± 3% to 1.5% ± 0.5%. Thus, limiting TH1 
differentiation limits the “IL-10-switch”. IL-10 neutralization did not decrease the cell 
numbers of any of the T cell populations induced but rather slightly increased their 
representation (IFN-γ+/IL-10(-) from 14% ± 4% to 17.5 ± 4%; IFN-γ+/IL-10+ from 
16% ± 2% to 19.5% ± 6.5%; IFN-γ(-)/IL-10+ from 18% ± 3% to 18.5% ± 2.5%, 
Figure 3.8). These data suggest at minimum that the continuous production of IL-10 
initially induced via CD3/CD46/IL-2-mediated signals does not depend on positive 
feedback by IL-10 itself. Second, purified CD4
+
 T cells were activated with plate 
bound mAbs to CD3 or CD3/CD46 in the presence of low concentrations of rhIL-2 (5 
U/ml). The resulting IFN-γ+/IL-10(-) cells were isolated via FACS sorting in 
collaboration with Dr Le Frïec. When, after 4 days of expansion, the cells were re-
stimulated by Dr Le Frïec via CD3/CD46, they produced a high percentage of IFN-
γ+/IL-10+ and IFN-γ(-)/IL-10+ cells (Figure 3.9). Taken together, these two data sets 
strongly suggest that CD46-induced IL-10-secreting T cells derive from an initial TH1 
phase. In fact, whilst the inhibition of IFN-γ through a blocking antibody showed that 
the induction of IFN-γ production by CD46-activated T cells, and consequently the 
signalling of this cytokine, is a requirement for the generation of IFN-γ+/IL-10(-), 
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IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells, these set of experiments were not definitive 
in determining whether IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ cells derived from the 
IFN-γ+/IL-10(-) population. However, the second set of experiments, where IFN-
γ+/IL-10(-) cells were isolated through FACS sorting and restimulated through CD3 
and CD46 were indicative of the ability of purified CD46-induced IFN-γ+/IL-10(-) T 
cells to switch towards the production of IL-10. Furthermore, the importance of CD46 
signalling in these experiments was highlighted by the weaker switch of IFN-γ+/IL-
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Figure 3.8 Anti-IFN-γ treatment inhibits the generation of CD46/IL-2 induced 
IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations. (a) CD46-
induced suppressive IL-10-secreting cells could originate via an initial TH1 ‘phase’ (1) 
or arise from a separate cell population (2). (b) CD4
+
 T cells were purified via 
magnetic cell sorting and were either left non-activated (NA) or activated with plate 
bound mAbs to CD3 and CD46 (αCD3 + αCD46) in the presence of 50 U/ml of rhIL-
2. Anti-CD3 plus anti-CD46 activated T cells were activated in the presence of an 
isotype (IgG1, 10 μg/ml) control antibody or in the presence of function-neutralizing 
mAbs to either IFN-γ (10 μg/ml) or IL-10 (10 μg/ml). After 48 hours of activation 
cytokine secretion was assessed using the cytokine secretion assay. Values shown are 
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Percentages of cytokine-positive cells (IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-
)/IL-10+) under each activation condition. Data shown represent mean +/- SD of three 
separately performed experiments with activation conditions analysed in duplicates. *p 
< 0.05 derived from Friedman’s test with Dunn’s multiple comparisons. ^, Data 
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Figure 3.9 CD46/IL-2 signals induce a switch from a TH1 into a suppressive 
phenotype in CD4
+
 T cells. CD4
+
 purified T cells were activated with plate bound 
mAbs to CD3 or CD3/CD46 each at 2 μg/ml for 36 hours in the presence of 5 U/ml of 
rhIL-2. Cells were stained through a secretion assay for IFN-γ(FITC) and IL-10(APC) 
secretion, FACS-sorted according to the gates shown and expanded for 4 days in 5 
U/ml IL-2. Cells were then restimulated with mAbs to CD3 (α-CD3) or CD3 plus 
CD46 (α-CD3+ α-CD46) and IFN-γ (FITC) and IL-10 (APC) secretion was assessed 
18 hours post activation through a secretion assay. Data shown are representative of 
two similarly performed separate experiments. ^Data in this figure were generated in 
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3.6 CD3/CD46-induced IL-10 cells retain TH1 markers 
T cell lineages are characterized by specific markers: TH1 differentiation is 
accompanied by signal transducer of activation (STAT)1 and STAT4 phosphorylation 
and T-box 21 (T-bet) expression; TH2 cells require STAT6 activation and expression 
of GATA-binding protein (GATA) 3 (Catalfamo and Henkart, 2003; Glimcher and 
Murphy, 2000); natural T-regs are characterized by forkhead box P3 (FoxP3) 
expression (Lewis et al., 2006). When purified CD4
+
 T cells were activated via 
CD3/CD46 for 36 hours in high IL-2, the resultant IFN-γ+/IL-10(-), and IFN-γ+/IL-
10+ and IFN-γ(-)/IL-10+ cells expressed predominantly a TH1 profile (Figure 3.10 and 
Table 3.1), as reflected by strong T-bet expression and STAT4 phosphorylation in 
conjunction with low GATA3 activation and STAT6 phosphorylation. In the mouse, 
maintenance of IL-10-producing TH1 cells requires sustained expression of pSTAT4, 
T-bet, the extracellular-signal regulated kinase (ERK), and the mitogen-activated 
protein kinase (MAPK) (Gabrysova et al., 2009; Saraiva et al., 2009). Likewise, 
CD46-dependent, TCR-independent induction of ERK1/2 in human CD4
+
 T cells was 
previously reported (Zaffran et al., 2001). It was confirmed that all three CD46-
induced T cell populations contained high amounts of pERK1/2 (Table 3.1). Signalling 
through the IL-2 receptor complex induces Janus kinase (JAK)-mediated STAT5 
phosphorylation. Consistent with the fact that CD46-induced IL-10 production is IL-2-
dependent, high expression of pSTAT5 was detected in IFN-γ+/IL-10(-), and IFN-
γ+/IL-10+ cells, although it was lower in IFN-γ(-)/IL-10+ T cells, perhaps consistent 
with their limited proliferative capacity (Catalfamo and Henkart, 2003). In summary, 
the data generated and shown in Figures 3.1 to 3.10 support the notion that the IL-10-
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Figure 3.10 p-STAT4, p-STAT5, p-STAT6 and ICER/CREM expression in the 
CD46-induced IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations. 
CD4
+
 T cells were purified via magnetic isolation (positive selection) and activated 
with plate-bound mAbs to CD3 plus CD46 (2 μg/ml) in the presence of 50 U/ml of 
rhIL2. After 36 hours of activation a secretion assay for IFN-γ (FITC) and IL-10 
(APC) was performed to discriminate the IFN-γ+/IL-10(-), and IFN-γ+/IL-10+ and 
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intracellularly for p-STAT4, p-STAT5, p-STAT6 or ICER/CREM. a) Unstained and 
isotype controls. b) Colour-coded gating strategy for IFN-γ+/IL-10(-) (green gate), 
IFN-γ+/IL-10+ (blue gate) and IFN-γ(-)/IL-10+ (red gate) populations and relative 
histograms. Values represent the mean fluorescent intensity (MFI) values for the 























T-bet +++ +++ +++ ++++ - 
Gata3
b
 -/+ + + -/+ ++++ 
Foxp3 - - - - - 
p-STAT4 ++ +++ ++ ++++ ++ 
p-STAT5 +++ +++ + ++++ ++ 
p-STAT6 + + -/+ + ++++ 
p-ERK ++ +++ +++ ++++ ++ 
ICER/CREM +++ ++ + ++ ++ 
 
Table 3.1 Expression profile of key T cell lineage transcription factors in CD46-
induced effector and suppressor cell populations. Purified CD4
+
 T cells were 
CD3/CD46-activated for 36 hours in 50 U/ml of  rhIL-2 and the subsequent IL-10 and 
IFN-γ secretion assays combined with intracellular FACS staining for the respective T 
cell lineage markers. 
a
, transcription factor expression levels were determined relative 
to the expression levels in either TH1 or TH2 cells with ++++, very strong (highest 
expression observed); +++, strong; ++, moderate; +, low; -/+, weak but detectable; -, 
not detectable. 
b
, due to the lack of a suitable Ab, mRNA GATA3 levels were 
determined using quantitative real-time RT-PCR analysis. 
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3.7 IL-2 regulation by CD3/CD46 
An interesting and widely accepted observation is that all IL-10-producing T cells with 
regulative capacity lose the capacity to coproduce IL-2 (Gabrysova et al., 2009; 
Saraiva et al., 2009; Meiler et al., 2008). This is particularly true for the IL-10-
secreting cells that arise from TH1 cells. Thus, to draw further parallels with TH1 cells, 
IL-2 expression in the three distinct IFN- and/or IL-10-secreting cell populations was 
examined (Gabrysova et al., 2009; Hayday, 2009). CD46-dependent IL-2 expression 
was detected in CD3/CD46-activated CD4
+
 T cell cultures (Figure 3.11). More than 
85% of IFN-γ+ cells actively secreted IL-2 at 36 hours post CD3/CD46 activation 
(Figure 3.11). However, less than 25% of IL-10-secreting cells were co-secreting IL-2. 
Thus, CD3/CD46-activated cells shared with TH1 cells the production of IL-2, which 
ceased with the induction of the IL-10-secreting state. Gene array data generated by 
Dr. Claudia Kemper previous to the start of the project were used to identify possible 
regulators of IL-2 transcription. The gene array was based on the comparison of 
CD3/CD46-activated versus CD3/CD28-activated primary CD4
+
 T cells and revealed 
significantly higher levels of mRNA encoding the ICER/CREM protein in CD46-
activated cells. Translocation to the nucleus of ICER/CREM causes transcriptional 
attenuation of IL-2 (Powell e al., 1999). When CD4
+
 T cells were activated through 
CD3 plus CD46 mAbs it was confirmed that CD3/CD46 ligation induced up-
regulation of ICER/CREM protein expression (Figure 3.12). The level of ICER CREM 
expression was also assessed by FACS on the three distinct populations induced by 
CD46 and IL-2 (i.e IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+) (Figure 
3.10). Unexpectedly, ICER/CREM expression was highest in IFN-γ+/IL-10(-) cells, 
which continue to express IL-2 (Figure 3.10). However, analysis by western blot of 
cytoplasmic and nuclear fractions revealed that ICER/CREM nuclear translocation was 
only consistently detected 48 hours post CD3/CD46 stimulation (Figure 3.13), which 
coincides with the appearance of IL-10 in the culture medium (Figure 3.4). Activation 
of T cells through CD3 and CD3/28 activation did not lead to ICER/CREM nuclear 
translocation at any time point (Figure 3.13). It is important to notice that the detection 
of ICER/CREM by flow cytometry (Figure3.12) did not reflect the findings of protein 
expression obtained by western blot (Figure 3.13). In fact, the staining for 
ICER/CREM in CD4
+
 T cells activated with anti-CD3 or anti-CD3 plus anti-CD28 by 
FACS showed increased ICER/CREM expression in comparison to unstimulated cells. 
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The same finding was not replicated in the western blot analysis where only activation 
conditions including CD46 determined ICER/CREM detection. A possible explanation 
is given by the sensitivity of the different techniques. Flow cytometry has higher 
sensitivity in the detection of antigens and this may explain the different results 
obtained. To determine if ICER/CREM bound preferentially to the IL-2 promoter in 
IL-10+ cells, chromatin Immunoprecipitation (ChIP) using an ICER/CREM-specific 
mAb was applied to IFN-γ+/IL-10(-) and IFN-γ(-)/IL-10+ cells purified 36 hours post 
CD3/CD46 activation. IL-2 promoter-specific DNA sequences were precipitated only 
from IL-10+ cells, and not from IFN-γ+ T cells (Figure 3.13c). Thus, CD3/CD46 
activation induces strong ICER/CREM expression in TH1 cells but this is inactive in 
IFN-γ+ cells that continue to produce IL-2. Instead, active nuclear translocation occurs 
preferentially in IL-10+ cells, consistent with their decreased IL-2 production. ChIP 
was only performed on the IFN-γ+/IL-10(-) and IFN-γ(-)/IL-10+ populations. The 
IFN-γ+/IL-10+ T cells were not considered in this set of experiments because it was 
postulated that the comparison between IFN-γ+/IL-10(-) and IFN-γ(-)/IL-10+ cells 
would have given a neat result in terms of IL-2 promoter binding by ICER/CREM 
when either IFN-γ or IL-10 were the main cytokine produced. However, the ChIP 
analysis of IFN-γ+/IL-10+ could have provided further evidence of ICER/CREM 
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Figure 3.11 CD3/CD46-induced IL-10 production is coupled with inhibition of IL-
2 secretion. Purified CD4
+
 T cells were either left non-activated or stimulated with 
plate bound mAbs to CD3 and CD46 (Anti-CD3/CD46) for 36 hours and active 
secretion of IFN-γ, IL-2 and IL-10 was measured through secretion assays. Top dot 
plots refer to the secretion assay conducted for the evaluation of IFN-γ and IL-2 
secretion using IFN-γ (FITC) and IL-2 (APC) as detection antibodies in non-activated 
and CD3/CD46-activated T cells. Lower dot plots refer to the secretion assay for the 
identification of IL-10 (PE) and IL-2 (APC) in non-activated and CD3/CD46-activated 
T cells. Values represent the percentage of positive cells within the relevant quadrant. 
Results are representative of three similarly performed experiments. 
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Figure 3.12 CD3/CD46-activation increases ICER/CREM expression. a) Purified  
CD4
+
 T cells were either left non-activated or stimulated with plate bound antibodies 
to CD3, CD3 plus CD28 (CD3/28), CD3 plus CD46 (CD3/46) or CD3 plus CD28 plus 
CD46 (CD3/28/46) used at a oncentration of 2 μg/ml. T cells were stimulated for 48 
hours in the presence of 50 U/ml of rhIL-2. Following stimulation T cells were 
harvested and assessed for ICER/CREM expression by intracellular staining. Data are 
reported as histograms of mean fluorescence intensity (MFI) of expression and are 
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Figure 3.13 CD46-mediated signals participate in the regulation of IL-2 expression by CD4
+
 T cells via nuclear translocation of ICER/CREM. a) 
Purified CD4
+
 T cells were either left non-activated (NA) or were activated with plate bound mAbs to CD3 plus CD46 (CD3/46) in the presence of 50U/ml of 
rh-IL2 for 24 and 48 hours. Nuclear (N) and cytoplasmic (C) protein fractions were obtained at each time point. Normalized protein samples were analyzed for 
ICER/CREM expression by Western blotting. Shown is one representative of three experiments. b) Purified CD4
+
 T cells were activated as in (a). In addition 
CD3, CD3/28, CD3/28/46 activations were performed for 24 (top panel) and 48 hours (bottom panel). T cells were activated with mAbs to CD3 plus CD46 
(2μg/ml) for 36 hours in the presence of 50 U/ml IL-2. Subsequently IFN-γ+/IL-10(-) cells and IFN-γ(-)/IL-10+ cells were then FACS sorted and 1.2 x105 cells 
for each population were used for chromatin immunoprecipitation using a mAb to ICER/CREM and IL-2 promoter specific primers. The left panel shows a PCR 
control reaction using the genomic DNA of both T cell populations and the right panel shows the PCR reaction using the respective DNA samples following the 
chromatin immunoprecipitation procedure. Data shown are representative of three independently performed experiments.
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3.8 Defective IL-10-switching in rheumatoid arthritis 
As mentioned previously, assessing the in vivo importance of CD46-mediated 
regulation of TH1 responses is currently hampered by the lack of a suitable small 
animal model. Thus, T cells from patients that suffer from a TH1-mediated 
autoimmune disease, rheumatoid arthritis (RA), were investigated to assess whether 
they present a defect in the CD46-mediated regulation of the TH1 induction and 
contraction pathway. The responses to CD3/CD46 activation in the presence of 25 
U/ml IL-2 of CD4
+ 
T cells from three healthy donors and three adult patients with 
inflammatory arthritis were compared. After 36 hours of activation the cultures from 
RA patients contained higher percentages of IFN-γ+/IL-10(-) and IFN-γ+/IL-10+ but 
very few and IFN-γ(-)/IL-10+ T cells (Figure 3.14). In addition, while amounts of IFN-
γ and IL-10 in the supernatants of T cells from healthy donors were roughly similar, T 
cells from RA patients produced >10 fold more IFN- γ than IL-10 (Figure 3.14b). 
Because chronic inflammatory conditions such as RA are often attributed to 
inappropriate responses to persistent antigen, cytokine expression was examined after 
T cell re-stimulation with CD3/CD46. Cultures of T cells from healthy donors showed 
increased switching to the IFN-γ(-)/IL-10+ state, now containing approximately equal 
distributions of IFN-γ-producing (IFN-γ+/IL-10(-) and IFN-γ+/IL-10+ and IL-10-
secreting (IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+) T cells (Figure 3.14c). In contrast, re-
stimulated cultures from RA patients lacked a significant IFN-γ(-)/IL-10+ population, 
with a diminution even in IFN-γ+/IL-10+ cells relative to the cells’ initial stimulation 
(Figure 3.14c). To further investigate IL-10-switching in arthritis, CD4
+
 T cells were 
isolated from the synovial fluid of both inflamed knee joints of a juvenile arthritis 
patient. Similar to the results obtained with blood-derived CD4
+
 T cells from RA 
patients, these synovial T cells did not switch to the IFN-γ(-)/IL-10+ state after an 
initial CD3/CD46 stimulation (Figure 3.14d); produced significantly more IFN-γ than 
IL-10 during expansion (Figure 3.14e); were mostly ‘locked’ into the IFN-γ+/IL-10(-) 
state upon restimulation (Figure 3.14f); These data strongly suggest that the 
TCR/CD46/IL-2-mediated switch from a pro-inflammatory TH1 to an 
immunoregulatory IL-10-secreting phenotype is dysfunctional in RA and juvenile 
arthritis patients. A different explanation to these set of data is linked to the kinetics of 
IL-10 expression and secretion in RA patients and healthy donors. It may be possible 
that CD4
+
 T cells from RA patients require longer activation through CD3 and CD46 
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signals in order to start producing IL-10 in higher amounts that could counteract the 
IFN-γ production. To address this point CD4+ T cells from RA patients could be 
activated for longer than 36 hours and cytokine secretion screened at different time 
points in a kinetic study. A different explanation for the low frequencies of IL-10 
producing cells could be linked to epigenetic changes of the IL-10 gene. The DNA 
methylation status (at CpG sites) is associated with cytokine expression (Fitzpatrick 
and Wilson, 2003). The IL-10 gene could present a hypermethylated status in CD4
+
 T 
cells of RA patients which would not allow for its expression. A further possibility that 
could explain the lower IL-10 production by RA patients in comparison to healthy 
donors is the inability of CD4
+
 T cells from RA patients to shutdown IFN-γ 
production; as a consequence the ratio between IFN-γ and IL-10 would strongly favour 
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 T cells from patients with rheumatoid arthritis are defective in 
the IFN-γ (TH1) to IL-10 switch induced by anti-CD3 and anti-CD46. (a) 
Comparison of cytokine-secreting cells among blood-derived T cells obtained from 
three healthy donors (HD-A–HD-C) and three patients with rheumatoid arthritis (RA-
A–RA-C) and activated for 36 h with anti-CD3 and anti-CD46 plus IL-2 (50 U/ml). (b) 
IFN-γ and IL-10 in supernatants of T cells activated as described in (a) and then 
maintained in culture for 5 days with IL-2 (50 U/ml). (c) Frequency of cytokine-




 Chapter 3 CD46-mediated regulation of cytokine secretion in CD4
+




with anti-CD3 and anti-CD46 plus IL-2 (50 U/ml); results presented as in (a). (d) 
Frequency of cytokine-secreting cells among T cells from the synovial fluid of the left 
knee (JA-lk) and right knee (JA-rk) of a patient with juvenile arthritis and blood-
derived T cells from two healthy donors (HD-D and HD-E) after primary stimulation 
with anti-CD3 and anti-CD46; results presented as in (a). (e) Secretion of IFN-γ and 
IL-10 by the cells in d during population expansion as described in (b). (f) Frequency 
of cytokine-secreting cells among the cells in d after secondary stimulation as in c. 
Data are representative of two experiments (a–f). ^Data generated by Dr Claudia 
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3.9 Local complement production drives IL-10 expression during T cell 
activation 
In the experimental in vitro system used, activation of CD4
+
 T cells was achieved by 
immobilised antibodies to CD3 and CD46. Engagement of the TCR in vivo is easy to 
envision as it is achieved through the presentation of peptide loaded MHCII by APCs. 
A more complicated scenario to envisage regards the engagement of CD46 during T 
cell activation. It could be argued that presence of a pathogen will activate the 
complement system and thereby lead to generation of C3b (the prime ligand for CD46) 
on the activated T cells. However, a more intriguing possibility is suggested by 
publications describing the generation of local complement activation fragments 
during cognate APC-T cell interactions in mouse systems (Heeger et al., 2005; Lalli et 
al., 2007; Strainic et al., 2008). To assess whether local complement fragments are also 
produced by human CD4
+
 T cells, the hypothesis according to which TCR-activation 
can locally induce CD46 ligands was investigated. Activation of CD4
+ 
T cells with 
anti-CD3 mAbs showed high C3b deposition onto T cells surfaces (Figure 3.15a). C3b 
generation was increased by co-stimulation with either CD28 or CD46 mAbs attesting 
the ability of TCR and CD46 engagement to locally induce CD46 ligands/signalling. A 
second important question that arose from these studies concerned the importance of 
CD46 signalling in comparison to the ‘classic’ co-stimulator CD28 in the IL-10 
induction pathway of human TH1 cells. In order to address this question, CD4
+
 T cells 
were purified via magnetic sorting. Subsequently Dr. Kemper activated the purified T 
cells through CD3- and CD3/CD28-activated in the presence of soluble recombinant 
CD46; this allowed locally produced C3b, generated upon TCR activation, not to bind 
cell membrane expressed CD46 and prevent signalling. Surprisingly, blocking 
endogenous CD46 engagement (by saturating the system with soluble CD46) 
determined a decrease of IL-10 production in both anti-CD3 and anti-CD3/CD28 
activated T cells. These data demonstrated that the activation of T cells provides the 
means to engage CD46 locally. In addition it confirmed that CD46, and not CD28, is 
the key co-stimulator for the IL-10 switch. 
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Figure 3.15 CD46 induced C3b drives IL-10 expression in CD4
+ 
T cells stimulated 
with anti-CD3 and anti-CD28. (a) Flow cytometry of C3b surface deposition on 
purified CD4
+
 T cells either non-activated or activated for 12 hours with immobilized 
mAbs to CD3, CD3 plus CD28 and CD3 plus CD46 (2 μg/ml). Data are representative 
of four experiments. (b) Production of IL-10 by purified T cells either left non 
activated or activated for 36 hours with mAbs to CD3 alone or mAbs to CD3 plus 
CD28 (horizontal axis) plus media alone or media plus soluble CD46 (sCD46). *p < 
0.05 derived from Friedman’s test with Dunn’s multiple comparisons. ^ Data 
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The increasing evidence for the importance of IL-10 in suppressing immunopathology 
is clearly documented in humans, where it has both biological and clinical implications 
(He et al., 2009). Despite the identification of IL-10 secreting Tr1 cells more than a 
decade ago, the inability to identify a marker/transcription factor associated to such 
cells has hampered progress in this field of research (Bacchetta et al., 1994; Groux et 
al., 1997). By contrast increasing evidence supports the concept of a switching model 
through which IL-10 secreting cells derive from an earlier incarnation of IFN-γ 
producing TH1 cells. Cultures that co-express IL-10 and IFN-γ have been clearly 
documented (Arase et al., 1994; Meisel et al., 1996; Taub et al., 1993a), and such a 
switch would have the advantage of inducing a regulatory cytokine and simultaneously 
suppressing an effector cytokine based on the recognition of the same antigen. The 
data shown in this chapter prove that human TH1 cells are promoted by the co-
engagement of the TCR and CD46. Increasing environmental IL-2, as could be 
envisaged during an effector response (Figure 3.16), promotes the switch of TH1 cells 
to IL-10 producing lymphocytes and concomitantly diminishes endogenous IL-2 
production via nuclear translocation of ICER/CREM.  
The temporally regulated induction of cytokines with opposing effects (i.e. IFN-γ and 
IL-10) mediated by CD46 clarifies the controversial findings regarding the ability of 
CD46-induced T cells to support DC maturation and B cell responses (Barchet et al., 
2006). In fact, although it is known that Tr1-derived IL-10 negatively affects DCs 
maturation by preventing the up-regulation of MHCII, CD80 and CD86, supernatants 
from CD46-activated T cells have been shown to be able to promote DC maturation, 
antigen presentation and T cell induction (Barchet et al., 2006). The latter effects were 
described in the original report by Barchet et al., (2006) as mediated by the cosecretion 
of granulocyte–macrophage colony-stimulating factor (GMCSF) and soluble CD40 
ligand (sCD40L) which neutralize the CD46-indued IL-10 inhibitory effects on DCs 
(Steinbrink et al., 2002). However, in light of the successive induction of the CD46-
mediated TH1 and IL-10 phases described in this chapter it is possible to speculate that 
mainly the TH1 phase of the switch (i.e. IFN-γ+/IL10-) would favor DC growth and 
maturation through the cosecretion of GMCSF and sCD40L. The accumulation of IL-2 
would then promote CD46-mediated IL-10 production during the double positive IFN-
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γ+/IL10+ and single positive IFN-γ-/IL10+ phases and would inhibit DCs function 
favoring the contraction of the immune response. Co-cultures of CD46-activated T 
cells have been shown to provide B cell help enhancing antibody production (namely 
IgG1 and IgM) in a cell-cell contact dependent mechanism (Barchet et al., 2006). The 
importance of this mechanism has been shown ex vivo; in fact T cells from a CD46 
deficient patient were not able to promote B cell help. The finding that CD46 induced 
signals primarily induce a TH1 response are in accordance with the data of Fuchs et al., 
(2009) and support the notion that TH1 are pivotal helpers of B cells responses and that 
defects affecting TH1 induction impair humoral immunity (Fremeaux-Bacchi et al. 
2006). 
It is now widely acknowledged that the complement system functions well beyond a 
simple danger recognition and microbial clearance system and participates actively in 
shaping adaptive immune responses (Carroll, 2004). In recent years the ability of 
complement to instruct the adaptive immune response has reinforced a novel concept: 
the one of local complement production. Thanks to the ability of bone marrow derived 
cells to produce complement components, studies utilising bone marrow chimeras 
have been essential in elucidating the role of local complement production and in 
discerning it from the role of systemic complement (Strainic et al., 2008; Pavlov et al., 
2008; Zhou et al 2011). Carroll’s group was among the first to show the importance of 
C3 derived from myeloid cells of WT bone marrows in restoring humoral responses 
within a C3
-/-
 animal (Verschoor et al., 2001). Strainic et al., described how local 
complement production is able to generate alternative pathways components (namely 
C3, fB, fD, C5) that can actively shape T cell immunity via APC (Strainic et al., 2008). 
The data shown in Figure 3.15 suggests that the engagement of human CD4
+
 T cells 
through the TCR alone or in conjunction with CD46, promotes the production of C3b 
and its binding to CD46 showing for the first time that local complement production 
may be an important process also in human systems. This finding also raises a vital 
question regarding the hierarchy of CD46 activation in relation to CD28 costimulation 
in the induction of IL-10 by TH1 cells. It is important to note that the concomitant 
activation of CD28 and CD46 on human CD4
+
 T recapitulated (if not with a stronger 
phenotype) the cytokine secretion pattern of TCR and CD46 activated T cells (Figure 
3.5). Hence, hypothetically engaging CD28 (through APCs B7-1) and CD46 (through 
local complement) would still favour the CD46-induced T cell switching model. 
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Importantly CD3/CD28 activation of CD4
+
 T cells induces C3b deposition and the 
complete inhibition of CD3/CD28-induced IL-10 production by interference with 
‘intrinsic’ CD46 activation (Figure 3.15) suggests a dominant role for CD46 in IL-10 
expression by CD4
+
/TH1 cells. Such ‘physiological’ CD46 engagement through 
C3b/C4b produced by activated T cells may provide the molecular mechanisms by 
which IL-10-secreting Tr1 cells are induced in vitro by other groups. In fact, the 
generation of ‘classic’ adaptive IL-10 (and IFN-γ)-producing Tr1 cells in culture 
requires minimally repetitive CD3/CD28 activation (or exposure to DCs) of CD4
+
 T 
cells in the presence of high IL-2 (Groux et al., 1997; Jonuleit et al., 2000), which are 
conditions conducive to CD46 engagement and CD46-induced IL-10 production.  
Testing the notion that CD46 is important in regulating CD4
+
 T cell responses in a 
small animal model is currently hampered by the fact that rodents lack CD46 
expression on somatic cells and that a murine molecule recapitulating CD46’s role in 
TCR/IL-2-dependent IL-10 induction has not yet been identified (Kemper and 
Atkinson, 2007). A previous study in humans, however, connects significantly 
decreased IL-10 expression upon CD46 activation of CD4
+ 
T cells with multiple 
sclerosis (MS) (Astier et al., 2006). Although the switch from the TH1 to Tr1 phase 
was not examined in this study, low IL-10 production by T cells from MS patients 
were shown upon CD46 engagement. These data combine with the novel observation 
presented in Figure 3.14 that T cells from RA patients are unable to promote the 
CD46-mediated TH1/Tr1 switch implicating defects in this pathway in a clinically 
significant autoimmune/inflammatory condition. The importance of TH1 switching in 
vivo is suggested by the observation that only continuous exposure of non-allergic 
beekeepers to high doses of bee venom induces a decrease of antigen specific IFN-γ-
secreting TH1 cells and a parallel increase in antigen specific IL-10-producing Tr1-like 
cells indicated by the decrease of T cell-mediated cutaneous swelling (Meiler et al., 
2008). After antigen withdrawal, bee venom-specific T cells produce again only high 
IFN-γ and no IL-10 upon first re-activation and increased IL-10 production by T cells 
only occurs upon repetitive stimulation. Although the data do not prove that the same 
antigen specific T cells producing IFN-γ are switching to IL-10 production, the authors 
suggest that this switch mechanism may be a viable one. The data presented in Figure 
3.7 showed that naive CD46-activated T cells follow a similar scheme by which they 
acquire an evident Tr1-like phenotype only upon repetitive stimulation. These data are 
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consistent with the recent concept that IL-10-secreting cells may not necessarily 
represent a lineage but rather the ‘endpoint’ of a successful effector T cell response. 
The model in Figure 3.16 summarizes and envisages how CD46 signals may be 
involved in the shaping of an immune response against pathogens inducing a TH1 
response (i.e. TB, Leishmania, Toxoplasma). During the “initiation phase” of an 
immune response set to eliminate a pathogen, TCR engagement through the pMHC II 
of APCs, would favour C3b production and consequently CD46 engagement; given the 
low micro-environmental IL-2 characteristic of the initial phase of an immune 
response (due to low T cell numbers), the CD4
+
 T cells would skew towards a TH1 
phenotype through the activation of STAT4, STAT1 and T-bet. During the “effector 
phase” of the immune response, intermediate/high environmental IL-2 derived from 
the expansion of T cells, would be implemented by CD46-activated T cells as the 
signal for the induction of IL-10 secretion and IFN-γ shutdown. IL-10 Tr1 cells 
(Foxp3-) would then drive the contraction after the pathogen has been cleared by 
inhibiting bystander TH proliferation, IL-2 and IFN- γ production and by negatively 
regulating DCs. Different approaches could be taken to verify the model in figure 3.16. 
Silencing CD46 in human T cells would represent an approach to prove the importance 
of the signalling through this molecule for the initiation of a TH1 response and for the 
production of IL-10. Co-cultures of DCs and T cells in which CD46 is not expressed 
(by RNA silencing or by using T cells from CD46 deficient patients) could be 
compared to co-cultures of DCs and CD46-expressing T cells. Evidence showing the 
involvement of CD46 in TH1 induction and switching could be provided by screening 
the amounts of secreted IFN-γ and IL-10 together with the expression of TH1 markers 
T-bet, STAT1 and STAT4 in the two different co-culture systems. 
Given the central role of IL-2 in the switch model proposed in figure 3.16, the 
importance of CD46 and IL-2 signals could be evaluated using co-cultures of DCs and 
T cells deficient for IL-2. In such experiments, CD4
+ 
T cells would be activated 
through CD46 with mAbs and subsequently co-cultured with DCs. C3b could be used 
as a stimulus to activate CD4
+ 
T cells through CD46 but the use of C3b as stimulus 
could have confounding effects since it would bind to CR1. CR1 engagement on T 
cells, negatively regulates proliferation and activation (Wagner et al., 2006). Co-
culturing CD46 activated T cells and DCs in an IL-2 deficient system would provide a 
setting of complete dependency on exogenous IL-2. Hence, CD46-activated T cells 
would be activated through TCR engagement by DCs and adding exogenous IL-2 
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could be an approach to test the model in figure 3.16. In fact, adding low, intermediate 
or high concentrations of IL-2 would enable to determine the generation of mainly 
IFN-γ producing T cells (low IL-2) or IFN-γ and IL-10 producing T cells (intermediate 
and high IL-2). Hence, the supernatants for each of these cultures (i.e. low, 
intermediate and high IL-2) could provide information on the production of IFN-γ, IL-
10 and C3b and allow to gather information on whether these components would be 
produced in a similar trend to the one shown in figure 3.16. Since one of the main 
issues in proving the model in figure 3.16 is the demonstration that the same T cell that 
responds to a specific antigen switches from the production of IFN-γ to the one of IL-
10, a technically challenging approach, would involve the generation of T cells with 
the genes for IFN-γ and IL-10 under different fluorescent proteins (e.g. in such system 
IFN-γ production could be detected through the expression of green fluorescent 
protein). An imaging experiment involving DCs and CD46-activated T cells co-
cultures could provide evidence of the different cytokines produced in different time 
points of a responding T cell. Importantly, the absence of a small animal model poses 
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Figure 3.16 CD46 and IL-2 mediated signals in the self-regulating loop of TH1 
lymphocytes. Representative figure of the implementation of T cell incoming signals 
induced by myeloid Dendritic Cells (mDCs) (TCR, signal 1), varying concentrations 
of micro-environmental IL-2 (Signal 2) and C3b (Signal 3) developed during an 
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Investigating the molecular signatures of the CD46-
mediated TH1 regulation  
 
 




4.1 Introduction  
The mechanism of T cell switching described in Chapter 3 ensures the important 
flexibility to respond appropriately to micro-environmental signals during an infection 
setting. However, it poses a major obstacle in the therapeutic usage of IL-10-secreting 
TH1 suppressor cells; in fact suppressive IL-10 T cells generated in a controlled in 
vitro environment may reacquire a pro-inflammatory TH1 phenotype after injection 
into autoimmune or transplant patients. Thus, a better understanding of the 
intracellular pathways driving the IFN-γ to IL-10 switch is necessary to provide 
potential targets to either induce or abrogate specific cytokine secretion in TH1 cells. 
During the next part of the thesis, the study concentrates on the definition of the 
molecular signature accompanying cytokine switching in human TH1 cells. In order to 
clearly define the molecular signals regulating the CD46/IL-2-mediated ‘life cycle’ of 
TH1 cells and highlight key molecules involved in cytokine switching, gene arrays 
from the three distinct IFN- and/or IL-10 expressing T cells were generated (see 
paragraph 4.3 and figure 3.16). The asparagine endopeptidase (AEP) was identified as 
among the highest differentially expressed genes between these populations. AEP is a 
lysosomal cysteine endopeptidase with a wide range of immunological functions 
including antigen processing, MHC II and TLR maturation (Sepulveda et al., 2009; 
Watts et al., 2003). The human homologue of AEP, firstly identified in legume seeds 
(Chen et al., 1997), was cloned and discovered in 1997 by Chen. The gene that 
encodes for human AEP is located on chromosome 14q32.1 (NCBI, Nucleotide) and 
encodes for a protein of 433 amino acids (Chen et al., 1997). AEP is translated as an 
inactive precursor which undergoes proteolytic cleavage in order to generate the active 
form of the peptidase (Li et al., 2003). AEP maturation requires two steps; the inactive 
form of 56 kDa located in pre-lysosomal compartments, is auto-catalytically converted 
into an active precursor of 46 kDa after the sequential cleavage of a C-terminal 110 
residue and an N-terminal 8 residue propeptide (Li et al., 2003). Auto-activation is a 
pH dependent process and is optimal for pH values ranging from 4.5 and 5.5 which are 
achieved during the endo/lysosomal maturation process. The second step is not 
autocatalytic but mediated by different lysosomal proteases and generates a mature 36 
kDa form (Li et al., 2003). Proteases are classified on the basis of the key amino acid 
found in the active site. They include Serine, Cysteine, Threonine, Aspartate and 
Glutamic proteases (Rawlings et al., 2012).  AEP is a unique cysteine protease as it 




specifically cleaves proteins after an asparagine (Asn) residue. AEP is a member of the 
peptidase family C13. Most of the known cysteine proteases, including cathepsins S, 
L, F, B and C are related to the enzyme papain and are grouped in the C1 family of 
peptidases (Chen et al., 1998; Rawlings et al., 2012; Watts et al., 2005). 
Initial data regarding the immunological role of AEP focused mainly on the antigen 
processing pathways. Manoury et al. (1998), showed that inhibition of AEP in vitro 
and in vivo affects the processing of tetanus toxin antigen and its presentation in 
association with MHC class II molecules in B cells  (Manoury et al., 1998). Further 
studies highlighted how the enzymatic activity of AEP induces the destruction of auto-
antigens such as MBP, playing an important role in protection from autoimmunity 
(Manoury et al., 2002). The finding that AEP is involved in the removal of the MHC 
Class II Invariant Chain Chaperone during the MCH class II maturation process 
reinforced the importance of this molecule in APCs. However, further in vivo analyses 
showed that AEP is not essential in the class II antigen presentation process since it 
shares redundancy of function with other lysosomal proteases (Maher et al., 2005). 
AEP mediates the initial processing of TLR3, TLR7 and TLR9 in conjunction with 
members of the cathepsins families (Sepulveda et al., 2009). Studies on AEP knockout 
mice showed that AEP is also important in the maturation of the lysosomal cystein 
protease known as Cathepsin (Cat) L. Maeher et al. (2005) showed that AEP-deficient 
cells fail to develop the mature two chain form of Cat L which is important in the 
development of CD4
+
 T cells. However, the authors reported that AEP knockout mice 
have normal numbers of CD4
+
 T cells when compared to WT mice (Maehr et al., 
2005). A second study on AEP knockout mice showed the development of a group of 
symptoms that resemble the human disease Hemophagocytic Lymphohystiocytosis 
which is characterised by an increase of lymphocytes and hystiocytes (i.e. 
macrophages and DCs). Pathological symptoms of spleno- and hepato-megaly were 
reported together with an increased level of TNF in the blood. Other cytokines 
including IFN-γ, IL-1β and IL-4 were not affected by the absence of AEP (Chan et al., 
2009). Together these data highlight how AEP has multiple immune related functions 
that can affect innate (e.g. TLR) sensing and adaptive initiation of immune responses 
(i.e. via APCs). 
  




4.2 Hypothesis and Aims 
Most of the data available on AEP is related to its function in antigen processing with 
particular focus on APCs (B cells, DCs and macrophages). Although Maher’s paper 
showed that AEP
-/-
 mice have normal numbers of CD4
+
 T cells, the study did not 
contain any subsequent functional assays in regards to cytokine production by 
activated mouse TH1 cells. In fact, the field currently dismisses a direct role for AEP in 
T cell function. Given the existence of a link between CD46 signalling and AEP 
expression, shown by gene array data on CD46-induced IFN-γ+/IL-10(-), IFN-γ+/IL-
10+ and IFN-γ(-)/IL-10+ cells, it was interesting to test the hypothesis by which AEP 
is a molecular regulator of IFN-γ and IL-10 production or secretion by human-CD46 
activated T cells. Therefore, the main aims were to confirm AEP expression on a gene 
and protein level, analyse the effects of AEP inhibition on human T cell activation and 
















4.3 Generation of gene arrays from CD46 induced IFN-γ+/IL-10(-), IFN-γ+/IL-
10+ and IFN-γ(-)/IL-10+ cells 
To understand the molecular signals regulating the CD46/IL-2 mediated switch of 
human TH1 into IL-10 regulatory cells, gene arrays were generated using mRNA 
isolated from the three distinct populations of IFN- and/or IL-10 secreting T cells 
(IFN-γ+, the IFN-γ+/IL-10+ and IL-10+). To obtain representative results and 
statistical significance two donors were selected for each gender and were aged 
matched (Table 4.1). Given that naïve and memory T cells respond similarly to 
CD3/CD46/IL-2 activation in regards to IFN-γ/IL-10 switching (Figure 3.7), and in 
order to obtain at minimum 10
6
 cells post sort for each of the three populations, whole 
CD4
+
 T cells were blood purified and activated through antibodies to CD3 and CD46 
in the presence of rhIL-2 (50 U/ml) for 36 hours. Following activation a secretion 
assay was performed in order to identify and sub-sort the IFN-γ producing cells, the 
IFN-γ/IL-10 co-secreting cells and the IL-10 secreting lymphocytes (Figure 4.1). Post 
sort the mRNA was isolated and screened for purity using a Nanodrop ND-1000 
spectrophotometer (Table 4.2). 
 
 Age Sex 
Donor 1 48 Male 
Donor 2 37 Male 
Donor 3 32 Female 
Donor 4 45 Female 
Table 4.1 Gene array donors, age and sex. The table reports the age and sex of the 
donors involved in the gene arrays study. From each donor CD4
+
 T cells were 
magnetically sorted via positive selection and subsequently activated with anti-CD3 
plus anti-CD46 mAbs in the presence of 50 U/ml of rhIL-2 for 36 hours. 














Figure 4.1 Sorting strategy for the isolation of IFN-γ+/IL-10(-), IFN-γ+/IL-10+ 
and IFN-γ(-)/IL-10+ cells induced by anti-CD3 plus anti-CD46 activated T cells. 
CD4
+
 T cells were isolated from 4 different donors (Table 4.1) and activated with 
mAbs to CD3 and CD46 (2 μg/ml) for 36 hours in the presence of 50 U/ml of rhIL-2. 
Following activation IFN-γ and IL-10 secretion assays were performed for each donor, 
in order to identify and sub-sort the three populations of IFN-γ+/IL-10(-), IFN-γ+/IL-
10+ and IFN-γ(-)/IL-10+ secreting cells. The gating strategy adopted for the sorting of 
IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ lymphocytes was based on 
FSC/SSC gating (gate P1, left panel), doublet depletion (central panel, gate P2) and 
IFN-γ (FITC-A) and/or IL-10 (APC-A) positive staining (right panel, gates P3-blue-, 
P4 –pink- and P5 –violet-). Unstained (a) and stained (b) samples are shown. Numbers 
























RNA Sample RNA ng/μl Absorbance Ratio 
260/280 
IFN-γ+ (Donor 1) 282 2.08 
IFN-γ+/IL-10+ (Donor 1) 128 2.09 
IL-10+ (Donor 1) 135 2.06 
IFN-γ+ (Donor 2) 66 2.03 
IFN-γ+/IL-10+ (Donor 2) 58 2.06 
IL-10+ (Donor 2) 179 2.05 
IFN-γ+ (Donor 3) 438 2.06 
IFN-γ+/IL-10+ (Donor 3) 280 2.01 
IL-10+ (Donor 3) 239 2.08 
IFN-γ+ (Donor 4) 244 2.01 
IFN-γ+/IL-10+ (Donor 4) 247 2.03 
IL-10+ (Donor 4) 248 2.04 




Table 4.2 mRNA purity screen. The mRNA extracted from IFN-γ+/IL-10(-), IFN-
γ+/IL-10+ and IFN-γ(-)/IL-10+ sorted cells of each donor was screened for purity 
using a Nanodrop spectrophotometer. The quality control was performed by analysis 
of the absorbance ratio between readings at 260 nanometers and 280 nanometers 
(A260/280). Ratios of A260/280 equal or greater than 2 indicated the absence of 
contaminants (e.g. proteins or phenols) and was indicative of high purity RNA. 
 
The gene chip was carried out on the Affymetrix GCS3000 platform provided by the 
KCL genomic centre in collaboration with Dr Matthew Arno. The quality controls that 
were performed for the validation of the gene array data are shown in figure 4.2 and 
included: positive vs negative area under the curve (AUC), all probe set relative log 
expression (RLE) mean, all probe set mad residual mean and box plots of raw and 
normalised intensity signals (Figure 4.2). The positive vs negative AUC value for a 
receiver operating characteristic (ROC) curve, plots the detection of positive controls 
(putative exon based probe sets of housekeeping genes) against negative controls 
(putative intron based probe sets of housekeeping genes). The positive vs negative 
AUC plot evaluates how the probe set signals differentiate the positive from the 
negative controls and is a measure of overall data quality. A value of 1.0 indicates 
perfect separation whilst a value of 0.5 indicates no separation. Values between 0.8 
and 0.9 reflect typical values (Affymetrix quality control guidelines). On the gene 
array performed the values were greater than 0.8 indicating coherent values for a 
positive quality control (Figure 4.2a). The all probe set RLE mean represents the mean 
absolute relative log expression and compares the signal of each probe set to the 
median signal value of the probe set in the study. This metric allows identification of 
outlier arrays. Values of samples that fall within a range of +/- 0.13 are considered non 
outliers (Affymetrix quality control guidelines). On the gene arrays performed in this 
study the all probe set RLE values were found within this range indicating the absence 
of outliers in the study (Figure 4.2a). The all probe set mad residual mean is the mean 
of the absolute deviation of the residual signal (i.e. difference between actual value and 
predicted value) from the median. This metric allows to identify gene chip arrays that 
are behaving differently from the predicted model and are highlighted by evidently 
greater values that do not fit within the range values of the other arrays (Affymetrix 
quality control guidelines). In this study the values of the all probe sets ranged between 
0.23 and 0.34 and no evident outlier was identified. Further assessment of the gene 




arrays quality control included the analysis of boxplots relative to signal log intensities 
which enable to gain information on outliers of signal intensities (Affymetrix quality 
control guidelines). Boxplots report log2 transformed values of non-normalised raw 
probe intensity (Figure 4.2b). Such analysis enables to verify the distribution of probes 
intensity levels between arrays. In each box, the middle line represents the median, the 
upper end represents the upper quartile and the lower end represents the lower quartile. 
Outliers are defined as values that are located more than 1.5 times the interquartile 
range from the edges of the box. In the gene array study carried out none of the arrays 
showed median values with an evident difference from the rest of the arrays indicating 
the absence of issues that required further validation analysis of the study. The 
normalisation of the probe set log2 intensities (Figure 4.2c) enabled to gain further 
information on outliers of signal intensities (Affymetrix quality control guidelines). 
The normalisation of the gene arrays in the study was carried out using the Robust 
Multi-Array Analysis (RMA) algorithm and upon normalisation the log2 intensity 
values were found to be within a smaller range than the non-normalised median values 
as expected in a positive outcome of quality control and excluding issues related to the 















































Figure 4.2 Quality control of gene arrays performed on the Affymetrix GCS3000 
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each of the 3 cell-sorted population of IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-
)/IL-10+ cells relative to each donor (4 donors) in order to verify the validity of the 
data for each of the 12 samples. a) The quality control study included analysis of the 
positive vs negative area under the curve (AUC) (a, red line), the all probe sets mad 
residual mean (a, blue line) and the all probe set relative log expression (RLE) mean 
(green line, a) in order to assess overall data quality, gene arrays quality and to identify 
possible array outliers to consider during the data analysis. Values are expressed in a 
log2 scale (a, b and c). Boxplots of non-normalised log2 intensity values (b) and 
normalised log2 intensities (c) were also drawn for each array to control for outliers of 
signal intensities. In each box, the middle line represents the median, the upper end 







































For the data analysis Dr Irene Rebollo Mesa utilised the Significance Analysis of 
Microarrays (SAM) software (Tusher et al., 2001). SAM’s algorithm highlights genes 
with statistically significant changes in expression by performing a gene-specific t test 
known as “di” for each gene “i”. A score (d) is assigned to each gene based on its 
change in gene expression relative to the standard deviation of repeated measurements 
for that specific gene. As a consequence scores that give values of fold change greater 
than the set threshold infer genes that are potentially significant. In this study, the 
analysis based on SAM computed a statistic di for each gene i, as a measure of the 
differences between the different population analysed of IFN-γ+/IL-10(-), IFN-γ+/IL-
10+ and IFN-γ(-)/IL-10+ cells which were compared in pairs. Repeated permutations 
of the data were used to determine if the observed differences are larger than expected 
by chance in the available data. The comparison between all possible combinations of 
the three populations was performed. The cutoff significance was chosen to minimize 
the false positive rate and was measured by the false discovery rate (FDR) which was 
set at ≤ 0.1 (i.e. ≤ 10%). This was combined with a threshold change of 2-fold as a 
minimum fold change in gene expression. The comparisons of IFN-γ+/IL-10- versus 
IFN-γ+/IL-10+  cells showed that the IL-10 gene was found to be among the most 
down regulated genes in the IFN-γ+/IL-10(-) cells when IFN-γ+/IL-10+ were set as 
reference of IL-10 gene expression (Figure 4.3). Similar results were obtained when 
comparing IL-10 levels between IFN-γ+/IL-10(-) cells and IFN-γ(-)/IL-10+ setting 
IFN-γ(-)/IL-10+ cells as reference of IL-10 expression. When the IFN-γ gene 
expression levels were compared between IFN-γ(-)/IL-10+ cells and IFN-γ+/IL-10- 
cells, setting the IFN-γ+/IL-10(-) cells as reference for the expression of IFN-γ, this 
gene was found to be among the most down-regulated genes in the IFN-(γ-)/IL-10+ T 
cells (Figure 4.3). Similar results were obtained comparing IFN-γ expression between 
IFN-γ+/IL-10+ cells and IFN-γ(-)/IL-10+ cells with IFN-γ+/IL-10+ cells set as 
reference (Figure 4.3). The statistical data regarding the expression of the key genes in 
the switch (i.e. IFN-γ and IL-10) was indicative of the accuracy of the gene array and 
its validity in the identification of candidate genes and molecules with a role in the 
CD46 mediated molecular switch (Figure 4.3b). The heat map generated from the gene 
arrays further showed the expression of IFN-γ and IL-10 being higher respectively in 
the IFN-γ+/IL-10(-) and IFN-γ(-)/IL-10+ cell sorted populations (Figure 4.4). 
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Figure 4.3 Statistical evaluation of gene array data and identification of IFN-γ 
and IL-10 differences in expression gene levels. a) Box plot indicating the relative 
expression levels of IL-10 (left box plot) and IFN-γ (right box plot) in a log2 intensity 
scale based on the pooled data analysed for the 4 donors. The middle line in each box 
represents the median, the upper and lower edges represent the respective quartiles. 
The q-value is the lowest FDR at which the gene is called significant. Median and 
quartile values of expression are relative to the comparisons between IFN-γ+/IL-10(-) 
versus IFN-γ+/IL-10+ or versus IFN-γ(-)/IL-10+ cells for the IL-10 gene (left box plot) 
and the IFN-γ+ gene (right box plot). References for each comparison are listed in 
paragraph 4.3 b) Down-regulated genes in IFN-γ+ compared to IL-10+ cells. The 
expression levels of IL-10 and asparagine endopeptidase (AEP, LGMN) were shown 
to be down-regulated in IFN-γ+ cells when IFN-γ+ cells and IL-10+ cells were 
compared and the IL-10+ population was set as reference for the comparison between 
the two populations. Changes in expression are expressed as a relative measure of the 
difference in fold change with a minimum cutoff of 0.5 (1/minimum fold change = 2). 
Statistical analysis derived from SAM. 
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Figure 4.4 Heat map of differentially expressed genes in the IFN-γ+/IL-10(-), IFN-
γ+/IL-10+ and IFN-γ(-)/IL-10+ cell populations. The heat map generated from gene 
arrays run on the Affymetrix GCS3000 platform visually summarizes the gene 
expression profiles in IFN-γ+/IL-10+ (yellow), IFN-γ(-)/IL-10+ (violet) and IFN-
γ+/IL-10(-) (blue) cells from the 4 different donors. The heat map was generated 
through Affymetrix software setting an FDR of 0.1. Each column represents a specific 
sorted population (e.g. IFN-γ+/IL-10(-), blue) of one donor and each row represents a 
specific gene. Each cell represents the expression level of a single transcript in a single 
sample. The blue/yellow colour-coded heat map represents relative gene levels with 
yellow indicating transcript levels above the median for that gene across all samples 
and blue indicating transcript levels below the median for that gene across all samples. 
Colour saturation is proportional to the scale of difference from the median. The rows 
relative to IFN-γ, IL-10 and asparagine endopeptidase (AEP) genes have been 
highlighted through white boxes. The hierarchical clustering tree shown on the left of 
the heat map is an agglomerative approach in which gene profiles are joined in groups 
which are further linked in groups until a single hierarchical tree has been formed. The 
tree is built through distance matrixes which are calculated by the Affymetrix software 
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4.4 AEP expression in human CD46 induced T cells 
The gene array study conducted using the three populations IFN-γ+, IFN-γ+/IL-10+ 
and IL-10+ derived from CD3/CD46-activated primary human CD4
+
 T cells showed 
significant down regulation in the IFN-γ+ population of the mRNA encoding for the 
asparagine endopeptidase (AEP) when IFN-γ+/IL-10(-) cells were compared to IFN-
γ(-)/IL-10+. To confirm the results obtained from the gene array with assessment of 
AEP mRNA induction, CD4
+
 T cells purified from 2 different donors were activated 
with mAbs to CD3 and CD46 in the presence of 50 U/ml of rhIL-2. The IFN-γ+/IL-
10(-) and IFN-γ(-)/IL-10+ cells were FACS sorted and the mRNA was extracted from 
each population. Real-time PCR was then performed on the reverse transcribed RNA 
(Figure 4.5a). AEP gene expression was confirmed to be up-regulated in the IFN-γ(-
)/IL-10+ cells induced by CD46 activation as previously detected in the gene array 
analyses. To determine whether AEP was detectable on a protein level, western blot 
analyses were performed on the nuclear and cytoplasmic fractions of purified CD4
+
 T 
cells. T cells activated for 36 hours with mAbs to CD3 showed higher AEP protein 
levels in comparison to CD3 plus CD46 activation (Figure 4.5b). Moreover, AEP 
protein levels were mostly up-regulated by activation conditions including mAbs to 
CD3 plus CD28. The down-regulation of protein levels of AEP upon CD46 
engagement during T cell activation may be due to the induction of a higher turnover 
of the enzyme upon such signals. It is important to consider that the western blot 
experiment was carried out using whole CD4
+
 T cells and that the difference on gene 
level expression highlighted by the gene array refers to the comparison of sorted IFN-
γ+/IL-10(-) versus IFN-γ(-)/IL-10+ cells induced by CD46. Hence, although the 
western blot analysis confirmed AEP expression in activated T cells, the modulation of 
gene expression shown in the gene arrays was not confirmed on the protein level. To 
investigate AEP cellular localisation, CD4
+
 T cells were activated with antibodies to 
CD3 and CD28 or CD3 and CD46 in the presence of 50 U/ml for 12 hours. Cells were 
then harvested and stained with antibodies for AEP and LAMP-1 (lysosomal marker). 
Interestingly, and in accordance with the Western blot data, AEP expression was 
upregulated upon TCR signals (Figure 4.6). The activation through CD3 and CD46 
showed AEP lysosomal colocalisation specifically in blasting cells. 
 





       
 
 
     
  
 
    
                                    
 
 
Figure 4.5 AEP mRNA and protein levels in CD46 activated T cells. a) CD4
+
 T 
cells were purified from 2 different healthy donors and activated with mAbs to CD3 
and CD46 in the presence of 50 U/ml of rhIL-2 for 36 hours. Post stimulation the 
induced IFN-γ+/IL-10(-) and IFN-γ(-)/IL-10+ populations were sorted by FACS. 
Subsequently mRNA was extracted and reversed transcribed to cDNA. AEP gene 
expression was assessed by qPCR normalised to 18S expression (as described in 
2.12.5) and is shown as a relative quantity of  fold change setting the reference level of 
expression to the IFN-γ(-)/IL-10+ sample. Data are representative of one experiment 
including 2 donors. b) CD4
+











































with immobilised mAbs to CD3, CD28 and CD46 or left untreated in the presence of 
50 U/ml of rhIL-2. Protein extraction was carried out from cytosolic and nuclear 
fractions after 36 hours of activation. Protein amounts from the different stimulation 
conditions were normalized using the Bradford assay and were confirmed by Western 
blot of cytosolic fractions with anti-β-actin mAbs. Nuclear and cytosolic fractions were 


















































           
 
 
          
Figure 4.6 AEP localisation in CD4
+
 T cells.  Confocal microscopy of CD4
+
 T cells 
left untreated (upper left panel) or activated with mAbs to CD3 and CD28 (lower right 
panel) or to CD3 and CD46 (lower left panel) in the presence of 50 U/ml of rhIL-2 for 
12 hours. Cells were stained for DAPI (blue; nuclear die), LAMP-1 (green; lysosomal 
marker) and AEP (red) and isotype controls (upper left panel) were included by adding 
secondary antibodies only (control). Yellow areas indicate co-localization of LAMP-1 











4.5 Functional inhibition of AEP in human CD4+ T cells 
Having confirmed the expression of AEP in human CD4
+
 T cells and its modulation by 
CD46 activation, the effect of AEP inhibition on T cell viability, activation and 
cytokine production/regulation was next assessed. In the following experiments, a 
chemical AEP inhibitor (AEPi) developed by Medivir (Stockholm, Sweden) (Figure 
4.6a) which has been shown to be highly specific for AEP in several sets of data 
(Costantino et al., 2008; Loak et al., 2003; Maehr et al., 2005; Manoury et al., 2003; 
Sepulveda et al., 2009) was used to test the functional significance of AEP inhibition 
in the TH1 switch described in Chapter 3. Since the AEPi is soluble in Dimethyl 
sulfoxide (DMSO) (Costantino et al., 2008; Loak et al., 2003; Maehr et al., 2005; 
Manoury et al., 2003; Sepulveda et al., 2009) control analyses were performed to 
assess whether DMSO alone as carrier could affect cellular viability in T cell cultures. 
T cells left unstimulated or activated through mAbs to CD3, CD28 and/or CD46 were 
treated with different concentrations of DMSO for 36 hours and analysed for cell 
viability through a colourimetric assay (Figure 4.6b). Although, no statistical 
difference was found in any of the conditions between the highest and the lowest 
concentrations of DMSO, the functional experiments were performed using the lowest 
concentration of DMSO (1/1000=0.1%). Viability assays were then performed using T 
cells isolated from four different donors to evaluate the effect of the AEPi on T cell 
viability. Several functional studies have used the AEPi in concentrations ranging from 
20 to 50μM and these concentrations were therefore used as a guide (Costantino et al., 
2008; Loak et al., 2003; Maehr et al., 2005; Manoury et al., 2003; Sepulveda et al., 
2009). Treating CD3 activated or CD3 and CD46 activated T cells with AEPi at 
concentrations ranging from 5 to 50 μM had no effect on cellular viability (Figure 
4.6c). However, the lack of a positive control for cell death in the viability assays 
conducted in figure 4.6 does not allow to determine the extent of cell death in the 
cultures. Inclusion of a positive control for cell death in the assay would have shown 
the range of absorbance measures associated with cell death which could have then 
been compared to the observed values for each activation condition.     
 
 









Figure 4.7 Cell viability of AEPi treated CD4
+
 T cells. a) Chemical structure of 
AEPi. b) CD4
+
 T cells were purified from peripheral blood of three healthy donors and 
activated with mAbs to CD3, CD28 and CD46 in the presence of 50 U/ml of rhIL-2. 
CD4
+
 T cells were activated in the presence of increasing concentrations of DMSO 
(1/1000=0.1%; 1/500=0.2%; 1/250=0.4%). Cellular viability was evaluated using the 
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Promega (paragraph 2.8.1). c) AEPi, solubilised in DMSO 0.1%, was added to cultures 
of activated CD4
+
 T cells in increasing concentrations (0 to 50 μM). Cellular viability 
was evaluated as in (b). Data represent results  SD of 4 separate experiments.  
  
 
4.6 Functional analysis of AEP inhibition on T cell proliferation and activation 
Having established a range of AEPi concentrations that had no effect on cell viability, 
the effects of AEP inhibition on cellular proliferation were assessed by analyses of 
CFSE labelled T cells either left non-activated or activated with anti-CD3 plus anti-
CD28 or anti-CD3 plus anti-CD46 antibodies in the presence or absence of the AEPi 
(Figure 4.8). AEP inhibition in unstimulated T cells did not evidently decrease or 
increase cellular proliferation.  
The effect on cellular proliferation on AEPi treated T cells activated with mAbs to 
CD3 plus CD28 (Figure 4.8b) or CD3 plus CD46 (Figure 4.8c) showed a similar trend 
in these two conditions; in fact proliferation was either not affected or marginally 
affected when cells were cultured in the presence of AEPi at a concentration of 25 μM. 
When the AEPi was used at a concentration of 50 μM, it decreased cellular 
proliferation in both activation conditions. In particular, AEP inhibition at 50 μM 
decreased cellular proliferation in anti-CD3/CD46 activated cells determining 15% less 
proliferation in donor 1, 25% less proliferation in donor 2 and 48% less proliferation in 
donor 3. Anti-CD3 plus anti-CD28 activated T cells cultured in the presence of AEPi 
at 50 μM decreased proliferation of 26%, 17% and 50% in donor 1, donor 2 and donor 
3 respectively. 
Of note is that AEPi at a 50 μM concentration had no effect on cell viability (figure 
4.7). Thus, AEPi at 50 μM seems to specifically impact on cell proliferation. Although 
experiments were conducted with both concentrations of the inhibitor it is important to 
consider that functional implications of AEP inhibition may be due to decreased 
proliferation when considering the 50 μM concentration. Hence, the 25 μM 
concentration is more indicative of functional consequences that may be due to the 
inhibition of AEP activity. 
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Figure 4.8 T cell proliferation in human AEPi treated CD4
+
 T cells. CD4
+
 T cells 
purified via magnetic cell sorting (positive selection) from peripheral blood of 3 
healthy donors were labelled with CFSE (paragraph 2.9.3) and either left unstimulated 
(a, Non-Activated) or activated with mAbs to CD3 plus CD28 (b) or CD3 plus CD46 
(c) in the presence or absence of DMSO only or DMSO solubilised AEPi at a 
concentration of 25 μM or 50 μM. Non-Activated and activated T cells were cultured 
for 5 days prior to FACS analysis of CFSE dilution (i.e. proliferation). Values shown 
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T cell activation was next assessed by analysing the pattern of expression of the T cell 
activation markers CD25 and CD69 in activated T cells of 3 different healthy donors 
(Figure 4.9). Comparison of anti-CD3 and anti-CD46 activated CD4
+
 T cells in the 
presence of the AEPi carrier only (i.e. DMSO) or of the AEPi at a concentration of 25 
or 50 μM showed no evident difference in the activation marker expression in the three 
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Figure 4.9 T cell activation status in human AEPi treated T cells. CD4
+
 T cells 
were magnetically sorted via positive selection from peripheral blood of 3 healthy 
donors and were either left non-activated or activated with mAbs to CD3 and CD28 or 
Donor 1 Donor 2 Donor 3 
Anti-CD3/28 
+ 25μM AEPi 
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CD3 and CD46 (2 μg/ml) in the presence of 50 U/ml of rhIL-2 for 36 hours. 
Unstimulated or activated T cells were cultured in the presence of DMSO or DMSO 
solubilised AEPi at a concentration of 25 μM (b, c and d; donors 1, 2 and 3) or 50 μM 
(b,c and d; donors 1 and 3). a) FSC/SSC gating strategy of non-activated cells, 
unstained control sample (top dot plots), isotype control staining for IgG1-FITC and 
IgG1-APC (lower dot plots). CD25 (FITC) and CD69 (APC) surface staining of 
unstimulated (b), anti-CD3 plus anti-CD28 (c) and anti-CD3 plus anti-CD46 (d) 




4.7 Effect of AEPi on cytokine synthesis and secretion 
To determine whether AEP inhibition could affect the CD46-mediated induction of the 
TH1 switch, the AEPi was added to cultures of activated CD4
+
 T cells. Because AEP 
was identified as the most differentially expressed gene between IFN-+ and IL-10+ T 
cells (Figure 4.3), it was anticipated that inhibition of AEP may impair IL-10 
production upon CD3/CD46-activation. First a secretion assay for IFN-γ and IL-10 
was performed to evaluate whether AEPi treatment could affect the secretory ability of 
T cells activated with mAbs to CD3, CD3 and CD28 or CD3 and CD46. Although 
AEP inhibition affected IL-10 secretion at 25 μM of AEPi the maximal decrease in IL-
10 secretion was obtained by adding AEPi at a concentration of 50 μM (Figure 4.10). 
Importantly the secretion of IFN-γ was also affected showing a negative effect of AEP 
inhibition not exclusively on IL-10 but also on IFN-γ secretion. A trend was observed 
in the suppression of cytokine secretion from CD3 and CD3/CD28-activated T cells; 
however, as expected, AEPi was mostly effective on CD3/CD46-activated T cells. To 
further corroborate this initial finding, the supernatants from AEPi-treated T cells were 
collected after 36 hours of activation to measure secreted IFN-γ and IL-10 (Figure 
4.10). The CBA analysis of the supernatants was fully in line with the initial secretion 
assay and showed that adding AEPi had an inhibitory effect on the overall secreted 
IFN-γ and IL-10 determining circa 50% less secreted cytokine in comparison to 
control DMSO treated T cells. Further, as shown in Chapter 3 (Figure 3.8), inhibition 
of the TH1 phase translates into a limitation of the switch into the IFN-γ(-)/IL-10+ 
phase. This finding was also verified here through the effect of AEPi (Figure 4.10 and 
11); in fact AEP inhibition led to less IFN- production and consequently to less IL-10 
secretion. This data rather indicate that AEP is required for initial IFN- production, 
and not only for IL-10 switching.  



















           
Figure 4.10 Effect of AEPi on IFN-γ and IL-10 secretion in CD46-induced T cells.  
CD4
+
 T cells were either left non-activated or activated with plate bound mAbs to 
CD3, CD28 and/or CD46 (2 μg/ml) in the presence of 25 U/ml of rhIL-2. T cells were 
either treated with DMSO only or AEPi at a concentration of 25 μM or 50 μM. 
Following 36 hours of activation secretion assays were performed to identify the IFN-γ 
(FITC) and IL-10 (APC) secreting T cells a) FSC/SSC gating strategy of non-activated 
and activated T cells. b) Percentages of IFN-γ and IL-10 secreting T cells relative to 
a 























the indicated activating conditions. Values are indicative of the percentage of positive 
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Figure 4.11 AEPi effects on IFN-γ and IL-10 secretion in CD46-induced T cells. 
Purified human CD4
+
 T cells were either left unstimulated (non-activated) or activated 
with plate bound mAbs to CD3, CD28 and/or CD46 (2 μg/ml) in a 48 well plate. Cells 
were seeded at a concentration of 2.5 x 10
5































































































the presence of 25 U/ml rhIL-2. Cultures were treated with DMSO only or AEPi at a 
concentration of 25 μM or 50 μM. Following 36 hours of activation supernatants were 
harvested to evaluate the amounts of secreted IFN-γ (black bars) and IL-10 (white 
bars). a) CBA standard curves for IFN-γ and IL-10 quantification expressed in pg/ml. 
b) IFN-γ and IL-10 quantification in non-activated (NA), anti-CD3, anti-CD3 plus 
anti-CD28 or anti-CD3 plus anti-CD46 activated samples.   
 
Because AEP is also involved in the activation of lysosomal pathways, the mechanism 
through which AEP may affect IFN- production was assessed. Intracellular staining 
for IFN-γ and IL-10 were performed (Figure 4.12) on CD4+ T cells activated with 
DMSO or AEPi at 25 and 50 μM. These experiments revealed that the frequency of 
IFN-γ+ T cells containing this cytokine intracellularly is only marginally affected with 
1-3% less IFN-γ+ T cells between DMSO versus AEPi treated cells. However, the 
transition of IFN-γ+ to IFN-γ+/IL-10+ T cells is highly affected with about 30 to 50% 
less double positive cells in AEPi treated cultures. Hence, AEPi treatment does not 
block IFN- expression per se but rather inhibits the secretion of this cytokine by 
activated T cells. It is being currently assessed whether IFN- is produced upon 












































Figure 4.12 AEPi effects on IFN-γ secretion and IL-10 synthesis in CD46-
activated T cells. CD4
+
 T cells were purified via magnetic sorting (positive selection) 
and activated in the presence of plate-bound mAbs to CD3 plus CD46 (2 µg/ml) in the 
presence of DMSO or AEPi (25 or 50 μM) and of 25 U/ml of rhIL-2. After 36 hours of 
IL-10  
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activation, T cells were treated with PMA/Ionomycin for 4 hours and monensin was 
added to the last 2 hours of culture. T cells were then assessed for intracellular 
cytokine production by FACS analysis as described in paragraph 2.10.1. a) FSC/SSC 
gating strategy b) Intracellular staining for IFN-γ (FITC) and IL-10 (APC) in anti-CD3 
plus anti-CD46 activated T cells. Values represent the percentage of positive cells 
within the relevant gate. 
 
 
4.7.1 Exogenous IFN-γ restores IL-10 production inhibited by AEPi 
The previous results demonstrate that AEP inhibition prevents the secretion of IFN- 
but not its production while it clearly reduces IL-10 production. The question that this 
observation triggered was whether the effect on IL-10 production was a direct effect of 
AEP inhibition or rather a consequence of the lack of IFN- secretion into the micro-
environment. To address this question, human CD4
+
 T cells were activated in the 
presence of the AEPi with or without the addition of recombinant human IFN- IFN- 
and IL-10 were then measured intracellularly whilst the culture supernatants were only 
assessed for IL-10 in order to avoid a false positive signal from the added exogenous 
IFN-. In accordance with the previous data (Figure 4.11) addition of AEPi evidently 
affected IFN-γ+/IL-10+ determining up to 50% less double positive cells in 
comparison to DMSO treated cultures (Figure 4.13). Importantly, addition of IFN-γ 
restored both the IFN-γ+/IL-10+ switching population and the synthesis of IL-10 as 
evaluated by the IL-10 levels in the supernatants of activated T cells (Figure 4.14). 
These results represent a preliminary set of data derived from one single donor are 
currently being repeated. However, in conjunction with the data showing that blocking 
initial TH1 also results in inhibition of TH1 switching (Figure 3.8), these findings 




























Figure 4.13 Addition of IFN-γ restores the switching of TH1 cells and the synthesis 
of IL-10. Purified human CD4
+
 T cells were left unstimulated (non-activated) or 
activated with plate bound mAbs to CD3 and CD46 (2 μg/ml) in the presence of 25 
U/ml of rhIL-2. Cells were treated with AEPi at 25 μM and 50 μM in the presence or 
absence of exogenous IFN-γ. IFN-γ was added at a concentration of 10 ng/ml. Cells 
were seeded at a concentration of 2.5 x 10
5
 per well. Following 36 hours of activation 
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2 hours of culture. Post stimulation T cells were fixed/permeabilized and stained for 





Figure 4.14 Addition of IFN-γ restores the production and secretion of IL-10. 
CD4
+
 T cells were activated as described in figure 4.13. Post stimulation (36 hours) 
supernatants were harvested and screened for secreted IL-10 through CBA. The top 
panel represents the CBA standard curve for IL-10 quantification, expressed in pg/ml. 
The lower panel reports the amounts of  IL-10 (pg/ml) in anti-CD3 plus anti-CD28 or 
anti-CD3 plus anti-CD46 activated T cells +/- 25 μM of the AEPi and in the absence or 


























To characterize the molecular switch from the effector (IFN-γ +) to the regulatory (IL-
10+) phase of TH1-Tr1 switching, gene arrays (Affymetrix) were performed using 
RNA isolated from blood-purified CD4
+
 T cells of healthy donors either left untreated 
(Fig.4.2) or CD3/CD46/IL-2 activated for 36 hours and then sub-sorted into the 
resulting IFN-γ+, IFN-γ+/IL-10+, and IL-10+ populations. Among the most 
differentially regulated genes was the AEP gene, which encodes a lysosomal cysteine 
protease with multiple immunological functions (Maehr et al., 2005; Manoury et al., 
2003; Sepulveda et al., 2009). Quantitative PCR (qPCR) analysis confirmed higher 
AEP gene expression in IL10+ T cells than in IFN-γ+ lymphocytes. Immunoblot 
analysis confirmed AEP expression in CD4
+
 T cells with a strong modulation upon 
TCR signalling. In particular, CD46-mediated signals determined a downregulation of 
AEP expression over time which is in contrast with data obtained through the gene 
array and the qPCR; this might be explained by the high turnover of the enzymatic 
activity of AEP upon CD46 activation. However, a more likely explanation is that the 
expression analyses were performed so far on bulk-activated CD4
+
 T cells and not on 
the sorted populations (IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+). This is 
currently under way and should then clarify this point more satisfyingly. 
The chemical inhibitor developed by Medivir, which is highly specific to AEP 
(Costantino et al., 2008; Loak et al., 2003; Maehr et al., 2005; Manoury et al., 2003; 
Sepulveda et al., 2009) was used as a tool to address the hypothesis that AEP is 
involved in CD46-mediated T cell activation influencing either the inflammatory 
pathway of IFN-γ, the generation of TH1 cells and/or the regulation of the TH1 switch 
into IL-10. CD46-driven IFN- secretion (but not expression) was substantially 
reduced by AEP inhibition and cells were unable to produce IL-10 and thus ‘switch’. 
However, re-establishing signalling through the IFN-γ receptor by adding exogenous 
IFN-γ into the cultures restored the generation of the usually observed IFN-γ+/IL-10(-
), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations. These data infer an important 
point: IFN- receptor signalling itself seems to be a prerequisite for subsequent IL-10 
production. This finding is in line with the suggestion that an effector T cell has to pass 
through a pro-inflammatory phase before it can enter a regulatory phase, a mechanism 
that prevents the direct induction of an immunosuppressive phase by pathogens 




(Kemper et al., 2011). Mechanistically, this could be achieved by the presence of 
binding sites within the IL-10 promoter for transcription factors that are activated by 
pro-inflammatory cytokines. Indeed, the IL-10 promoter contains STAT1 and STAT5 
binding sites (Schaefer et al., 2009; Tsuji-Takayama et al., 2008). Although the data 
relative to the addition of IFN- in the presence of the AEPi showed a tendency for the 
restoration of the IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations 
(Figure 4.13) and of IL-10 secretion (Figure 4.14) in CD46-activated T cells, it does 
not indicate the molecular mechanism/pathway by which this restoration may take 
place. Since AEP is a lysosomal enzyme it is likely that targets of AEP’s enzymatic 
activity reside in this cellular organelle and are not processed in the presence of the 
AEP inhibitor. In the absence of redundant activity for cleavage/maturation of such 
targets with other lysosomal enzymes, AEP inhibition may drastically reduce the 
processing of molecules that are important for the synthesis or secretion of IFN-γ. An 
important target of AEP’s enzymatic activity is represented by prothymosin alpha 
(ProTα) a short peptide of 109 amino acids, highly conserved and found to be 
abundant in the thymus (Haritos et al., 1985; Sarandeses et al., 2003). As a result of 
AEP’s activity ProTα is cleaved to generate thymosin α1 and thymosin α11, smaller 
fragments characterised by immunoregulatory functions (Sarandeses et al., 2003). 
Thymosin α1 has been shown to be able to prime DCs for antifungal TH1 resistance 
through TLR/MyD88-dependent signalling conferring in vivo protection to Aspergillus 
(Romani et al., 2004). The mechanisms through which thymosin α1 exerts these 
functions include up-regulation of TLR2 and TLR9 expression, in both murine and 
human DCs, and promotion of IL-12 synthesis and secretion. Importantly thymosin α1 
has also been shown to promote interferon-α/γ dependent effector pathways through 
augmentation of T cell proliferation and activation of T cell effector function (Bozza et 
al., 2007). Hence, it could be postulated that the inhibition of AEP in CD46-induced T 
cells interferes with the processing of  ProTα into thymosin α1 which could in turn 
decrease T cell activation and the production of cytokines including IFN-γ. Future 
experiments addressing this point would shed light on whether CD46 signals are linked 
to increased ProTα processing, thymosin α1 generation and IFN-γ 
production/secretion. The unexpected finding that AEP is not directly inducing IL-10 
production but is rather required for the secretion of IFN- (which in turn leads to IL-
10 switching) may help explain the seemingly counter-intuitive gene array data shown 




in Figure 4.2. The array and real time PCR data clearly show highest mRNA 
production in the IL10+ and not IFN-+ T cells, and activated (non-switched) T cells 
contain higher amounts of AEP protein (Figure 4.5). Together with the observation 
that CD46-induced T cells switching towards an IL-10 phase have the ability to revert 
to a pro-inflammatory IFN-γ programme, the following model can be derived: resting 
T cells contain already sufficient amounts of AEP to drive quick and efficient IFN- 
secretion upon CD3/CD46-activation. However, up-regulation (or fresh induction) of 
AEP gene expression may be important to restore these AEP basal levels and set IL-
10+ cells again to be reactive towards new incoming inflammatory stimuli which 
require IFN- secretion. This explanation is in line with the role of AEP in the 
activation of inflammatory receptors such as TLR3, TLR7 and TLR9 (Ewald et al., 
2011; Sepulveda et al., 2009). TLRs have been shown to play a pivotal role in the 
induction of  signals in APCs (O'Neill, 2006) and reports of TLR signalling in T-regs 
have shown that it may increase their regulatory function (TLR5). A recent study 
identified TLR9 as an important receptor in adaptive IL-10-producing CD4
+
 T-regs 
induced by vitamin D. Engagement of TLR9 through its physiological ligand (CpG) in 
IL-10 secreting T cells induced by vitamin D was able to induce IFN-γ production and 
loss of their regulatory capacity (Urry et al., 2009). With CD46 being able to induce 
the switch of IFN- γ/TH1 cells to IL-10/Tr1 it is tempting to link CD46 signals to 
TLR9 in CD4+ T cells. In fact the up-regulation of AEP, involved in the cleavage of 
TLR9 at the level of the lysosomes, may influence T cell receptivity towards TLR9 
ligands and tip the balance towards a pro- or anti-inflammatory state. According to the 
model suggested CD46-derived IL-10+ T cells would have upregulated the AEP gene 
expression rendering themselves reactive to the presence of pro-inflammatory stimuli 
such as the ligand for TLR9, CpG. 
Future studies including the usage of inhibitors for the lysosomal and secretory 
pathways should address whether AEP is important for the maturation of secretory 
lysosomes (Blott et al., 2002) and highlight the role of AEP in TH1 induction and 
switching. In order to develop a better understanding of the exact function of AEP in 
human TH1 induction and regulation, gene array analyses are being performed in 
which mRNA profiles of CD3/CD46/IL-2-activated T cells are compared in the 
presence or absence of the AEPi. The data obtained should deliver vital clues for the 
AEP targets and downstream pathways required for its function in normal TH1 




induction and then guide future experiments. A second strategy is also currently being 
adopted to further pinpoint the exact function of AEP in TH1 cells. The usage of a 
specific and widely acknowledged AEP inhibitor is helpful but also has disadvantages. 
It is difficult to conclusively assess how well AEP activity is inhibited in the T cells 
during activation. Thus, it cannot be gauged how vital AEP is in IFN-γ production or if 
another protein may be able to partially compensate for AEP inhibition. To address 
this point, TH1 cell induction (via TCR/CD28 and IL-12) in murine CD4
+
 T cells from 
AEP-deficient mice is being compared to WT animals. The reasoning behind this is 
two-fold: if a similar phenotype is observed in T cells from AEP
-/-
 mice (thus, lack 
IFN- production and secretion and IL-10 switching), a small animal model to further 
address the novel role of AEP in TH1 regulation in vivo would be available. Secondly, 
although there would be major differences in the upstream signalling that is related to 
the CD46 induction of TH1 cells in humans and the CD46-independent induction of 
TH1 mouse cells, AEP might represent a converging point of such pathways and the 
downstream molecules might be shared between human and mouse TH1 cells. Hence, 
AEP
-/-
 animals may possibly prove to become an invaluable tool to analyse TH1 
regulation in vivo. 
 







Chapter 5  














The gene arrays performed using the sub-sorted three populations of the 
CD3/CD46/IL-2-driven TH1 life cycle, IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-
)/IL-10+, also revealed an additional interesting pattern: while the IFN-γ+ T cell 
population expressed genes connected with pro-inflammatory responses, the switched 
IL-10-secreting cells were enriched for genes that are commonly connected with extra 
cellular matrix remodelling (e.g. metalloproteinases, collagens) and receptors 
responding to clotting cascade activation fragments (e.g. protease-activated receptors, 
thrombin receptors). These data suggested that TH1 cells may impact differently on 
their surrounding tissue depending on which phase of their ‘life cycle’ they are. Thus 
while IFN-γ+ T cells may be destructive for tissue as it is commonly observed during 
pathogen clearance (Gazzinelli et al., 1996; Hunter et al., 1997), the switched IL-10 
cells may not only induce TH1 response contraction but possibly also contribute to the 
tissue repair required after pathogen clearance. In order to address such crosstalk 
between CD46-activated T cells and tissue (here epithelial cells were chosen), a 
suitable model would be the co-culture of epithelial cells and T lymphocytes in a 
wound healing assay. However, several studies suggest that CD46 can also signal on 
epithelial cells and may play a role in epithelial cell barrier integrity. Hence, the 
consequences of CD46 activation on epithelial cells need to be assessed for the future 
distinction of each cell contribution in the T cell/epithelial cell crosstalk model. For 
example, CD46 plays a role in the polarization of human epithelium; in fact the tail 
CYT-1 of CD46 binds to the protein discs large homolog (DLG) 4 in kidney epithelial 
cells and this interaction is important for cellular polarization (Ludford-Menting et al., 
2002). The interaction of CD46 with Neisseria meningitidis or N. gonorrhoeae (two of 
the CD46-binding pathogens) also plays an important role in colonization of several 
human epithelial cells by this pathogen. The CD46/Neisseria interaction leads to 
different epithelial cell modifications including: rearrangement of the cytoskeleton, 
calcium flux and ultimately bacterial uptake by the epithelial cell (Crimeen-Irwin et 
al., 2003; Kallstrom et al., 1998; Lee et al., 2002). In addition, data generated and 
published in Dr Claudia Kemper’s laboratory showed that CD46 and the Ste20/SPS1-
related serine/threonine kinase (SPAK) interact in human CD4
+
 T cells and this 
interaction is required to switch IFN--producing TH1 cells into the IL-10-secreting 
self-regulative state (Cardone et al., 2010). SPAK is better known for its function in 




osmotic stress regulation (Li et al., 2004; Smith et al., 2008) as well as regulation of 
intestinal barrier integrity (Yan et al., 2009; Yan et al., 2007). In fact mutations of 
SPAK in humans are connected with reduced epithelial cell/cell adhesion and onset of 
IBD (Yan, et al., 2007). Further, the same yeast-two-hybrid screen (performed by Dr 
Kemper) that indicated SPAK as a potential binding partner also indicated E-cadherin 
and a-E-catenin as potential binding partners for the intracellular domain(s) of CD46. 
α-E-catenin and E-cadherin are key constituents of the E-cadherin/catenin network 
forming adherens junctions that are vitally required for normal cell/cell interactions 
and epithelial cell layer maintenance (Kobielak and Fuchs, 2004; Van Aken et al., 
2001; Vermeulen et al., 1999; Yamada et al., 2005). These observations suggested that 
CD46-mediated signalling events could communicate with the E-cadherin/catenin 
network and/or SPAK in intestinal epithelial cells and contribute to epithelial cell 
barrier integrity. The involvement of CD46 in the regulation of integrity and inter-
cellular communication of intestinal epithelial cells has not been investigated before.  
 
 
5.2 Hypothesis and Aims 
The observations reported above led to the hypothesis that CD46-mediated signalling 
events communicate with the E-cadherin/catenin network and/or with SPAK in 
intestinal epithelial cells and contribute to epithelial cell barrier integrity. Hence, the 
main aim of this chapter was to assess whether CD46 interacts with SPAK and/or E-
cadherin and a-E-catenin and to evaluate if the CD46-mediated signalling in intestinal 










5.3 CD46 interacts with proteins required for intestinal epithelial cell layer 
integrity  
Several signalling molecules have been described to be involved in signal transduction 
mediated by the intracellular domains of CD46, CYT-1 and CYT-2 (Astier and Hafler, 
2007; Riley-Vargas et al., 2004). Despite this knowledge, the signalling pathways and 
their functional significance in different cell types are mostly unknown. To first assess 
whether CD46 is expressed on the intestinal epithelial cell line Caco-2, cells were 
stained for CD46 and were shown to be positive for CD46 surface expression (Figure 
5.1a). Experiments conducted in collaboration with Dr Clauda Kemper were then 
performed in order to determine whether CD46 binds to SPAK, a-E-catenin or E-
cadherin in the human epithelial colorectal adenocarcinoma cell line, Caco-2, cells 
were either left unstimulated or activated for 3 hours through anti-CD46 mAbs. 
Following stimulation cells were lysed and immunoprecipitated with an anti-CD46 
mAb overnight. Immunoblottings were then performed by Dr Kemper for SPAK, a-E-
catenin or E-cadherin (Figure 5.1b). The data showed that SPAK constitutively bound 
to CD46 in Caco-2 cells, while the E-cadherin/CD46 interaction was only observed 
when the cells were activated with monoclonal antibodies (mAbs) to CD46. In 


































Figure 5.1 CD46 expression in Caco-2 cells and interaction with proteins required 
for intestinal epithelial cell layer integrity. a) Caco-2 cells were seeded in 48 well 
plates (5x10
4
 cells per well) and
 
cultured in the appropriate media without stimulation 
as described in paragraph 2.2.2. Upon confluence Caco-2 cells were harvested and 
stained for CD46. Gating strategy for unstained, unstimulated isotype control stained 









of positive cells within the relevant gate or quadrant. b) Caco-2 cells were activated for 
3 hours by receptor cross-linking using the antibodies indicated, and cell lysates used 
for immunoprecipitation with a CD46-specific or isotype control mAb. 
Immunoblotting with anti-SPAK, anti-a-E-catenin and anti-E-cadherin antibodies was 
then performed revealing an association between CD46 and SPAK and CD46 and E-
cadherin. Untreated lysates from non-activated cells were loaded as positive control 
(“lysate”). Data are representative of three similarly performed experiments. 
^Immunoblots performed by Dr Claudia Kemper. 
 
5.4 CD46 signals impact on epithelial cell barrier function 
The functional implications of the interaction between CD46 and SPAK or E-cadherin 
in Caco-2 cells were next assessed. To determine whether CD46-induced signals can 
modulate epithelial barrier integrity, a trans-well system was used to test epithelial cell 
barrier function. The formation of intercellular tight junctions (TJ) and adherens 
junctions is a rate-limiting barrier, inhibiting paracellular flow of ions and larger 
solutes resulting in measurable differences in the ion concentration between the upper 
and lower chamber of the trans-well. These ion concentrations differences are 
measured and expressed as trans epithelial resistance (TER). Caco-2 cells were 
cultured for up to 10 days and functional barrier formation through TJ and AJ 
assembly monitored via increasing TER (Figure 5.2a). Monoclonal antibodies to CD46 
were added to Caco-2 cultures with a TER ≥ 1000 Ω/cm2. Within 30 min post 
activation TER decreased by 70% of the initial value while an isotype control mAb 
showed only marginal TER decrease (Figure 5.2b). Ethanol (EtOH), was added at a 
concentration of 15% to the cultures as a positive control of barrier disruption and 
reduced TER to about 60% albeit with slower kinetics compared to CD46 activation 
(Figure 5.2b). Reduction of TER was maintained in the presence of CD46 activation 
for up to 36 hours (Figure 5.2b).  
The biological function of TER regulation includes epithelial cell growth control and 
the controlled transport or transmigration of solutes and particles between the 
paracellular space of epithelial cells via the ‘opening’ of TJs and AJs. Evidence 
underpinning that CD46 activation of Caco-2 cells regulates paracellular permeability 
was provided by the observation that the addition of CD46 cross-linking mAbs to cell 
cultures increased the transmigration of FITC-labeled 5 kDa dextran beads from the 
upper to the lower trans-well chamber significantly (Figure 5.2c). Importantly, the 
kinetics of CD46-induced bead transmigration were fully in line with those observed 




for CD46-mediated TER changes (Figure 5.2b). To assess CD46’s function in 
epithelial cell barrier function towards a more physiological ‘agent’, the transmigration 
of the uropathogenic E. coli strain J96 in the presence of CD46 activation was next 
analysed (Figure 5.2d). Similarly to the experiments using beads, E. coli bacteria 
accumulated faster and in higher numbers in the lower trans-well chamber when CD46 
activation took place. The high statistical deviation observed when bacteria were used 
in the transmigration experiments is likely due to the more complex interaction of the 
microbes with the epithelial cells (e.g. concurrent activation of toll-like receptors etc.) 
compared to the usage of beads.  Importantly, the observed CD46-mediated increase in 
TER and paracellular permeability in Caco-2 cell cultures are not due to increased 
apoptosis as neither the addition of mAbs to CD46 nor the isotype control mAb 
increased Annexin V binding (Figure 5.3). Thus, these data indicate that CD46 
activation modulates TJ and AD expression or function and by this decreases barrier 















Figure 5.2 CD46 regulates epithelial cell barrier integrity in Caco-2 cell 
monolayers.  (a) Caco-2 cells were seeded at 5 x 10
4
 cells/well in the upper well of a 
trans-well system. Trans-epithelial resistance was assessed every 2 days for a period of 
10 days using the EVOM2 voltohmmeter. Shown is the TER measured in 4 wells over 
10 days. Data are representative of 3 similarly performed experiments. (b) Caco-2 cells 
were cultured in trans-wells until a minimum trans-epithelial resistance of 1000 Ω/cm2 
was reached. Subsequently anti-CD46 mAb (10 µg/ml), isotype control mAb (10 
µg/ml) or 15% final concentration EtOH were added to the upper well and TER 
measured at the indicated time points. Activation conditions were performed in 
triplicate and shown is the result of one of three similarly performed experiments. (c) 
Caco-2 cells were grown and activated as in (a) but with the addition of FITC-labelled 
dextran beads (5 kDa size) into each upper chamber. At indicated time points, sample 
aliquots were taken from the lower trans-well chambers and the amount of 
transmigrated beads measured. Data shown are mean  SD of three experiments. p-
values derive from one-way ANOVA test and were assessed by Bonferroni post-test 
for multiple comparisons. (d) Experiments were performed as under (c) but with the 
addition of J96 bacteria instead of dextran beads into the upper chamber. Data shown 






































































































































Isotype CD46-activated Staurosporin 










                             
Figure 5.3 CD46 activation does not induce apoptosis in Caco-2 cells. Caco-2 cells 
were seeded at 1 x 10
5
 cells per well and cultured in 24-well plates for 6 days. At day 6 
cells were either left non-activated or treated with mAb to CD46 (10 µg/ml), isotype 
control mAb (IgG1; 10 µg/ml) or staurosporin (200 μM), an apoptosis-inducing agent. 
Apoptosis was analysed by combined Annexin-FITC and propidium iodide staining at 
4 and 24 hours post activation. a) FACS plots relative to unstained non-activated Caco-
2 cells (top left), non-activated stained cells (top right), isotype treated (lower left), 
anti-CD46 activated (lower centre) and staurosporin treated cells at 4 hours (lower 
right). b) FACS plots relative to cells either non-activated or activated as in (a) and 
stained at 24 hours.  c) Summary of the percentage of apoptotic cells (Annexin-FITC 
positive, PI-) for four similarly performed experiments. Data shown are the mean  SD 
and representative of four experiments. NA, non-activated; Stau, staurosporin; ns, 
























5.5 CD46 activation promotes cell growth and accelerates wound healing in 
intestinal epithelial cells 
Proliferation of epithelial cells is controlled by contact inhibition. In this process, the 
formation and constellation of TJ and AJ eventually induces growth stop while a 
decrease in TJ and/or AJ or impairment of their integrity initiates cell proliferation 
(Zeng and Hong, 2008). Therefore CD46-mediated modulation of TJ and AJ formation 
on Caco-2 cell proliferation was assessed. Caco-2 cells were activated with either 
CD46 mAbs, an isotype-specific control mAb or treated with staurosporin for 24 or 48 
hours and then assessed for cell proliferation (Figure 5.4a). Whilst staurosporin 
treatment induced cell death (as expected), CD46-activated cells showed a significant 
increase in proliferation compared to the control mAb-treated cultures.  
The effect of CD46-mediated signals on epithelial cell growth was confirmed using a 
wound healing assay. Caco-2 cells were cultured on 24-wells with a removable insert 
that created a defined ‘wound-like’ area upon removal (Figure 5.4b, photographs). 
CD46 engaged via the addition of mAbs to CD46 and cell growth monitored via time-
lapse microscopy over 18 hours. In agreement with the data obtained in the 
proliferation assay (Figure 5.4a), CD46 engagement accelerated would closure 










Figure 5.4 CD46 activation accelerates wound healing. (a). Caco-2 cells were 
seeded into 24-wells at 1.5 x 10
4
 cells/well and allowed to adhere overnight. Wells 
were then left untreated or treated with 10 g/ml mAb to CD46, an isotype control 
mAb or staurosporin (200 μM) and cell proliferation measured 24 and 48 hrs post 
treatment. Data shown are the mean  SD and representative of four experiments. (b) 
Caco-2 cells were cultured on 24-wells with a removable insert. After 6 days, the insert 
was removed and revealed a defined ‘wound-like’ area (upper panels). mAbs to CD46 
or an isotype control Ab was added and cell growth monitored via time-lapse 
microscopy. Lower panel shows the statistical analysis using MetaMorph of the data 
obtained visually. Data shown are the mean  SD and representative of three 












Utilizing Caco-2 in vitro trans-well and culture systems, CD46 activation was found to 
reduce transepithelial resistance and increased paracellular permeability of intestinal 
epithelial cell monolayers (Figure 5.2). However, though CD46 activation allowed for 
an increased transmigration of pathogenic bacteria across the cell layer, it also induced 
increased cell proliferation and accelerated wound healing (Figure 5.3). These data 
suggest that CD46 plays a previously unacknowledged role in the regulation of 
epithelial cell barrier integrity and repair. These findings would be fully in line with an 
expected protective role of the complement system at such vital host/environment 
interface. Although in the in vitro systems used CD46 was engaged though a mAb, 
such engagement in vivo is easy to envisage. The intestinal lumen contains high 
amounts of C3 and C3b and several types of epithelial cells secrete C3 (which is then 
converted to C3b) upon activation by cytokines, tissue damage or other stress signals 
(Moon et al., 1997). Thus, CD46 activation at this location can easily be envisioned in 
an in vivo setting. It is important to notice that the engagement of CD46 in the data 
provided in this chapter was performed using a monoclonal antibody to CD46. The 
strength of such signal is deemed to be greater than the one of the physiological ligand 
of CD46, C3b. The use of C3b as a stimulus in this set of experiments could have led 
to different results for two main reasons: -the engagement may not trigger the same 
level of signalling strength as the monoclonal antibody –C3b may engage other 
receptors (e.g. CR1) or complement regulators (Factor H) which in turn allow for 
cleavage of C3b in smaller fragments (e.g. iC3b, C3dg and C3f) which can bind other 
complement receptors (e.g. CR2) rendering difficult to discriminate the role of CD46 
engagement in epithelial cells from the engagement of other receptors. The observation 
that the addition of mAbs to CD46 decreased epithelial barrier was unexpected – 
specifically in the presence of pathogenic bacteria as one would content that ‘sensing’ 
of danger by a complement component would rather increase barrier function to 
protect the host from infection. The data presented in this chapter are in good 
agreement with the observation that mice transgenic for human CD46 show increased 
transmigration of pathogenic Neisseria through the blood brain barrier and subsequent 
high infection and mortality rate (Johansson et al., 2005). In fact, mice do not express 
CD46 on somatic cells (Inoue et al., 2003) and are usually not susceptible to pathogens 
targeting CD46 as cell entry receptor (Kemper et al., 2005).  The finding though that 




CD46 activation also increased cell proliferation and wound healing suggests that 
CD46’s normal functional role on intestinal epithelial cells may rather be homeostatic 
via the induction of barrier repair after pathogen breach or other injury (and that some 
pathogens plainly take advantage of this ‘house-keeping’ function). The induction of 
epithelial cell proliferation and repair mechanism are induced via changes in TJ and AJ 
formation and signalling events triggered by those changes. Although the underlying 
mechanism is undefined, a vital role for complement activation in the repair after liver 
injury has previously been proposed as mice deficient for C3 and/or C5 fail to initiate 
hepatocyte proliferation and tissue repair in a liver injury model (He et al., 2009). 
Accordingly, patients with liver cirrhosis and impairment of tissue repair present with 
very low levels of circulating C3 and C4 (Nakagawa et al., 1998). A better 
understanding of the exact mechanism(s) by which CD46 regulates TJ and/or AJ 
formation or activation will now require an assessment of the CD46-mediated 
signalling events post activation in these cells. There are several possibilities as to how 
CD46 could participate in barrier homeostasis. CD46-mediated signals could impact 
(possibly via SPAK and/or a-E-catenin) on the expression level of TJ and AJ proteins. 
Changes in E-cadherin expression are generally connected with AJ functional changes 
(Ayollo et al., 2009). Interestingly, this has also been observed for changes in a-E-
catenin and SPAK levels or functions (Kobielak and Fuchs, 2004). Studies of CD46-
mediated impact in the expression of TJ proteins such as occludins and claudins have 
so far not been performed but will likely unravel also a cross-connection or -regulation 
axis as both TJs and AJs need to undergo modifications for TER changes. As an 
interesting third option (and these models may not be mutually exclusive), there could 
a potential crosstalk between CD46 and the Notch and/or Wnt system in intestinal 
epithelial cells. This idea is based on recent observations showing that CD46 regulates 
the expression of Notch 1 and 2 as well as their ligands jagged-1 and delta-1 in human 
CD4
+
 T cells (Le Friec and Kemper, 2010; Cope et al., 2011). A role for CD46 in the 
regulation of barrier function and growth could have major implications for several 
disease states. For example, disturbance in CD46-mediated TJ and AJ function (via 
mutations in CD46 leading to suboptimal or excessive signalling) could induce 
‘leakage’ of the gut flora from the lumen into the surrounding tissue and may cumulate 
into chronic inflammation such as observed in IBD (Hugot et al., 2001). This 
‘phenotype’ may be further potentiated by an impairment of CD46-mediated 




tissue/barrier repair. On the other hand, increased or uncontrolled induction of CD46-
mediated cell proliferation may induce malignant transformation of epithelial cells and 
adenocarcinoma formation. Indeed, a mutation in CD46 that retains expression, 
complement regulatory and ligand binding function but induces a non-sense mutation 
in the intracellular domains has been identified in a colon cancer patient (Sjoblom et 
al., 2006). In summary, these data are in further support of the increasing 
understanding that complement is not only a pillar in the defence against invading 
pathogens and the shaping of the adaptive immune response, but also a key player in 
immune homeostasis and tissue repair.  







Chapter 6  





















The identification of CD46 as a unique co-receptor for the TCR in the induction of IL-
10 production was the first evidence bridging human complement to T cell-mediated 
immunosuppression describing an interesting further link between innate and adaptive 
immunity (Zaffran et al., 2001). The ability of complement-induced T cells (via CD46) 




 (Kemper et al., 2003; Capasso et al., 2006) and γδ 
T-cells (Truscott et al., 2010) raised controversy in regards to the paradigmatic role of 
complement activation. In fact, as complement is firstly a pathogen clearance system 
with broad properties, the identification of how it negatively regulates adaptive 
immunity and how it could be approached therapeutically was and still is a major 
challenge for immunologists. 
The data presented in this thesis added knowledge to the field of T cell regulation via 
complement signals introducing the novel concept of complement-mediated TH1 
“switching”. It unified previous controversial findings on the role of CD46 in CD4+ T 
lymphocytes which reported either the induction of a predominant immunoregulatory 
phenotype (Kemper et al., 2003) or a TH1 biased differentiation of CD4
+
 T (Sanchez et 
al., 2004). As summarized in the model represented in figure 3.16, the findings in this 
thesis showed that cross-linking CD46 on the surface of CD4
+
 T cells does not induce 
directly an immunosuppressive Tr1-like phenotype but rather initiates a more complex 
process of temporally regulated cytokine production. In this process engagement of 
CD46, which may occur via C3b, pathogen interaction or mAb cross linking (Kemper 
et al., 2003; Price et al., 2005), in the presence of low concentrations of IL-2 (i.e. 
resembling the initiation phase of an immune reaction) induces a TH1 response with 
correspondent IL-2 and IFN-γ production. In the presence of high micro-environmental 
IL-2, which would be characteristic of the immune effector phase, the signaling 
through CD46 drives the switch of TH1 cells into an IL-10 (Foxp3-) phase with 
regulatory properties. Such switch model clarifies how complement activation would 
primarily favour an immune response in the initial phase (CD46 induction of TH1 
cells) of an infection, and then modulate it so to re-establish a normal immune 
homoeostasis during the IL-10 phase. Hence, the findings in Chapter 3 and 4 
highlighted how, in the contest of CD46 induced T cells, the implementation of signal 
1 (TCR) signal 2 (CD46) and signal 3 (IL-2) results in the switching of TH1 to Tr1 
cells highlighting a novel pathway of T helper cell auto-regulation. 




Since the identification of Tr1 cells 18 years ago (Bacchetta et al., 1994; Groux et al., 
1997) no transcription factor has been associated to this immunoregulatory class of 
lymphocytes. Hence, their cellular origin, tissue location and function cannot be 
ascertained in vivo or ex vivo limiting the knowledge regarding the involvement of Tr1 
lymphocytes in health and disease. Although CD46 activated lymphocytes were 
initially defined as Tr1-like T cells, the findings described in this thesis support the 
theory that IL-10 secreting cells may not necessarily represent a distinct T cell lineage. 
The data presented in Figure 3.4 clearly showed that the IL-10-secreting cells induced 
via TCR, CD46 and IL-2 signals do not generate from the expansion of an existing 
regulatory population. These results are in accordance with the accumulating set of 
data showing that IL-10 production from CD4
+
 T cells can arise, according to 
environmental cues, from different TH cell lineages including TH2, TH9 and TH17 cells. 
Thus the T cell auto-regulation pathways may not be restricted to TH1 lineages 
(McGeachy et al., 2009; Murphy and Stockinger, 2010). The data presented show how 
CD46-induced T cells are not a distinct lineage of Tr1 cells but rather represent the end 
point of a TH1 response. Whether IL-10-secreting TH1 cells and Tr1 cells represent 
different T cell lineages of a common precursor that has implemented micro-
environmental cues differently is not a question that to date can be addressed given the 
absence of a marker for Tr1 identification.  
Similarly, assessing the in vivo importance of CD46-mediated T cell regulation is 
equally difficult as rodents do not express CD46 on somatic cells and a suitable small 
animal model is therefore not available. However, data presented in Chapter 3 support 
that an in vivo role for CD46 exists in human. The observations showed for the first 
time that CD46-induced TH1 cells are defective in RA. This is in accordance with 
previous findings regarding an altered CD46 immunoregulatory function in 
autoimmune diseases (Astier et al., 2006; Le Buanec et al., 2011). However, the defect 
in RA rather related to the inability in shutting down the TH1 phase that consequently 
tipped the balance of IFN-γ versus IL-10 production in drastic favor of IFN-γ. These 
findings, taken together with unpublished results showing that T cells from RA in 
remission are able to correct this defect and revert to normal cytokine secretion, have 
at minimum two implications: 1. identifying key molecular clues in the shutdown of 
IFN-γ may provide a viable option for therapeutic translational applications since this 
seems to be a revertible defect in vivo. 2. IL-10-secreting T cells are able to revert in 




vitro to IFN-γ production highlighting that a more detailed study of the pathways and 
epigenetic modifications involved is necessary in order to prevent a deleterious 
production of inflammatory cytokines in an attempt to ameliorate an autoimmune or 
inflammatory disease.  
A further key point when considering the therapeutic potential of CD46-activated T 
cells is related to local complement production. Data generated from several groups 
(Heeger et al., 2005; Lalli et al., 2007; Peng et al., 2006; Pratt et al., 2002; Strainic et 
al., 2008) highlight immune-derived complement as a key player in the shaping of T 
cell immunity. Hence the development of complement drugs aimed towards the 
amelioration of autoimmune disorders, graft acceptance or inflammatory diseases must 
take into consideration this source of complement components. Tissue/organ delivered, 
cell-permeable complement inhibitors may be more effective than systemic inhibitors 
and pose lower risks in terms of infection related contraindications.  
The data reported in Chapter 4 identified the protease AEP as a key player in the CD46 
mediated switch at a molecular level. AEP has been highly investigated following its 
discovery in 1997 (Chen et al., 1997) mainly in APCs. The data generated in this thesis 
add to the knowledge of the field since it shows AEP expression and modulation in 
CD4
+
 lymphocytes with an important functional consequence on the secretion of pro-
inflammatory cytokines. In the bigger picture of the CD46-mediated switch, AEP is an 
important molecular target. Since inhibiting this protease clearly affects secretion of T 
cell derived IFN-γ, it could be argued that in a setting of autoimmune disease, where 
excessive IFN-γ is an important issue, targeting AEP and blocking its activation in the 
site of inflammation could potentially be beneficial. In the case that further work on 
AEP knockout mice would reinforce these findings, an animal model to assess AEP 
function in TH1 cytokine secretion could be a viable option and answer the question of 
whether AEP targeting for amelioration of autoimmune diseases can be achieved. 
The findings in Chapter 5 described an unacknowledged role for CD46 in intestinal 
epithelial wound healing reporting a novel role for complement in this cell type. 
Complement has previously been shown to be important in processes of wound repair. 
Several reports have shown that deficiency of complement components C3 and C5 is 
associated to impairment of hepatocyte regeneration in models of hepatic injury (He et 
al., 2009; Markiewski et al., 2004; Strey et al., 2003). Moreover, the central 




complement component C3, can be produced by intestinal epithelium upon stimulation 
with pro-inflammatory signals (Moon et al., 1997). At the level of the gut, the 
production of complement components seems to be particularly important to maintain 
a state of tolerance. In fact, C3 deficient mice present with higher levels of pro-
inflammatory cytokines and lower IL-10 in comparison to C3 sufficient mice 
(Pekkarinen et al.). Given the role of CD46 as a pathogen receptor, several studies 
have focused on the importance of CD46 engagement by pathogens at the level of 
epithelial tissues. For instance, CD46 interacts with Neisseria meningitidis and 
Neisseria gonorrhoeae and this interaction leads to different epithelial cell 
modifications including rearrangement of the cytoskeleton, calcium flux and bacterial 
uptake by epithelial cells (Crimeen-Irwin et al., 2003; Kallstrom et al., 1998; Lee et al., 
2002). CD46 has also been described to be involved in the polarization of human 
epithelium. In fact, CD46 binds to the protein DLG4 in kidney epithelial cells and this 
interaction is important for cell polarization (Ludford-Menting et al., 2002). Hence, it 
is clear that CD46 engagement impacts epithelial cell biology. In this thesis the direct 
effects of CD46-activation through monoclonal antibodies, were investigated in 
intestinal epithelial cells. It was shown that Caco-2 monolayers cultured in a trans-well 
system have decreased trans-epithelial resistance when CD46 is engaged via 
antibodies. The reduction in trans-epithelial resistance was associated with an increase 
in paracellular permeability to dextran beads and pathogenic E. Coli. Importantly, 
although CD46 engagement decreased barrier permeability, it also increased cellular 
proliferation and accelerated the closure of a wound-like injury in an in vitro model of 
wound healing. Hence, these data highlighted an important role for CD46 in the 
regulation of epithelial cell barrier integrity and repair.  
An important aspect which should be investigated in future studies is whether CD46 
engagement induces the secretion of specific cytokines by epithelial cells. The 
complex cellular and cytokine environment of the gut has profound effects on the 
differentiation and function of the different cell types involved. It is known that 
intestinal epithelial cells are able to produce several cytokines in response to 
inflammatory stimuli, including; IL-1β, IL-6, IL-7, IL-8, TGF-β and chemokines such 
as IFN-γ inducible protein-10, IFN-inducible T cell alpha chemokine and CCL5 
(Dignass and Podolsky, 1993; Dotan et al., 2007; Dwinell et al., 1999; Mazzucchelli et 
al., 1996; McGee et al., 1993; Seydel et al., 1997). Cytokines derived from IECs can 




impact directly on neighbouring epithelial cells inducing differentiation and wound 
healing (TGF-β) or promoting epithelial cell survival (IL-6) (Beck et al., 2003; Jin et 
al., 2010; Kurokowa et al., 1987) but could also impact on bystander T cells promoting 
the production of pro-inflammatory or anti-inflammatory cytokines and/or the 
migration of T cells via the secretion of chemokines/chemoattractants (Pratt et al., 
2002; Reinecker and Podolsky, 1995). Given the multiple functions of epithelial-
derived cytokines it would be interesting to investigate whether CD46 stimulation of 
intestinal epithelial cells drives the production of chemokines and/or cytokines which 
could impact on both T cell and epithelial cell biology.  
An additional aspect which requires further investigation is represented by the 
complement components produced by epithelial cells and their effects on bystander T 
cells. Several studies have highlighted the importance of epithelial-derived 
complement in the regulation of epithelial cell biology and in the modulation of T cell 
responses (Pekkarinen et al., 2012; Pratt et al. 2002). Although local complement 
induction has been mainly addressed in APCs and T cells, an elegant study by Pratt et 
al. (2002) firstly highlighted the importance of local complement production by 
epithelial cells and its effect on CD4
+
 T cells in a transplant setting (Pratt et al., 2002). 
The authors showed that C3 deficient renal grafts had prolonged survival, in 
comparison to wild type renal grafts, when transplanted in C3 sufficient animals; at the 
same time they proved that a C3 sufficient graft did not have prolonged survival in C3 
deficient recipients. The source of C3 was identified in the epithelial cells of the 
kidney and the authors showed that local C3 has an important immunomodulatory 
effect on T cells. In fact, stimulation of T cells in the presence of C3 deficient 
epithelial cells induced less IL-2 production than C3 sufficient epithelial cells. Hence, 
studying co-cultures of C3 sufficient and deficient intestinal epithelial cells and human 
CD4
+
 T cells could shed light on whether C3 derived from intestinal epithelial cells 
impacts T cell biology and whether it induces a similar cytokine profile to CD46 
activated of T cells. 
CD46 mediated signals on T cells indeed up-regulate the expression of gut associated 
receptors (e.g. α4β7 and CCR9) (Alford et al., 2008) and regulate the function of the 
kinase SPAK which was shown in this thesis to be a signalling molecule able to 
associate to CD46 in epithelial cells. These findings support the hypothesis of the gut 




being a likely site where CD46 induced T cells may reside in vivo. This hypothesis 
would support a dual role of complement-mediated signals particularly at 
host/environmental interfaces, including the intestine, lung and skin. In fact, on one 
hand complement’s inflammatory function would be necessary to prevent infection or 
clear infecting pathogens but on the other hand complement’s regulatory function 
would be essential for the regulation of T cell responses and for the repair of tissue 
injury accompanying the inflammatory response. This role for complement-mediated 
signals is supported by the gene array data from CD46-induced T cells showing mainly 
the expression of inflammatory related genes in the TH1 phase induced by CD46 but 
also the expression of wound healing genes (e.g. metalloproteinases for tissue 
remodelling) in the contraction phase. Hence in future studies supernatants from CD46 
mediated IFN-γ+/IL-10(-), IFN-γ+/IL-10+ and IFN-γ(-)/IL-10+ populations should be 
prepared and tested on epithelial cultures to evaluate their ability to promote epithelial 
wound repair. Moreover, the sorted three populations might be used in a co-culture 
system with epithelial cells and DCs to attest for DCs influence on cytokine production 
and wound healing. Vaknin-Dembinsky showed how IL-23 increased expression by 
myeloid DCs activated through CD46 was able to induce IL-17 secretion by T cells 
(Vaknin-Dembinsky et al., 2008). It would be interesting to evaluate the role of CD46 
in intestinal DCs and add a level of complexity to the system by co-culturing T cells, 
DCs and epithelial cells. Additionally, since AEP is expressed in mice the 
development and investigation of the role of TH1 cells in an in vivo model of wound 
healing could add knowledge to the understanding of the complex networks of signals 
that are implicated during the clearing of an intestinal infection. 
In summary, this thesis further supports the following two emerging new paradigms in 
the complement field 1- complement is required for tissue and immune homeostasis 
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